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wasn’t easy, I know. In fact, I suspect it was a little tougher than you realize. 




Introduction to osteoarthritis and its prominent risk factor obesity
Chapter 2 27
Do knee abnormalities visualised on MRI explain knee pain in knee osteoarthritis? 
A systematic review
Chapter 3 55
Association between several clinical and radiological determinants with long-term 
clinical progression and good prognosis of lower limb osteoarthritis 
Chapter 4 75
Repeated measurements of uCTX-II, sCOMP, sPIIANP, uCTX-I, and hsCRP as 
biomarkers of progression or efficacy of intervention 
Chapter 5 91
Association between weight or body mass index and hand osteoarthritis: a 
systematic review
Chapter 6 115
Association between leptin, adiponectin and resistin and long-term progression of 
hand osteoarthritis
Chapter 7 127
Difference in the association between obesity and pain in hip and knee 
osteoarthritis 
Chapter 8 143
Body mass index and alignment and their interaction as risk factors for progression 
of knees with radiographic signs of osteoarthritis
Chapter 9 159
Summary, discussion and future direction
Chapter 10 169
Samenvatting, discussie en aanbevelingen
Appendices 181
















































































Osteoarthritis (OA) is perhaps the oldest disease of humanity. Throughout history, 
a condition where cartilage loss presents together with bone features such as 
osteophytes have been described.1 The pathology was found in the fossils of our 
early ancestor Neanderthal man from La-Chapelle-aux-Saints (who lived about 
500.000 years B.C.) and seen regularly on radiographs of Egyptian mummies (who 
lived about more than 3000 years ago). Several terminologies have been used to 
describe this disease: osteoarthrosis, degenerative joint disease, arthrosis deformans 
and osteoarthritis. However, it is not until 1890 that the term ‘osteoarthritis’ is used 
in its modern sense for the first time by A.E. Garrod.2 
1. 2. Osteoarthritis is a disorder of the joint
OA should be considered as a joint disorder, which could result from problems in 
cartilage, subchondral bone, synovium and other tissues in and around the joint.3 
The main reason why someone seeks medical attention for OA is pain related to use.4 
The holy grail in OA research is to find out whether and how this pain originates from 
the joint structures that are damaged in OA. Other clinical presentations of OA are 
short-lasting inactivity stiffness, disability, and cracking of joints (crepitus).3
OA can be defined by pathology or symptoms.5 The main method to assess the 
OA pathology is by using radiographs of the joint. On radiographs, changes in joint 
structure associated with OA can be visualized. Yet, the changes that can be seen 
are limited to changes in cartilage and bone. The change in cartilage can only be 
seen indirectly, and is estimated as joint space narrowing (JSN).3 For epidemiological 
studies, the Kellgren and Lawrence (K&L) grading system (table 1.1 and appendix 
C.1) is the most frequently used radiographic system.6 To define OA for the knee 
and hip joint, K&L score is often combined with the presence of clinical findings. 
This combination is often used by authors of epidemiological studies, such as the 





































Table 1.1 The Kellgren and Lawrence grading system of osteoarthritis.7
Grade Findings
0 None No features of OA
1 Doubtful Minute osteophyte, doubtful significance
2 Minimal Definite osteophyte, unimpaired joint space
3 Moderate Moderate diminution of joint space
4 Severe Joint space greatly impaired with sclerosis of subchondral bone
Table 1.2. American College of Rheumatology criteria for OA of the hand, hip and knee.7
Sites Criteria OA is present if items 
present are
Hand Clinical
1. Hand pain, aching or stiffness for most days or prior month
2. Hard tissue enlargement of two or more of ten selected hand 
joints
3. MCP swelling in two or more joints
4. Hard tissue enlargement of two or more DIP joints
5. Deformity of one or more of ten selected hand joints
1, 2, 3, 4 or 1, 2, 3, 5
Hip Clinical and radiographic 
1. Hip pain for most days of the prior month
2. Erythrocyte sedimentation rate ≤20 mm/h 
3. Radiograph femoral and/or acetabular osteophytes
4. Radiograph hip joint-space narrowing
1, 2, 3 or 1, 2, 4 
or 1, 3, 4
Knee Clinical
1. Knee pain for most days of prior month
2. Crepitus on active joint motion
3. Morning stiffness ≤30 minutes in duration
4. Age≥38 years
5. Bony enlargement of the knee on examination
Clinical and radiographic
1. Knee pain for most days of prior month
2. Osteophytes at joint margin (radiograph)
3. Synovial fluid typical of OA (laboratory)
4. Age≥40 years
5. Morning stiffness ≤ 30 minutes
6. Crepitus on active joint motion
1,2,3,4 or 1,2,5 
or 1,4,5
1.3. Epidemiology
The prevalence of OA varies and depends on the definition used (purely radiographic 
criteria versus based on clinical findings). In a large population-based radiographic 






































had knee OA, and more than 50 % had hand OA of the distal interphalangeal joint 
(figure 1.1).8 It is interesting to compare these data with data from autopsy studies 
in the 70’s that showed that the prevalence of cartilaginous erosions and underlying 
bony change in the knee ranged between 17 (advanced) to 70 % (mild) of the 
population who died around the age of 70.9 When OA is defined purely by history, 
the prevalence of OA on any site as estimated in Tecumseh Community Health Study 
in the USA was 17 % in men and 30 % in women older than 60 years.10 
Figure 1.1 Prevalence of radiographic osteoarthritis affecting distal interphalangeal (DIP), knee 
and hip joints in Zoetermeer study. (From: Van Saase et al. Epidemiology of osteoarthritis: 
Zoetermeer survey. Comparison of radiological osteoarthritis in a Dutch population with that 
in 10 other populations. Annals of Rheumatic Disease 1989).11 
1.4. Risk factors of OA
Since different joints affected by OA have different biomechanics and different types 
of injuries, the risk factors of OA are not uniform across the joints. In general, several 
factors are frequently shown in OA studies to increase the risk of occurrence (i.e. 
incidence) of OA:  obesity, genetic predisposition, malalignment, race, hormonal 





































Many of these risk factors for OA development are also recognized as risk factors for 
the progression of OA.5 The observation that risk factors for occurrence of OA are not 
always risk factors for worsening (i.e. progressive) of OA is probably due to limitations 
in epidemiologic studies.13 Among the limitations are: conditioning on preexisting 
knee OA, patients loss to follow-up in observational studies, bias on measurement of 
effect and ceiling effect.
1.5. Pathophysiology of OA
Each risk factor (A, B, C, D, E, F or G in figure 1.2) could be considered as a component 
cause in the causal pie model. Combination of the component causes is a sufficient 
cause. A sufficient cause is sufficient to give a start to a series of processes that are 
considered as pathophysiological process. Theoretically, there is more than one 
sufficient cause. 
Figure 1.2 Causal pie model. A, B, C, D, E, F, and G are component causes (risk factors). The 
combination of risk factors could give a sufficient cause to start a disease (osteoarthritis). 
There is more than one sufficient cause.
In OA, we can consider a synovial joint as having three different levels: the level below 
cartilage (subchondral bone), at the level of cartilage and the level above cartilage 
(synovium) (figure 1.3). The sufficient cause can start from any of these levels and 






































Figure 1.3 Anatomy of a synovial joint (From: Hunter and Felson. Osteoarthritis. BMJ. 2006).15
Figure 1.4 The intricate balance between risk factors, pathophysiological process and disease 






































Sufficient cause can lead to subchondral bone damage that consequently resulting 
in cartilage damage. Following cartilage damage, changes occur in the subchondral 
bone with the formation of bony outgrowth (osteophytes), and mediators such as 
cytokines and proteolytic enzymes are produced causing inflammation of synovium 
(synovitis). Synovitis contributes to more cartilage defects and consequently leads to 
more subchondral bone damage.
As not only good things come from above (such as cartilage nutrition from the 
synovium), the presence of the sufficient cause can also start from the level above 
cartilage (synovitis) instead of from the level below cartilage (subchondral damage). 
Synovitis can lead to cartilage breakdown. The cartilage breakdown accordingly leads 
to more synovitis.14
The pathophysiological process in OA could ultimately lead to symptoms such as 
pain. Since cartilage is aneural, intuitively, it is not possible that cartilage damage (a 
central feature in OA) generates pain.3 The source of nociceptive stimuli in OA should 
be sought in other joint structures involved in OA pathology, such as subchondral 
bone and synovium.3 As reviewed by Wieland et al., it has been speculated that the 
invading sensory nerve fibers at the area of bone remodeling in OA could be the 
source of pain in OA.12 Synovium is also richly innervated by sensory nerve fibers 
that can be stimulated by interleukin-1 (IL-1), tumor necrosis factor-alfa (TNF-alfa), 
PGE-2, histamine and bradykinin. These cytokines are often released from damaged 
synovium and cartilage.12
1.6. Monitoring the OA progression 
OA is often detected when the symptoms are experienced. Clinical trials on therapies 
to prevent the development of OA symptoms are therefore difficult or impossible 
to perform. Lengthy trials are needed to follow patients since the presence of the 
pathologic features until the symptoms present. Due to this practical limitation, 
trials on preventing the progression of OA are more feasible than trials preventing 
the incidence of symptomatic OA. However, until now, no effective methods for 






































on novel drugs to modify OA failed, is because the heterogeneity between OA 
patients. Not every patient with OA will show progression. When clinical trials are 
‘contaminated’ with patients who are not prone to disease progression, this could 
lead to underestimation of the effect. Therefore, to optimize clinical trial efficiency, it 
is important to know at baseline which patients are at risk for progression. 
The most common method used to monitor the progression of OA in epidemiologic 
studies is radiography.16,17 The preferred method to assess progression on radiographs 
is measuring joint space narrowing (JSN) since this is an estimation of cartilage 
thinning.18,19 The knee joints with OA are placed in a positioning frame to facilitate 
uniform alignment of the knees, and radiographs are made at baseline and at follow-
up. Progression is measured as increase in JSN above a predefined threshold, or 
above the smallest detectable change (SDC). SDC is a statistical method to define 
real change, i.e. change above measurement error.20 Another imaging technique that 
is increasingly used to monitor the progression of OA is Magnetic Resonance Imaging 
(MRI).21,22 The major advantage of MRI over radiographs is that MRI can depict all 
components of the joint; not only cartilage but also synovium, bone contours and 
bone marrow. Yet, at present, the change of other features of OA beside cartilage 
is not commonly used. Increased cartilage volume loss (quantitative measure) and 
increased cartilage defect (semi-quantitative) are currently the most commonly used 
ways to monitor OA progression on MRI.21,23,24
A promising way to monitor the change in OA pathology is by using biomarkers. 
Biomarkers are objective measures that can be derived from body fluid such as blood 
or urine.16 Interestingly, several biomarkers have been developed not only to monitor 
change in cartilage, but also to monitor change in bone and inflammation.25 Among 
the biomarkers that have been developed to monitor cartilage processes are urinary 
excretion of β-isomerized terminal cross-linking telopeptide of collagen type II (uCTX-
II), serum N propeptide of collagen type IIA (sPIIANP) and serum cartilage oligomeric 
matrix protein (sCOMP). Among biomarkers that could be used to monitor bone 
turnover are uCTX-I and serum total osteocalcin. Examples of biomarkers to monitor 






































From a patient perspective, the most important measure for OA progression is not 
imaging and biomarkers, but clinical progression. However, clinical progression is 
difficult to define. This may be the underlying reason why data on clinical progression 
are lacking compared to data on radiological progression. At this moment, there is no 
consensus on a clinical definition of knee and hip OA progression. 
1.7. Obesity 
1.7.1. Why is obesity important in OA?
Among the risk factors for occurrence and progression of OA, obesity is the most 
appealing for several reasons. Firstly, obesity is a strong risk factor 26 that is consistently 
reported to be associated with OA.9,27,28 Secondly, obesity is a factor that can be 
modified. Having more knowledge on how obesity is involved in pathophysiology 
of OA will consequently lead to better measures to prevent the occurrence and the 
progression of OA on an individual level. When it seems to be difficult to stop the 
global epidemic in obesity 29 , individual approaches tailored for OA might be more 
efficient.   
1.7.2. Body Mass Index (BMI) and the epidemiology of obesity 
Obesity should be considered as excess of fat. The most popular way to asses fatness 
is by measuring body mass index (BMI).30 Due to its widespread use, it is sometimes 
forgotten that BMI is just a proxy of human body fat.31 It was not invented to study 
obesity but to define the characteristics of a ‘normal man’. In 1832, 2 years after the 
independence of Belgium from The Netherlands, Adolphe Jacques Quetelet (1796-
1874), who was the president of the Belgian Royal Academic of Science, concluded 
that weight increases as the square of height. This was known as Quetelet Index until 
the term BMI was coined in 1972 by Ancel Keys (1904-2004).32 Despite the fact that 
it is just a vague measurement of adiposity, it correlates well with body fat mass.30 
According to the World Health Organization (WHO), adults with a BMI between 25 
and 30 kg/m2 are considered to be overweight and those with BMI > 30 kg/m2  are 






































Using this WHO definition, a survey in 2007-2008 showed that more than 30% of 
people in the US are obese.29 In the UK, this number is 23% in 2004.30 Data from the 
Dutch National Institute for Public Health and the Environment showed that 11% of 
the Dutch population are obese.34 Despite the awareness that obesity is a danger to 
health, the number of people with obesity has increased compared with one decade 
earlier.29 Increasing consumption of fatty food in combination with more sedentary 
lifestyle are factors that contribute to the obesity epidemic. Several public health 
measures have been taken to fight against the epidemic of obesity. However, these 
measures have to overcome several problems. Since the number of obese subjects 
in the population is high, any public health measure will be quite expensive. Another 
complicating factor is that we have no idea yet how to reverse the obesogenic 
environment (availability of fat food and sedentary life style).
1.7.3. Why fat is dangerous for the joint health 
The real interest in fat and its health effect began just after the second world war.35 
In a paper in Science, Gofman used a newly invented technique to separate plasma 
lipoprotein and showed that this lipoprotein was related to atherosclerotic disease.36 
At the same time Ancilla Keys, who coined the term BMI, also published several 
papers on dietary fat and mortality due to cardiac disease.35 The first studies on 
the association between obesity and OA were also published in the fifties of the 
last century by Lewis-Fanning (1946) and Kellgren and Lawrence (1958).37 Probably 
because the gross damage in OA is easier to assess in larger joints than in smaller 
joints, research on the effect of obesity in OA focused mainly on knee and hip joints. 
This might also be the reason why the effect of obesity has been regarded simply as a 
consequence of the added mechanical load to articular damage and bone.38 However, 
several studies have shown that obesity is also associated with the presence of OA in 
non weight-bearing joints such as hand joints.39,40 These observations challenge the 
view that the mechanical explanation is the sole explanation for the involvement of 





































Until recently, adipose tissue was considered as a passive store of energy.41 In 1994, 
due the discovery of leptin, a 16 kDa protein produced by the obese gene (ob), 
adipose tissue came to be considered as an endocrine organ.42 At present, at least 50 
cytokines and other molecules are produced by fat.42 Adipokines is the term coined 
to describe biologically active substances found in the adipose tissue. It is noteworthy 
to mention that these substances could also be made by tissues other than fat.42 
Adipokines include a variety of pro-inflammatory peptides, such as IL-1 and TNF-alfa 
and peptide hormones, such as leptin, adiponectin and resisitin. Interestingly, these 
adipokines are also shown to be involved in inflammatory and immune responses 
and therefore are not only of interest in OA but also in rheumatoid arthritis (RA).
1.8. Outline of this thesis
The research projects described in this thesis are aimed to give more insight into how 
obesity links with the development and progression of OA. The knowledge derived 
from the investigations in this thesis will shed more light on the pathophysiology of 
obesity in OA. When more is known about the role of obesity in OA in the future, 
effective personalized strategies to treat OA can be pursued. These individual 
measures are needed besides public health measures to reduce obesity since public 
health measures seem to struggle in stopping the global epidemic of obesity.
This thesis starts with three chapters aimed at increasing insight into OA. To treat 
OA in the future, knowledge on the structures involved in OA and knowledge on the 
progression of OA are needed. The development of new treatments for OA (novel 
drugs or novel conservative therapies) warrants better methods of monitoring OA 
progression and of stratifying patients (i.e. to differentiate patients who will have 
progression and who will not have progression in the future) at an early stage. 
Knowing how to monitor OA progression and how to stratify patients will lead to 
more effective clinical trials in OA.
In Chapter 2, we perform a systematic review to investigate the possible joint 
structures visible on MRI that could be the source of pain in knee OA. Not long ago, 






































of cartilage damage is assessed indirectly as the narrowing of the space between 
two bones that formed a synovial joint. It might sound strange, but the presence of 
cartilage is not strongly associated, let alone pathognomonic for the presence of joint 
pain. Many people with JSN do not have joint pain, and vice versa. The pathology in 
OA can also be assessed by modern imaging techniques such as MRI. MRI has several 
advantages above radiography. Firstly, it visualizes cartilage itself. Secondly, it can 
visualize more structures such as bones and synovium. Due to these advantages, MRI 
has been used in research investigating the possible source of pain in OA. When a 
tissue is shown to be associated with pain in OA, it could be investigated more deeply 
to understand its pathology and to test treatment aimed to recover this tissue. Such 
treatment might reduce pain, the reason why patients with OA seek medical help. 
In Chapter 3, we select patients with either clinical knee or clinical hip OA, and 
investigate factors that are associated with the clinical progression (worsening) and 
the good prognosis of lower limb OA. The choice for the population and outcomes 
is motivated by several reasons. We combine patients with either knee or hip OA 
in our study because knee and hip OA often occurs simultaneously.43,44 Moreover, 
validated questionnaires on OA symptoms consist of questions on pain related to 
daily activities involving all lower limb joints, such as climbing the stairs. We assess 
clinical progression because this is relevant for the patient. 
OA is a progressive disease and thus as a consequence, methods are needed to 
monitor its progression. In Chapter 4, we investigate the possible use of several 
biomarkers as a predictor of progression or as a sensitive measurement of OA change 
at multiple sites. These biomarkers are developed to represent several processes in 
tissues involved in OA such as cartilage, bone and inflammation. Using biomarkers for 
these purposes has several possible advantages above the radiographs (the present 
widespread method to asses OA progression). Firstly, biomarkers are more sensitive 
to change in the disease process. For example, it is not necessary to wait until the 
cumulative effect of cartilage damage is seen on radiographs to get information 
about the actual OA state. Secondly, biomarkers give more information about 





































synovium. The study presented in this chapter was unique because we used multiple 
measurements of biomarkers. Multiple measurements might be more informative 
than a single measurement. Moreover, we assessed multiple instead of separate 
joints.  We did this because all joints could contribute to the measured biomarkers.
The following three chapters of this thesis try to answer several questions on how 
obesity influences the development and progression of OA. 
In chapter 5, we perform a systematic review on the association between obesity 
and the development of hand OA. This to provide a ‘proof of principal’ that obesity 
leads to OA not simply by added mechanical force. Since we do not walk on our 
hands, it could be suggested, when such a ‘proof’ is established, that metabolic 
factors associated with fat might also play a role in OA. 
Consequently, in chapter 6, we investigate the association between the products of 
fat tissue (adipokines) and the progression of radiographic hand OA. We investigate 
the following adipokines: leptin, adiponectin, and resistin. In this study, the hand is 
investigated instead of weight bearing joints such as the knee or hip joint because we 
want to investigate the metabolic effect and exclude the mechanical effect. 
In chapter 7, we investigate the association between obesity and pain in patients who 
are visiting orthopedic surgeons to discuss the possibility of having joint prosthesis. 
Since obesity has been shown to be associated with chronic pain, fibromyalgia, 
abdominal pain and migraine 45 it is thus reasonable to hypothesize that obesity could 
also cause joint pain independent of structural damage in an OA joint. Therefore, 
in this study we also investigate the role of the radiographic severity of OA on the 
association between BMI and pain. Since the mechanical effect of obesity differs on 
hip and knee, we also investigate the difference in the association between obesity 






































In chapter 8, we investigate the possible interaction between obesity and another 
strong risk factor of OA, i.e. malignment in ‘causing’ the progression of knee OA. 
Arguably, when the two forces—overweight and malalignment—are present 
together in one knee, the chance of having knee OA progression will increase.
Finally, we present our conclusions and discuss possible future researches on obesity 






































 (1)  Dequeker J, Luyten FP. The history 
of osteoarthritis-osteoarthrosis. Ann 
Rheum Dis 2008 Jan;67(1):5-10.
 (2)  Benedek TG. When did “osteo-
arthritis” become osteoarthritis? J 
Rheumatol 1999 Jun;26(6):1374-6.
 (3)  Dieppe PA, Lohmander LS. 
Pathogenesis and management of 
pain in osteoarthritis. Lancet 2005 
Mar 12;365(9463):965-73.
 (4)  Dieppe P. Development in 
osteoarhtritis. Rheumatology 
(Oxford) 2011;50:245-7.
 (5)  Felson DT, Lawrence RC, Dieppe PA, 
Hirsch R, Helmick CG, Jordan JM, et 
al. Osteoarthritis: new insights. Part 
1: the disease and its risk factors. Ann 
Intern Med 2000 Oct 17;133(8):635-
46.
 (6)  Schiphof D, de Klerk BM, Koes 
BW, Bierma-Zeinstra S. Good 
reliability, questionable validity of 
25 different classification criteria 
of knee osteoarthritis: a systematic 
appraisal. J Clin Epidemiol 2008 
Dec;61(12):1205-15.
 (7)  Arden N, Nevitt MC. Osteoarthritis: 
epidemiology. Best Pract Res Clin 
Rheumatol 2006 Feb;20(1):3-25.
 (8)  van Saase JL, van Romunde LK, Cats 
A, Vandenbroucke JP, Valkenburg 
HA. Epidemiology of osteoarthritis: 
Zoetermeer survey. Comparison of 
radiological osteoarthritis in a Dutch 
population with that in 10 other 
populations. Ann Rheum Dis 1989 
Apr;48(4):271-80.
 (9)  Felson DT. Epidemiology of hip and 
knee osteoarthritis. Epidemiol Rev 
1988;10:1-28.
 (10)  Lawrence RC, Helmick CG, Arnett 
FC, Deyo RA, Felson DT, Giannini EH, 
et al. Estimates of the prevalence of 
arthritis and selected musculoskeletal 
disorders in the United States. 
Arthritis Rheum 1998 May;41(5):778-
99.
 (11)  Van Saase JL, van Romunde LK, Cats 
A, Vandenbroucke JP, Valkenburg 
HA. Epidemiology of osteoarthritis: 
Zoetermeer survey. Comparison of 
radiological osteoarthritis in a Dutch 
population with that in 10 other 
populations. Ann Rheum Dis 1989 
Apr;48(4):271-80.
 (12)  Wieland HA, Michaelis M, Kirschbaum 
BJ, Rudolphi KA. Osteoarthritis - an 
untreatable disease? Nat Rev Drug 
Discov 2005 Apr;4(4):331-44.
 (13)  Zhang Y, Niu J, Felson DT, Choi HK, 
Nevitt M, Neogi T. Methodologic 
challenges in studying risk factors for 
progression of knee osteoarthritis. 
Arthritis Care Res (Hoboken) 2010 
Nov;62(11):1527-32.
 (14)  Findlay DM. If good things come 
from above, do bad things come 
from below? Arthritis Res Ther 
2010;12(3):119.
 (15)  Hunter DJ, Felson DT. Osteoarthritis. 
BMJ 2006 Mar 18;332(7542):639-42.
 (16)  Bauer DC, Hunter DJ, Abramson 
SB, Attur M, Corr M, Felson D, et 
al. Classification of osteoarthritis 
biomarkers: a proposed approach. 
Osteoarthritis Cartilage 2006 
Aug;14(8):723-7.
 (17)  Guermazi A, Burstein D, Conaghan 
P, Eckstein F, Hellio Le Graverand-
Gastineau MP, Keen H, et al. Imaging 
in osteoarthritis. Rheum Dis Clin 
North Am 2008 Aug;34(3):645-87.
 (18)  Ravaud P, Giraudeau B, Auleley GR, 
Chastang C, Poiraudeau S, Ayral X, et 
al. Radiographic assessment of knee 
osteoarthritis: reproducibility and 
sensitivity to change. J Rheumatol 
1996 Oct;23(10):1756-64.
 (19)  Sharma L, Song J, Felson DT, Cahue 
S, Shamiyeh E, Dunlop DD. The 
role of knee alignment in disease 
progression and functional decline 






































1 (20)  Bruynesteyn K, Boers M, Kostense 
P, van der Linden S, van der Heijde 
D. Deciding on progression of joint 
damage in paired films of individual 
patients: smallest detectable 
difference or change. Ann Rheum Dis 
2005 Feb;64(2):179-82.
 (21)  Dore D, Martens A, Quinn S, Ding 
C, Winzenberg T, Zhai G, et al. Bone 
marrow lesions predict site-specific 
cartilage defect development and 
volume loss: a prospective study 
in older adults. Arthritis Res Ther 
2010;12(6):R222.
 (22)  Raynauld JP, Martel-Pelletier J, 
Haraoui B, Choquette D, Dorais M, 
Wildi LM, et al. Risk factors predictive 
of joint replacement in a 2-year 
multicentre clinical trial in knee 
osteoarthritis using MRI: results from 
over 6 years of observation. Ann 
Rheum Dis 2011 May 8.
 (23)  Berry PA, Wluka AE, Davies-Tuck 
ML, Wang Y, Strauss BJ, Dixon JB, et 
al. The relationship between body 
composition and structural changes 
at the knee. Rheumatology (Oxford) 
2010 Dec;49(12):2362-9.
 (24)  Raynauld JP, Martel-Pelletier J, 
Berthiaume MJ, Labonte F, Beaudoin 
G, de Guise JA, et al. Quantitative 
magnetic resonance imaging 
evaluation of knee osteoarthritis 
progression over two years and 
correlation with clinical symptoms 
and radiologic changes. Arthritis 
Rheum 2004 Feb;50(2):476-87.
 (25)  Meulenbelt I, Kloppenburg M, 
Kroon HM, Houwing-Duistermaat JJ, 
Garnero P, Hellio-Le Graverand MP, 
et al. Clusters of biochemical markers 
are associated with radiographic 
subtypes of osteoarthritis (OA) in 
subject with familial OA at multiple 
sites. The GARP study. Osteoarthritis 
Cartilage 2007 Apr;15(4):379-85.
 (26)  Zhang Y, Jordan JM. Epidemiology of 
osteoarthritis. Rheum Dis Clin North 
Am 2008 Aug;34(3):515-29.
 (27)  Doherty M, Spector TD, Serni U. 
Epidemiology and genetics of 
hand osteoarthritis. Osteoarthritis 
Cartilage 2000;8 Suppl A:S14-S15.
 (28)  Lane NE. Clinical practice. 
Osteoarthritis of the hip. N Engl J 
Med 2007 Oct 4;357(14):1413-21.
 (29)  Flegal KM, Carroll MD, Ogden CL, 
Curtin LR. Prevalence and trends in 
obesity among US adults, 1999-2008. 
JAMA 2010 Jan 20;303(3):235-41.
 (30)  Canoy D, Buchan I. Challenges in 
obesity epidemiology. Obes Rev 2007 
Mar;8 Suppl 1:1-11.
 (31)  Roubenoff R. Applications of 
bioelectrical impedance analysis for 
body composition to epidemiologic 
studies. Am J Clin Nutr 1996 Sep;64(3 
Suppl):459S-62S.
 (32)  Eknoyan G. Adolphe Quetelet (1796-
1874)--the average man and indices 
of obesity. Nephrol Dial Transplant 
2008 Jan;23(1):47-51.
 (33)  World Health Organization. Obesity: 
Preventing and Managing the Global 
Epidemic. Geneva; 2000. 
 (34)  Rijksinstituut voor Volkgezondheid 
and Milieu (Dutch National 
Institute for Public Health and the 
Environment). Zorgbalans 2010. 
2010. 
 (35)  Kritchevsky D. History of 
recommendations to the public about 
dietary fat. J Nutr 1998 Feb;128(2 
Suppl):449S-52S.
 (36)  Gofman JW, Lindgren F. The 
role of lipids and lipoproteins in 
atherosclerosis. Science 1950 Feb 
17;111(2877):166-71.
 (37)  Kellgren JH, Lawrence JS. Osteo-
arthrosis and disk degeneration in 






































 (38)  Teichtahl AJ, Wluka AE, Proietto J, 
Cicuttini FM. Obesity and the female 
sex, risk factors for knee osteoarthritis 
that may be attributable to systemic 
or local leptin biosynthesis and its 
cellular effects. Med Hypotheses 
2005;65(2):312-5.
 (39)  Carman WJ, Sowers M, Hawthorne 
VM, Weissfeld LA. Obesity as a risk 
factor for osteoarthritis of the hand 
and wrist: a prospective study. Am J 
Epidemiol 1994 Jan 15;139(2):119-
29.
 (40)  Oliveria SA, Felson DT, Cirillo PA, 
Reed JI, Walker AM. Body weight, 
body mass index, and incident 
symptomatic osteoarthritis of the 
hand, hip, and knee. Epidemiology 
1999 Mar;10(2):161-6.
 (41)  Pottie P, Presle N, Terlain B, Netter 
P, Mainard D, Berenbaum F. Obesity 
and osteoarthritis: more complex 
than predicted! Ann Rheum Dis 2006 
Nov;65(11):1403-5.
 (42)  Lago F, Dieguez C, Gomez-Reino J, 
Gualillo O. Adipokines as emerging 
mediators of immune response 
and inflammation. Nat Clin Pract 
Rheumatol 2007 Dec;3(12):716-24.
 (43)  Lacey RJ, Thomas E, Duncan RC, Peat 
G. Gender difference in symptomatic 
radiographic knee osteoarthritis in 
the Knee Clinical Assessment--CAS(K): 
a prospective study in the general 
population. BMC Musculoskelet 
Disord 2008;9:82.
 (44)  O’Reilly SC, Muir KR, Doherty 
M. Occupation and knee pain: a 
community study. Osteoarthritis 
Cartilage 2000 Mar;8(2):78-81.
 (45)  Wright LJ, Schur E, Noonan C, 
Ahumada S, Buchwald D, Afari 
N. Chronic pain, overweight, and 
obesity: findings from a community-
based twin registry. J Pain 2010 
Jul;11(7):628-35.
Chapter 2
Do knee abnormalities visualised on MRI explain knee 
pain in knee osteoarthritis? A systematic review
Erlangga Yusuf1, Marion C Kortekaas1, Iain Watt2, Tom WJ Huizinga1, 
Margreet Kloppenburg1
From:
Leiden University Medical Center, 
Leiden, The Netherlands 
1 Department of Rheumatology
2 Department of Radiology
The first two authors contributed 
equally. 
Published in:








































To systematically evaluate the association between MRI findings (cartilage defects, 
bone marrow lesions (BML), osteophytes, meniscal lesion, effusion/synovitis, 
ligamentous abnormalities, subchondral cysts and bone attrition) and pain in patients 
with knee osteoarthritis (OA) in order to establish the relevance of such findings 
when assessing an individual patient.
Methods 
The Medline, Web of Science, Embase and Cumulative Index to Nursing & Allied 
Health Literature (CINAHL) databases up to March 2010 were searched without 
language restriction to find publications with data on the association between MRI 
findings of knee OA (exposure of interest) and knee pain (outcome). The quality of 
included papers was scored using a predefined criteria set. The levels of evidence 
were determined qualitatively using best evidence synthesis (based on guidelines on 
systematic review from the Cochrane Collaboration Back Review Group). Five levels 
of evidence were used: strong, moderate, limited, conflicting and no evidence.
Results 
A total of 22 papers were included; 5 had longitudinal and 17 cross-sectional data. 
In all, 13 reported a single MRI finding and 9 multiple MRI findings. Moderate levels 
of evidence were found for BML and effusion/synovitis. The odds ratio (OR) for BML 
ranged from 2.0 (no CI was given) to 5.0 (2.4 to 10.5). The OR of having pain when 
effusion/synovitis was present ranged between 3.2 (1.04 to 5.3) and 10.0 (1.1 to 
149). The level of evidences between other MRI findings and pain were limited or 
conflicting.
Conclusions 
Knee pain in OA is associated with BML and effusion/synovitis suggesting that these 
features may indicate the origin of pain in knee OA. However, due to the moderate 







































Knee is the major site of osteoarthritis (OA), the most common rheumatic disorder 
which is characterized by pain that leads to significant restriction in patients’ daily 
activity.1,2 Despite its importance, the source of pain remains unclear.3 To treat OA 
optimally, knowledge of the source of pain is important since new therapies can be 
specifically targeted.
An important element in understanding pain is to know which structures produce 
it inside the knee since the pathology of knee OA involves the whole knee joint.3 
To assess knee structures in vivo, imaging modalities are needed. On radiographs, 
hallmarks of knee OA such as bony outgrowth and cartilage loss, which are visualised 
as osteophytes and joint space narrowing, respectively, do not show a consistent 
association with knee pain.4 Other potential sources include abnormalities in 
subchondral bone, ligamentous damage, meniscal injury and synovitis.5 However, 
these potential sources cannot be assessed on conventional radiographs. More 
advanced imaging techniques are needed currently best exemplified by MRI. 
Several studies have investigated MRI findings related to pain but to our knowledge, 
no summarization of data has been performed in a systematic manner. Such a review 
requires a focused research question, an explicit research strategy and a system to 
evaluate the quality of evidence.6 Therefore, we sought to evaluate the relationship 
between MRI findings in knee OA and knee pain. We summarized eight commonly 
reported MRI findings: cartilage defects, bone marrow lesions (BML), osteophytes, 
meniscal lesion, effusion/synovitis, ligamentous abnormalities, subchondral cysts 





































Table 2.1 Definitions of the lesions associated with knee OA viewed on MRI. 
Lesions Definition
Cartilage defects Cartilage abnormalities scored on MRI images using semi-
quantitative method or determined using quantitative method.
Bone marrow lesion (BML) Ill-defined lesions in the medullary space with high signal on T2-
weighted imaging or low-signal on T1-weighted imaging scored 
using semi-quantitative method. 
Osteophytes Focal bony protrusion that extended from bones cortical surface 
scored for presence or using semi-quantitative scoring methods.
Meniscal abnormalities Tear of meniscus or meniscus lesion or subluxation scored semi-
quantitatively.
Effusion/ synovitis Effusion: Fluid in synovial space scored for presence or scored 
using semi-quantitative method.
Synovitis: synovial layer scored on the presence of thickening or 
scored semi-quantitatively.
Synovitis and effusion scored together using semi-quantitative 
method.
Ligaments abnormalities Tear of ligaments or lesion of the ligaments scored semi-
quantitatively. 
Subchondral cysts Marginated circular area filled in with fluid under the cartilage 
scored for presence or scored using semi-quantitative method. 
Bone attrition Flattening or depression of the articular cortex scored using 
semi-quantitative method. 
2.2. MATERIALS AND METHODS
The present review is systematic review of observational studies. Therefore, we 
adhered to a protocol developed from a widely recommended method for systematic 
review/meta-analysis of observational studies (MOOSE).7 We included studies with 
data on the association between MRI features of knee OA (exposure of interest) and 
knee pain (outcome). The following studies were excluded: reviews, abstracts, letters 
to the editor, case reports, case series and studies concerning study population with 
other underlying musculoskeletal diseases.
2.2.1. Data sources, searches and extraction
Using the following key words: ‘knee’, ‘knee pain’, ‘MRI’, ‘osteoarthritis’ in combination 
with all possible key words concerning MRI features we wanted to investigate, we 
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Science Citation Index through Web of Science (from 1945), Embase (from 1980) 
and, Cumulative Index to Nursing & Allied Health Literature (CINAHL) (from 1982). 
No language restriction was applied and no search of unpublished studies was 
performed. Additionally, the reference lists of all relevant identified articles were 
screened and Google Scholar was searched to find additional papers. 
Two reviewers, EY (a PhD student) and MCK (a rheumatologist) independently 
screened the titles of retrieved references for obvious exclusion and read the 
remaining abstract to determine eligible studies. Differences were solved by 
discussion or by consulting a third reviewer (MK, a senior rheumatologist). From 
eligible papers, information was collected on the following categories: (i) type of 
study, performed by looking at the method of data analysis (when a study provided 
data on the association between MRI features change in time with change in pain 
level in time, the study was considered to be a prospective cohort study; if this 
analysis was not available, such as in a case-control study, the study was regarded 
to be of a cross-sectional design); (ii) study population (patient characteristics, size, 
gender and age); (iii) definition of knee OA; (iv) assessment of MRI findings; (v) 
assessment of pain; (vi) potential confounders; and (vii) results of the association 
between MRI features and pain.
2.2.2. Assessment of study quality
Independently, the same two reviewers assessed the methodological quality 
of included studies using a predefined criteria set which was previously used in 
systematic reviews in the area of musculoskeletal disorders (table 2.2).8,9 Several 
domains were assessed: population, selection bias, assessment of determinants on 
MRI, assessment of the outcome, follow-up analysis and data presentation. 
For each criterion met in the article, a ‘1’ was given; otherwise, a ‘0’ was given. We 
defined rules on how to assess specific situations. A study could describe multiple MRI 
features but not all were assessed reproducibly (criterion 5) or using standardized 
criteria (criterion 6). For such a study, the criteria are scored as a proportion of MRI 
features which were assessed reproducibly or using standardised criteria from the 





































Differences in scoring were resolved by discussion or by consulting the third reviewer. 
Maximum scores possible were 11 for prospective cohort and 9 for cross-sectional 
study design. The total score for a study (in %) is the total score given for a study 
divided by the maximum possible score. The mean of the quality scores of all studies, 
which was 62%, was used to classify studies as high or low quality.
Table 2.2 Criteria for the quality evaluation of the included studies. 
Item Criteria Applicable for 
Study Population: Definition of Study Population
1. Sufficient description of characteristics of the study population. 
Sufficient is when age, sex and settings are mentioned.
C/ CS
Study Population: Selection Bias
2. Clear description of selection of study subjects. C/ CS
3. Participation rate >= 80% for study population. C/ CS
Assessment of findings on MRI
4. Findings were assessed reproducibly. If multiple findings were 
assessed, the score will be the number of findings assessed 
reproducibly divide by all findings studied.
C/ CS
5. Findings were assessed using validated criteria. If multiple findings 
were assessed, the score will be the number of findings assessed by 
using standardized criteria divide by all findings studied.
C/ CS
6. MRI readers were blinded to clinical findings. C/ CS
7. The sequence of scans were unknown to the MRI readers. C
Assessment of the outcome: Knee Osteoarthritis pain
8. Presence of pain was assessed using validated scales. C/ CS
Follow-up
9. No difference in characteristics between withdrawal and completers 
groups.
C
Analysis and Data Presentation
10. 
11.
Appropriate analysis techniques were used. 
Adjusted for possible confounders.
At least adjustment should be made for age and sex.
C/ CS
C/ CS
C: prospective cohort studies and CS: cross-sectional studies
2.2.3. Rating the body of evidence
The summary of evidence for each MRI feature was given by using best evidence 
synthesis based on the guidelines on systematic review of the Cochrane Collaboration 
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included studies were heterogenous.8 The synthesis has five levels of evidence: (1) 
strong, when general consistent findings were reported in multiple high-quality 
cohort studies; (2) moderate, when one high-quality cohort study and at least two 
high-quality cross-sectional studies show general consistent findings or when at 
least three high quality cross-sectional studies who general consistent findings; (3) 
limited, when general consistent findings were found in a single cohort study, or in 
maximum two cross-sectional studies; (4) conflicting, when no consistent findings 
were reported; and (5) no evidence, when no study could be found. This synthesis 
puts more weight on a prospective cohort design which is appropriate for our review 
question since it takes into account the change in determinant (MRI feature) and 
change in outcome (pain). 
Sensitivity analyses by defining other cut-offs (median score of all studies instead 
of mean) of high quality studies were performed. We also present the number 
of positive studies without quality assessment to give readers the opportunity to 
compare this with the best evidence synthesis results. A study that investigated 
multiple features was counted as a single study for each MRI feature investigated. 
A study was regarded as positive if it showed a significant association between an 
MRI feature and knee pain. When a study included subfeatures of an MRI finding, 
that is, tear and subluxation for meniscal lesion, the study was regarded as positive 
when at least one of these showed positive association. Since effusion and synovitis 




After screening their title, 2144 of 2629 identified references were excluded (figure 
2.1). From the 485 remaining references, 19 papers were included. We selected 
the most recent publication 12 of two publications with overlapping results.12,13 Four 





































We therefore selected two of them.14,16 These two selected studies defined cartilage 
loss as determinant and pain as outcomes, contradictory to the two others which 
defined the determinant and outcomes conversely. After additional searching, 
another three papers were found.16,18,19 In total, 22 papers were selected. In all, 5 
studies reported longitudinal data 12,14,16,20,21 and 17 18,19,22-36 were cross-sectional 
studies.
Figure 2.1 Identified references.
2.3.2. Characteristics of included studies
Of the 22 analysed papers, 8 published associations of multiple MRI features (table 
2.3), 19,25,26,29,30,32,34,36 the others investigated only a single MRI feature. Of these 
papers, 10 were results from 3 studies: the Boston Osteoarthritis Knee Study (BOKS) 
12,18,22,24,28,33 , the Southeast Michigan OA (SEM) cohort 26,34 and the Genetic Arthrosis 
Progression Study (GARP).20,29 Most studies used a General Electric MRI system 
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publications 14,25,27,31 and a Philips MRI system was used in two publications.20,29 Two 
studies 35,36 used a 3 T magnetic field system, all others used a 1.5 T system. Only one 
study 35 used MRI contrast agent.
Patients investigated in the included studies were of both sexes and older than 50 
years, except for one which studied women alone with mean age of 47 years (table 
2.3).26 Almost all studies defined knee OA by using clinical and radiographic criteria of 
American College of Rheumatology, which requires at least knee pain and osteophyte 
on radiograph. Only five studies defined knee OA purely radiographically.19,23,26,27,31
2.3.3. Study quality assessment
We agreed on 212 of 227 (93%) quality assessment items scored. Most disagreement 
focused on the clarity of description of the study population (criterion 2) and 
participation rate (criterion 3). Based on quality assessment, the mean of the quality 
scores of all studies was 61%. In general, many publications either did not assess MRI 
findings using standardised and validated criteria or they did not inform the reader 
about this (criterion 5). In many prospective cohort studies the researchers were 
not blinded for the time order of MRI scans (criterion 7) and differences between 
withdrawal and completed groups were not described (criterion 10). In cross-
sectional studies, the most common limitations were participation rate (criterion 3) 





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































2.3.4. Association between MRI features and pain (best-evidence synthesis) (table 
2.4)
Cartilage defect
Six studies 19,26,29-32 investigated cartilage defects using semiquantitative scores, five 
14,16,23,25,34 used quantitative methods and one used quantitative method on contrast-
enhanced MRI.35 The level of evidence on the association between cartilage defects 
and pain was conflicting: three 16,19,34 of five high-quality studies showed a positive 
association with pain. When all 12 studies which investigated cartilage defects 
14,16,19,23,25,27,29-32,34,35 were summarised, 50% showed a positive association independent 
of study quality.
Bone marrow lesions
The evidence about the association between BML and pain was moderate. Four 
19,24,34,36 of five high-quality studies showed an association between BML and pain. 
One high-quality cohort study showed no association.20 Three of the four high-
quality cross-sectional studies that demonstrated a positive association presenting 
an odds ratio (OR) as quantitative measure of association. The OR ranged from 2.0 
(adjusted for effusion and synovitis) 36 to 5.0 (unadjusted, 95% CI 2.4 to 10.5).34 One 
study reported a β coefficient of 3.72 (95% CI 1.76 to 5.68).19 When all eight studies 
investigating BML 19,20,24,26,30,32,34,36 were taken into account 63% reported a positive 
association between BML and pain.
Osteophytes
Neither of the two high-quality studies showed a positive association between 
osteophytes with pain.29,33 According to best evidence synthesis this gives limited 
level of evidence on the no association between osteophytes and knee pain.
Meniscal lesions
Only one 19 of three high-quality cross-sectional studies showed a positive association 
resulting in a conflicting level of evidence for the association between meniscal 








































A moderate association was found for effusion/synovitis, since all four 12,19,29,36 
high-quality studies showed a positive association. One of which was a high-
quality cohort study.12 This study performed separate analyses for effusion and 
synovitis: the analysis between effusion and pain showed no association whereas 
the association between synovitis and pain was positive. We regarded this study as 
positive, because we deemed a study was as a positive study when at least one of 
the subfeatures showed a positive association. Four high-quality studies reported 
quantitative measures of association. Three reported the OR of having pain when 
effusion/synovitis was present, ranging between 2.6 (adjusted for synovitis and BML) 
36 and 10.0 (adjusted for age, sex BMI and intrafamily effects, 99% CI 1.13 to 149).29 
One other study reported β regression of 9.82 (95% CI 0.38 to 19.27).19 When no 
quality assessment was performed, 86% of included studies 12,19,21,25,26,29,30,36 showed a 
positive association with pain.
Ligament disease
Two studies 28,30 classified ligament abnormalities as presence or absence of tears, 
and three studies 19,22,26 used semiquantitative scores. Since only two high-quality 
studies 19,22 were available, which showed positive association, this resulted in a 
limited level of evidence for a positive association between ligament abnormalities 
and pain. When all five studies 19,22,26,28,30 were taken in account, only 40% showed a 
positive association.
Subchondral cyst
Subchondral cysts were not associated with pain. Two high-quality studies showed 
no association and this resulted in a limited level of evidence.19,29
Bone attrition 
Conflicting evidence was found on the association between bone attrition and pain. 
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































When we used median score of all studies instead of mean score as the cut-off 
of high-quality studies, the level of evidence of the association of all MRI finding 
investigated remained the same. The number of positive studies without quality 
assessment is shown in table 2.4.
2.4. DISCUSSION
Pain is the most disabling symptom of OA. Knowledge about the structures that 
cause pain is crucial, because in the future it may be possible to specifically target 
interventions. For a long time, research on the structural cause of pain has been 
focused on cartilage defects, even though cartilage does not have pain fibres.3 
Further, research on structures that produce pain in the knee was hampered by the 
limited ability of radiographs to visualise knee structures extensively. MRI has been 
shown to be superior to plain films. It demonstrates the whole joint organ. Since 
several initial reports seemed positive about the association between MRI findings 
and pain, we therefore investigated the evidence between the MRI findings and knee 
pain in patients with knee OA. Our findings will be relevant to researchers, clinician 
and radiologists reporting MRI studies.
We identified a moderate level of evidence for a positive association for BML and 
effusion/synovitis with pain in knee OA. The level of evidence was limited for a 
positive association for knee ligamentous abnormalities. We found limited levels of 
evidence for no association for osteophytes and subchondral cysts. Conflicting levels 
of evidence were found for cartilage defects, meniscal lesions and bone attrition. 
We did not investigate studies found during the literature search which investigated 
features beyond the scope of this review: patella alignment, 37 peripatelar and other 
periarticular lesions, 38 popliteal or synovial (Baker’s cyst).13,26,29
In our review, we used a priori defined qualitative levels of evidence to reach 
a summary. We consider this as a strength because we provide an alternative to 
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included several aspects of studies that were heterogenic. However, simply counting 
positive studies also has several drawbacks. It does not take into account the size 
of the studies, and the decision on ‘positive or negative’ studies was based only on 
statistical significance. In meta-analysis, it is theoretically possible that individual 
studies are negative but the pooled effect is positive.39 Another technical limitation 
of our review is the use of quality scores to assess the methodological quality of the 
studies. It could be that when different quality score sets were used, the interpretation 
of the results could be influenced.40 Other limitations of this review mostly reflect the 
limitations of the studies investigated. First, no publication bias could be assessed 
using a funnel plot due to the limited number of studies that reported their results 
in relative risk (RR) or OR.41 Therefore, we do not know whether preferentially 
positive findings were published. Second, the quality of included studies was not 
excellent. There are several obvious examples of limitations of the studies. MRI scan 
interpretation is by nature subjective, as few, if any, quantitative methods exist. 
Attempts at standardization may not be generally used. Also, most scans were read 
unblinded to order. It is possible that MRI readers define the later findings as more 
severe than the first findings. This could lead to misclassification.
The moderate associations found in the review have the consequence that more 
research is needed.42 Epidemiological studies about BML and effusion/synovitis could 
strengthen the levels of association. An ideal epidemiological study design would be 
a case-crossover study where individual MRI findings in the presence of knee pain 
at one time point are compared with MRI findings in the same patient without knee 
pain at another time point. The ideal data analysis would give an association size and 
permit adjustment for confounders, including age and sex, and also for other MRI 
features when multiple MRI findings are studied simultaneously.
The causal relationship between BML and effusion/synovitis and pain in knee OA 
needs further study. Our knowledge is now limited to the fact that BML, defined 
as ill-defined hyperintensities on T2-weighted MRI, 43 comprises normal tissue, 
oedema, necrosis and fibrosis in histological slices.44 Further, although knee OA is not 





































in knee OA and the potential use of anti-inflammatory treatments in knee OA should 
also be pursued in the light of the possible association between effusion/ synovitis 
with knee pain in knee OA. Evaluation of effusion and synovitis can be improved 
by using contrast enhancement, since it can highlight inflammation and improve 
the distinction between synovitis and effusion.12,19 Gadolinium contrast diffusion is 
affected in synovitis tissue, where the blood flow and permeability are changed.45 In 
the present review, no included papers performed contrast-enhanced MRI. 
Beyond the knee itself further research needs to be focused on the origin of pain in 
OA and representation in the central nervous system. Some observations have shown 
that pain in arthritis is also characterised by abnormal pain response (hyperalgaesia) 46 
and functional MRI has the potential to study hyperalgaesia and other pain response.
Knowing which structures in the knee are associated with knee OA will add to our 
understanding of OA and, in the long term, will lead to rational therapeutic targets 
for OA. This will mean improvement in patient care, since at this moment the 
therapeutic options against OA are limited.47 At present, the clinical implication of 
BML is not clear, despite being a common finding in knee OA, being present in 78% 
of patients with knee OA with pain and in 30% of patients with knee OA without 
pain.24 BML is plainly not pathognomonic of knee OA as it is also found in a range of 
conditions such as trauma, osteoporosis and rheumatoid arthritis.48 Moreover, BML 
is also not a static finding. Almost every BML in knee changes in size over a period 
of 3 months.49 The clinical implications of effusion/ synovitis may be clearer, since 
they might permit the potential use of anti-inflammatory drugs in treatment of OA. 
Effusion/ synovitis is common in knee OA. Moderate effusion being seen in 36% of 
patients with knee OA and synovitis present in (84%) of knees.26 
The finding that ligamentous abnormalities may associate with pain is of special 
interest. While the exact aetiology and management of these finding remains 
unclear it may be that surgical intervention could in theory be aimed at repair of 
these structures to alleviate pain. However, based on present knowledge, surgical 
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In summary, this systematic review has shown that BML and effusion/synovitis were 
associated with knee OA pain. However, the level of evidence is moderate and these 
features need to be explored further.
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To investigate the factors associated with clinical progression and good prognosis in 
patients with lower limb osteoarthritis (OA).
Methods 
Cohort study of 145 patients with OA in either knee, hip or both. Progression was 
defined as (i) new joint prosthesis or (ii) increase in WOMAC pain or function score 
during 6-years follow-up above pre-defined thresholds. Patients without progression 
with decrease in WOMAC pain or function score lower than pre-defined thresholds 
were categorized as good prognosis. Relative risks (RRs) for progression and good 
prognosis with 95% confidence interval (95% CI) were calculated by comparing the 
highest tertile or category to the lowest tertile, for baseline determinants (age, sex, 
BMI, WOMAC pain and function scores, pain on physical examination, total range 
of motion (tROM), osteophytes and joint space narrowing (JSN) scores), and for 
worsening in WOMAC pain and function score in 1-year. Adjustments were performed 
for age, sex, and BMI.
Results
Follow-up was completed by 117 patients (81%, median age 60 years, 84% female); 
62 (53%) and 31 patients (26%) showed progression and good prognosis, respectively. 
These following determinants were associated with progression: pain on physical 
examination (RR 1.2 (1.0 to 1.5)); tROM (1.4 (1.1 to 1.6); worsening in WOMAC pain 
(1.9 (1.2 to 2.3)); worsening in WOMAC function (2.4 (1.7 to 2.6)); osteophytes 1.5 
(1.0 to 1.8); and JSN scores (2.3 (1.5 to 2.7)). Worsening in WOMAC pain (0.1 (0.1 
to 0.8)) and function score (0.1 (0.1 to 0.7)), were negatively associated with good 
prognosis.
Conclusions
Worsening of self-reported pain and function in one year, limited tROM and higher 
osteophytes and JSN scores were associated with clinical progression. Worsening 
in WOMAC pain and function score in 1- year were associated with lower risk to 








































Osteoarthritis (OA) of the lower limbs accounts for problems in performing lower 
extremities tasks such as walking and stair climbing.1 Some of the patients with lower 
limb OA show progression of their OA with some progressing to total joint failure 
needing joint replacement.2 Knowing those who will progress is important because it 
will improve patient information on the prognosis of OA.
Several studies have investigated determinants of the progression of knee and hip 
OA 3-5 and several remarks could be made on these studies. Firstly, none of the 
studies investigated knee and hip together. Investigating knee and hip separately is 
easy to understand but it does not reflect the clinical practice. In more than 30% of 
knee OA patients, hip OA is present at the same time 6 and up to 78% of patients 
have bilateral OA in knees or hips.7 Concomitant presence of OA in lower limb joints 
will affect the experience of pain and influence disability in all lower limb joints. 
Arguably, it is difficult for a patient to allocate complaints to a particular knee or 
hip joint. The questionnaires used in OA, such as Western Ontario and McMaster 
Universities Osteoarthritis Index (WOMAC) (appendix B.1) asked questions on daily 
life activities such as climbing the stairs, where knee and hip joints are simultaneously 
needed.8 Secondly, in most studies, progression was defined as joint deterioration 
on a radiograph while from the patient’s perspective clinical progression is more 
important.2,9 Thirdly, almost exclusively baseline determinants of progression were 
investigated. However, OA patients are included in cohort studies at varying stages of 
the OA disease course, which make changes in determinants over a short time period 
of interest as prognostic factors on the long term. 
Clinical progression is relevant for patients, but it is difficult to define. Probably 
this is one of the reasons why data on clinical progression are lacking compared 
to data on radiological progression. At this moment, there is no consensus on how 
to define clinical progression of knee and hip OA progression.10,11 Obviously, total 
joint replacement should be considered as OA disease progression. However, not 





































factors such as patient’s comorbidity and surgeon’s preference. Self-reported pain or 
disability could be used to define clinical progression, yet at present no standardized 
‘cut-off’ for progression on self-reported outcome measures exists. 
To deal with the abovementioned issues, we propose in the present study a composite 
outcome which combines total joint replacement and increase in self-reported pain 
and function during 6-years follow-up above a clinically relevant cut-off 8 as clinical 
progression. We sought to identify determinants associated with clinical progression 
and determinants associated with good prognosis of lower limb OA (knee and hip 
OA together). We assessed baseline determinants and determinants which were 
measured repeatedly over time. 
3.2. PATIENTS AND METHODS
3.2.1. Study design and patient population
This study is part of the Genetic ARthrosis and Progression (GARP) study, a cohort 
study aimed at identifying determinants of OA susceptibility and progression.12 In this 
cohort, 192 Caucasian sib-pairs (384 patients), aged 40 to 70 years were included. To 
be included, patient should have symptomatic OA at multiple joint sites in the hands 
or OA in two or more of the following joint sites: hand, spine (cervical or lumbar), 
knee, or hip. Patients were recruited from the rheumatologic, orthopedic and general 
practice clinics around Leiden, The Netherlands. Patients with secondary OA, familial 
syndromes with a clear Mendelian inheritance, and a shortened life expectancy (<1 
yr) were excluded. Patients underwent baseline assessment between August 2000 
and March 2003 and filled-in questionnaires one year after this baseline visit. From 
April 2007 to June 2008 patients who consented for a follow-up evaluation (mean 
follow-up 6.1 years (range 5.1 to 7.5 years) were assessed. 
To be eligible for the present study, patients needed to have OA in either knee or 
hip, or both. Knee OA was defined according to American College of Rheumatology 
(ACR) criteria as pain or stiffness in the knee on most days of the prior month and 
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according to ACR criteria as pain or stiffness in the groin and hip region on most 
days of prior month together with femoral or acetabular osteophytes or joint space 
narrowing on the radiograph.14  There were 168 patients with knee or hip OA in 
the GARP cohort. Of these patients, 23 patients with prosthesis at baseline were 
excluded leaving 145 patients eligible for the follow-up. Patients with prosthesis at 
baseline were excluded because these patients could be considered as already having 
progressive disease at baseline and because having first prosthesis could influence 
the decision in having another prosthesis (confounder). This study was approved 
by the Medical Ethics Committee of the Leiden University Medical Center. Written 
informed consents form were obtained from all participants. 
3.2.2. Clinical assessment
Demographic data at baseline were recorded using standardized questionnaires. 
Self-reported pain (five items) and functional limitations (17 items) were evaluated 
by using the Dutch version of the WOMAC (appendix B.1) in 100 mm visual analogue 
scale format at baseline, at 1-year and at 6-year follow-up. It considered both knees 
and hips in the last 48 hours. Total scores on the pain and function subscales range 
from 0 to 100, higher scores indicated worse outcome. 
Physical health at baseline was assessed with the summary component scales for 
physical health (PCS) of the Dutch validated Medical Outcomes Study Short Form-
36 (SF-36, appendix B.4) derived from norm based data from the Dutch population 
(mean 50, standard deviation (SD) 10).15,16 Higher scores indicate better physical 
health. 
Physical examinations were performed at baseline. Pain on passive movement of 
the knee and hip joint was assessed using the modified articular index described by 
Doyle et al. 17 (range 0 to 3; 0: no pain, 1: patient expressed tenderness, 2: patient 
expressed tenderness and winced, 3: patient expressed tenderness, winced and 
withdrew the joint). The total pain score ranged from 0 to 12. Flexion and extension of 
the knee and flexion and endorotation of the hip were measured using a goniometer 






































Radiographs of the knees (posterior-anterior (PA); weight-bearing, non-fluoroscopic 
fixed-flexion protocol) and hips (PA; weight-bearing) at baseline were taken by a single 
experienced radiographer using a standard protocol with a fixed film focus distance 
(1.30 m). These analogue films were digitized using a film digitizer at a resolution 
corresponding to a pixel size of 100 mu. Using the OARSI atlas (appendix C.2) 18, 
two readers (EY, JB) scored the radiographs by consensus opinion. Osteophytes were 
graded 0 to 3 in the hip, on the medial and lateral femur and in the medial and 
lateral tibia. Joint space narrowing (JSN) was graded 0 to 3 in the hip, and in medial 
and lateral tibiofemoral compartments of the knees. Total scores for osteophytes 
ranged from 0 to 24 in the knees and 0 to 6 in the hips. Total scores for JSN ranged 
from 0 to 12 in the knees and 0 to 6 in the hips. Intra-reader reproducibility based on 
25 randomly selected pairs of radiographs was excellent, with intra-class correlation 
coefficient (ICC) of 0.99 for osteophytes and 0.98 for JSN. 
3.2.4. Definition of progression and good prognosis
Clinical progression was defined as: (i) the acquirement of joint replacement during 
follow-up or (ii) an increase in self-reported (WOMAC) pain or function from baseline 
to 6-years follow-up above the predefined MPCI (minimum perceptible clinical 
improvement). The joint replacement should be due to OA and not due to other 
forms of arthritis or trauma. MPCI was originally developed as threshold value to 
define treatment response in OA. The threshold values were 9.7 for WOMAC pain 
and 9.3 for WOMAC function.8 
These threshold values with negative sign, were used to define good prognosis. 
Patients without progression who had decrease in WOMAC pain or function score in 
6-years lower than -9.7 or -9.3, respectively, were defined as having good prognosis.
3.2.5. Statistical analysis
Data were analyzed using PASW Statistics 17 (SPSS Inc., Chicago, Ill, USA). Mean 
changes (SD and 95% confidence interval (95% CI)) for WOMAC pain and function, 
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from follow-up scores. Mean changes of scores with the 95% CI that did not cross 0 
was considered as significant. The self-reported pain and function change scores of 
every patient were plotted in cumulative probability plot. 
Determinants of clinical progression were assessed using logistic regression analysis. 
We assessed the following baseline determinants: age, sex, BMI, WOMAC pain and 
function scores, pain on physical examination, total range of motion (tROM) and 
radiographic scores. We also assessed the determinants worsening in WOMAC pain 
and function score in 1-year.
The following baseline determinants were categorized in tertiles: BMI, WOMAC 
pain and function, tROM, osteophytes, and JSN. Also categorized in tertiles were 
worsening in WOMAC pain and function in 1-year. Pain on physical examination was 
categorized into presence or absence of pain. In the logistic regression analysis, the 
odds ratios (ORs) were calculated by using the lowest category or the lowest tertile 
as reference except for tROM where the highest tertile was used as reference. The 
ORs were transformed to risk ratio (RRs) using the approximation formula of Zhang 
because ORs of common outcomes in a fixed cohort are not a good approximation of 
RRs.19 Since the population of this study consists of sib pairs, intrafamily effect were 
taken into account by computing robust standard errors using Stata version 8 (Stata, 
College Station, Tx, USA). In the analyses, adjustments were made for age, sex, and 
BMI. A significant determinant of progression was defined as a determinant that the 
95% CI of its RR did not cross 1. 
The significant determinants were included in a multivariate model to investigate 
whether these determinants could independently predict the clinical progression. 
To get an impression on how good these determinants predict clinical progression 
when they presented together, the R2 of this model was determined. Additionally, to 
investigate the discriminative ability of the multivariate model, we fitted a receiver 
operating characteristics curve (ROC) and calculated the area under the curve (AUC). 
We compared the predicted risk of progression with the observed clinical progression 







































Of 145 patients eligible for the follow-up, 117 (81%) gave consent for follow-up 
assessment. The reasons for non-consent were: no interest in the follow-up study 
(n=8), unavailability of transport (n=8) health problems not associated with OA (n=4), 
emigration (n=1), and unknown (n=2). Five patients died during follow-up.  
Baseline characteristics of patients with and without follow-up and excluded patients 
due to joint prosthesis at baseline are presented in table 3.1. No difference was found 
between baseline characteristics of patients with and without follow-up (table 3.1). 
Table 3.1 Baseline characteristics of 168 patients with knee and/or hip OA stratified by 
availability of follow-up.
Follow-up (n=117) No follow-up (n=28) Joint prosthesis at 
baseline (n=23)
Age, yrs, median (IQR)
60 (55 to 66) 62 (53 to 58) 64 (61 to 68)
Female, no (%)
98 (84) 24 (74) 13 (72)
BMI, kg/m2, mean (range)
28.0 (20 to 47) 27.3 (20 to 38) 29.3 (22 to 43)
Patients with OA, no (%)
Knee 74 (63) 18 (55) 3 (17)
Hip 31 (27) 6 (18) 6 (33)
Knee and hip 11 (10) 9 (27) 9 (50)
Total range of motion, °, mean (range)
258 (133 to 389) 257 (219 to 441) 251 (48 to 360)
Knee flexion 86 (1 to 155) 86 (0 to 155) 85 (16 to 135)
Knee extension     -4 (-30 to 10) -3 (-30 to 16) -2 (-15 to 16)
Hip flexion 134 (100 to 176) 134 (8 to 166) 133 (8 to 175)
Hip extension 41 (0 to 80) 39 (0 to 80) 26 (8 to 49)
Joint prosthesis, no.
n/a n/a 23
Hip prosthesis 16 
Knee prosthesis 6 
Knee and hip prosthesis 1 
Presence of pain on physical examination, no (%)*
85 (73) 20 (71) 17 (74)
Hip 30 (26) 9 (32) 14 (61)
Knee 64 (55) 16 (57) 11 (48)
* Patients may have OA at multiple joints at one time and can have pain in the knee and hip 
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3.3.2. Clinical course of lower limb osteoarthritis 
The mean changes (95% CI) of self-reported (WOMAC) pain and function scores of all 
patients were -2.6 (-8.9 to 3.7) and 0.5 (-5.9 to 6.9), respectively (table 3.2). 
During follow-up, 36 patients (31%) received at least one joint replacement; 15 
for the hip, 16 for the knee, and five for both knee and hip. In these patients with 
new joint replacements, the mean WOMAC pain score (95% CI) decreased over the 
six years of follow-up (-8.5 (-17.8 to -0.1)). In the patients without new prosthesis 
(n=81), WOMAC pain and WOMAC function scores did not change significantly over 
time: -0.1 (-8.3 to 8.1) and 1.9 (-6.3 to 10.1), respectively.
Cumulative probability plots show the variation in natural course of self-reported 
pain and function in the sub-group of patients without prosthesis (n=81) (figure 3.1). 
Fifteen and 22 patients showed progression of WOMAC pain and WOMAC function 
based on changes above the MPCI, respectively. In total, 26 patients (19.7%) showed 
clinical deterioration. Together with the 36 patients receiving joint replacement 
during follow-up, 62 of 117 patients (53.0%) showed clinical progression. Thirty-
one patients showed good prognosis, based on change in WOMAC pain or WOMAC 
function score change lower than -9.7 (n=23) or -9.3 (n=22), respectively. 
In the total study sample, in the subgroup of patients with new prosthesis, and in 
patients without new prosthesis, physical health summary measures using SF-36 did 
not change during follow-up (table 3.2). Compared to the general population (mean 
of 50 with SD of 10), physical health of lower limb OA patients was consistently 
shown to be worse at baseline and follow-up.
Pain during physical examination was worsened in the total population (table 3.2). In 





































Figure 3.1 Cumulative probability plot of Western Ontario and McMaster Universities 
(WOMAC) scores change of patients without prosthesis during follow-up (n=81) for WOMAC 
pain scores change (above) and WOMAC function scores change (below).
The horizontal line above is the line set at minimal perceptible clinical improvement (MPCI) 
score which is used as the cut-off to define progression and the horizontal line below is the line 
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Table 3.2 Mean (standard deviation (SD)) baseline, follow-up (FU), and change scores on self-
reported pain and function (WOMAC), physical health (PCS), and pain on physical examination 
(PE) for the total population and sub-groups.
Baseline Follow-up Change (95% CI)
All patients (n=117) WOMAC pain 36.2 (23.5) 33.6 (25.7) -2.6 (-8.9 to 3.7)
WOMAC function 33.1 (24.3) 33.6 (24.8) 0.5 (-5.9 to 6.9)
PCS 41.8 (9.8)‡ 42.0 (10.1)‡ 0.2 (-2.4 to 2.8)
Pain on PE 1.7 (1.7) 2.4 (2.4) 0.7 (0.2 to 1.2)‡
Patients receiving 
prosthesis during FU 
(n=36)
WOMAC pain 36.5 (18.2) 28.0 (21.0) -8.5 (-17.8 to - 0.1)‡
WOMAC function 32.4 (20.1) 30.0 (20.6) -2.4 (-12.0 to 7.2)
PCS 40.8 (9.1)‡ 40.7 (10.0)‡ -0.1 (-4.6 to 4.4)
Pain on PE 1.8 (1.6) 2.8 (3.1) 1.0 (-0.2 to 2.2)
Patient not receiving 
prosthesis during FU 
(n=81)
WOMAC pain 36.1 (25.6) 36.0 (27.2) -0.1 (-8.3 to 8.1)
WOMAC function 33.4 (26.1) 35.3 (26.4) 1.9 (-6.3 to 10.1)
PCS 42.3 (10.1)‡ 42.6 (10.0)‡ 0.3 (-2.8 to 3.4)
Pain on PE 1.7 (1.8) 2.3 (2.1) 0.6 (-0.01 to 1.2)
‡: statistically significant; the significance of physical health summary were tested by comparing 
the study sample with the norm based population (mean=50, SD=10).
3.3.3. Determinants of clinical progression of lower limb osteoarthritis
Determinants of clinical progression of lower limb OA are shown in table 3.3. Age, 
female sex, and BMI, were not associated with clinical progression. Worsening 
of WOMAC pain and function scores in the first year were associated with 6-year 
progression while WOMAC pain and function score at baseline were not. Subjects in 
the highest tertile of WOMAC pain and function worsening in 1 year had a RR (95% 
CI) of 1.9 (1.2 to 2.3) and 2.4 (1.7 to 2.7), respectively, for clinical progression. The 
presence of pain on physical examination at baseline was associated with clinical 
progression (1.2 (1.0 to 1.5)). Patients in the lowest tertile of tROM had a higher risk 
for clinical progression RRs of 1.4 (1.1 to 1.6). 
Osteophytes and JSN at baseline were associated with clinical progression, RR for 
being in the highest tertile of osteophytes and JSN scores were 1.5 (1.0 to 1.8) and 
2.3 (1.5 to 2.6), respectively. In a multivariate regression model, WOMAC function 
worsening in 1 year, limited t ROM, and JSN scores were found as independent 
determinants of clinical progression (table 3.3). With these variables, explained 





































Table 3.3 Determinants for clinical progression over 6 years of lower limb osteoarthritis 
Determinant Number of patients Risk ratio (95% CI) 1 Risk ratio (95% CI) 2
+ (%) - (%)
Age > 60 years 59 (50) 50 (43) 1.0 (0.9 to 1.1) na
Female sex 48 (41) 50 (43) 0.6 (0.3 to 1.0) na
Body mass index (kg/m2)
< 25.5 19 (16) 20 (17) 1 na
25.5 to 29.1 16 (14) 21 (18) 0.9 (0.5 to 1.2)
> 29.1 27 (23) 14 (12) 1.3 (0.9 to 1.7)
WOMAC pain scores
0 to 23.2 21 (18) 18 (15) 1 na
23.2 to 45.9 20 (17) 18 (15) 0.9 (0.5 to 1.3)
> 45.9 21 (18) 19 (16) 1.1 (0.7 to 1.4)
WOMAC function scores
0 to 18.0 20 (17) 20 (17) 1 na
18.0 to 40.9 22 (19) 16 (14) 1.2 (0.7 to 1.6)
> 40.9 20 (17) 19 (16) 1.1 (0.7 to 1.5)
Change in WOMAC pain score in 1 year 
< - 3.3 10 (9) 16 (14) 1 na
- 3.3 to 10.1 15 (13) 11 (9) 1.6 (0.8 to 2.2)
> 10.1 17 (15) 9 (8) 1.9 (1.2 to 2.3)‡
Change in WOMAC function score in 1 year 
< - 1.4 9 (8) 17 (15) 1 1
- 1.4 to 6.7 13 (11) 14 (12) 1.5 (0.9 to 2.7) 1.9 (0.9 to 2.6)
> 6.7 20 (17) 5 (4) 2.4 (1.7 to 2.7)‡ 2.3 (1.2 to 2.8)‡
Pain on physical examination 44 (38) 13 (11) 1.2 (1.0 to 1.5)‡ 1.2 (0.8 to 1.2)
Total range of motion (°)
> 554 14 (12) 25 (21) 1 1
522 to 554 25 (21) 14 (12) 1.4 (1.01 to 1.7) 1.2 (0.9 to 1.2)
< 522 23 (20) 16 (14) 1.4 (1.1 to 1.6)‡ 1.2 (1.03 to 1.3)‡
Osteophyte scores
1 19 (16) 28 (24) 1 na
2 to 4 19 (16) 10 (9) 1.4 (1.0 to 3.8)‡
> 4 11 (9) 8 (7) 1.5 (1.0 to 1.8)‡
JSN scores
1 19 (16) 32 (27) 1 1
2 to 4 16 (14) 12 (10) 1.5 (0.9 to 2.1) 1.6 (0.7 to 2.4)
> 4 14 (12) 2 (2) 2.3 (1.5 to 2.6)‡ 2.4 (1.9 to 2.7)‡
1 except for determinants age, sex and BMI themselves, adjustment was made for age, sex 
and BMI
2 multivariate model using a backward selection (R2=48.6%). The independent variables with 
univariate associations with a p-value ≤0.10 were included 
Both models are calculated using approximation formula of Zhang.19 
+: with progression; -: without progression
‡: statistically significant
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Table 3.4 Determinants of good prognosis of lower limb osteoarthritis over 6 years.  
Determinant Number of patients Risk ratio (95% CI) 1 Risk ratio (95% CI) 2
+ (%) - (%)
Age > 60 years 28 (24) 3 (3) 1.0 (0.7 to 1.0) na
Female sex 29 (25) 68 (58) 2.8 (0.8 to 6.3) na
Body mass index (kg/m2)
< 25.5 14 (12) 25 (21) 1 na
25.5 to 29.1 12 (10) 25 (21) 0.9 (0.4 to 1.6)
> 29.1 5 (4) 35 (30) 0.3 (0.1 to 0.9)
WOMAC pain scores
0 to 18.0 4 (4) 34 (29) 1 na
18.0 to 45.9 14 (12) 24 (20) 2.7 (0.7 to 3.6)
> 40.9 13 (11) 27 (23) 2.2 (0.7 to 3.8)
WOMAC function scores
0 to 18.0 6 (5) 34 (29) 1 na
18.0 to 40.9 13 (11) 24 (20) 2.5 (0.1 to 4.5)
> 40.9 12 (10) 27 (23) 1.9 (0.7 to 3.8)
Change in WOMAC pain score in 1 year 
< - 3.3 14 (12) 12 (10) 1 na
- 3.3 to 10.1 5 (4) 21 (18) 0.3 (0.1 to 0.6)‡ 0.6 (0.1 to 1.3)
> 10.1 3 (3) 23 (20) 0.1 (0.1 to 0.8)‡ 0.5 (0.1 to 1.1)
Change in WOMAC function score in 1 year 
< - 1.4 15 (13) 11 (9) 1 1
- 1.4 to 6.7 5 (4) 22 (19) 0.3 (0.1 to 0.7)‡ 0.3 (0.1 to 0.8)‡
> 6.7 2 (2) 23 (18) 0.1 (0.1 to 0.7)‡ 0.2 (0.1 to 0.8)‡
Pain on physical examination 20 (17) 11 (9) 0.9 (0.6 to 1.1) na
Total range of motion (°)
> 554 12 (10) 27 (23) 1 na
522 to 554 9 (8) 30 (26) 0.8 (0.3 to 1.7)
< 522 10 (9) 28 (24) 0.9 (0.4 to 1.8)
Osteophyte scores
1 17 (15) 30 (26) 1 na
2 to 4 6 (5) 23 (20) 0.6 (0.2 to 1.2)
> 4 4 (3) 15 (13) 0.5 (0.2 to 1.3)
JSN scores
1 18 (15) 33 (28) 1 na
2 to 4 7 (6) 21 (18) 0.7 (0.3 to 1.4)
> 4 2 (2) 14 (12) 0.4 (0.1 to 1.4)
1 except for determinants age, sex and BMI themselves, adjustment was made for age, sex 
and BMI
2 multivariate model using a backward selection (R2=48.6%). The independent variables with 
univariate associations with a p-value ≤0.10 were included 
Both models are calculated using approximation formula of Zhang.19 
+: with good prognosis; -: without good prognosis
‡: statistically significant






































3.3.4. Determinants of good prognosis of lower limb osteoarthritis
Worsening in WOMAC pain and function score in 1 year were negatively associated 
with good prognosis, i.e. patients in highest tertile of 1-year increase in WOMAC 
pain and function scores had lower risk to have good prognosis (table 3.4). Patients 
in the highest tertile of worsening of WOMAC pain and function in 1 year, had RR of 
0.1 (95% CI 0.1 to 0.8) and 0.1 (0.1 to 0.7), respectively to have good prognosis of 
their lower limb OA compared to patients with WOMAC pain and function change in 
the lowest tertile. When these significant determinants were analyzed in one model, 
only worsening in WOMAC function in 1- year was negatively associated with good 
prognosis. The R2 of this model was 43.3% and the AUCs of the ROC curves were 0.78 
(0.68 to 0.89).
3.4. DISCUSSION
To our knowledge, the present study is the first which investigated determinants of 
clinical progression of knee and hip together. Clinical outcome is chosen because it 
is essential to patients. Clinical progression was present in 53% of patients; 33% by 
receiving joint prosthesis and 20% by deteriorating of self-reported pain or function. 
Self-reported pain improved over 6 years in patients who received prostheses. Self-
reported function did not change over 6 years regardless of joint replacement. The 
combination of WOMAC function changes in 1 year, limited tROM, and JSN scores 
provided the best explanation of variation in clinical progression of lower limb OA. 
Worsening WOMAC pain and function in 1 year were negatively associated with good 
prognosis. Patients in the highest tertile of worsening in WOMAC pain and WOMAC 
function in 1-year had 90% less chance to have good prognosis of their lower limb OA 
compared to patients with pain and function change in the lowest tertile. 
The proportion of the study sample showing clinical progression in our study is 
comparable to results from the Bristol ‘OA 500 study’. In that descriptive study, 
where the majority of the study population was also female, clinical change was 
reported by the patients as: better, same, and worse. They found that 63% and 
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respectively, after 8 years follow-up.9 In the present study, self-reported pain and 
function for the whole group did not change in 6 years. This can be explained by 
the variation in progression between individuals as depicted in the cumulative 
probability plots (figure 3.1). Although some patients remained stable and even 
reported improvement, a considerable proportion of patients reported more pain 
and worse function. As a result the mean change is small. As expected in the sub-
group of patients receiving joint prosthesis during follow-up, self-reported pain 
improved over 6 years, however, self-reported function did not. These results are 
consistent with the notion that joint replacement is an effective treatment for pain 
in lower limb OA. However, it seems that joint replacement cannot replace the 
function of the natural joint. Our results showed some parallels with a recent study 
by Nilsdotter et al.20 They showed that patients had high preoperative expectations 
concerning reduction of pain and function but one year after knee replacement only 
the expectation regarding reduction of pain was fulfilled. 
While self-reported pain at baseline was not associated with clinical progression, rapid 
deterioration in self-reported pain and function in the first year (even after correction 
for WOMAC scores at baseline that could confound the association) was associated 
with higher risk of progression over 6 years. This has not been studied before in 
OA, but it is in accordance with studies in rheumatoid arthritis (RA): worsening in 
self-reported disability measured with the health assessment questionnaire was 
a predictor for severe RA outcomes on the long term.21 Interestingly, worsening in 
WOMAC pain and function score in 1-year were negatively associated with good 
prognosis. The consequence of these findings is that by following lower limb OA 
patients for 1 year, doctors can inform the patients about the progression of the 
OA in the long term. Therefore, it might advisable that doctors see their patients 
again 1-year after the first visit. It will be also interesting to investigate in a clinical 
trial whether modification of self reported pain or function one year after the 
presentation by means of physical therapy or better pain medication could stop the 





































Pain on physical examination at baseline was associated with clinical progression. It 
was also the only pain variable that deteriorated over time. This observation reflects 
that pain as reported by the patient differs from pain on passive movement as found 
during physical examination as shown previously.22 
Limited tROM (RR 1.4, 95% CI 1.1 to 1.6) and presence of pain on physical 
examination at baseline (RR 1.2, 95% CI 1.0 to 1.5) probably reflected the structural 
damage and might be used as a surrogate for osteophyte and JSN scores. In a recent 
EULAR recommendation for the diagnosis of knee OA, limited movement was indeed 
proposed as one of the clinical signs needed to make the diagnosis, probably because 
it was associated with radiological OA.23 
Osteophytes and JSN scores were also identified as determinants of lower limb 
OA progression. Our findings support the findings of Lane and colleague, that 
osteophyte, JSN together with subchondral bone sclerosis were associated with hip 
OA progression.4 
We showed that the WOMAC function changes in 1 year, limited tROM and higher 
JSN scores were independently significant determinants of clinical progression of 
lower limb OA. Although the main aim of this paper was to identify the determinants 
that were associated with clinical progression and not to build a prognostic model, 
we tried to get an impression on how good these determinants in predicting clinical 
progression when they were present together. We also tested the discriminative ability 
of this model to get an indication on how good the presence of these determinants 
predicts the clinical progression of lower OA. Their cumulative presence provided a 
very good explanation of variation in clinical progression, as shown with R2 of 48.6%. 
The AUCs of the ROC curves of 0.80 also indicates a reasonable discriminative ability. 
This means that performing assessment on these three determinants in clinical 
practice will help clinician much in predicting the progression of lower limb OA and 
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Roos et al. showed that female sex was associated with worsening in self-reported 
pain and function and that older age and higher BMI were associated with 
worsening in function assessed on physical examination. On the other hand, we 
found no associations between demographic determinants and clinical progression.5 
Determinants for incidence are often failed to be identified as determinant of 
progression. The failure in finding determinants for progression is a common 
phenomenon that might be caused by methodological problem in studies restricted 
to subjects with existing disease.24 Unfortunately, no method is yet available to 
overcome this problem. Another possible explanation in the difference in our results 
and results from Roos et al. is the difference in patient population. The population 
in the study of Roos was a mix of knee OA patients and participants who underwent 
menisectomy in the past. 
Our study sample that consists of selected sib-pairs with OA at multiple sites has 
strengths and limitations. Since generalized OA (GOA) population is associated with 
rapid OA progression 25 , our study population is suitable to investigate OA progression 
within a relatively short period. However, the generalizability of our results in other 
population settings, especially to general practice clinics is arguably limited and we 
could not investigate GOA as determinant for progression. Yet, if we compare the 
‘severity of OA’ by taking the incidence of joint prosthesis, we did not see much 
difference in the incidence of joint prosthesis in our study sample and in a hospital 
based OA population which was not selected for GOA, for a comparable follow-up 
time.9 It supports the observations in other patient populations that generalized 
OA is also common and it is important to bear in mind that OA is often present at 
multiple sites while only the most symptomatic sites draw attention.9,25 To leave out 
the familial effect, we have performed a correction for familial factors in analysis. 
The choice of the composite outcome that is a combination of two outcomes: joint 
prosthesis and increase in WOMAC pain or function scores above MPCI rewards 
comments. The two outcomes might be different; increase in WOMAC scores above 
MPCI might not always results in joint prosthesis. Also, the use of MPCI in defining 





































trials.8 However, since no clinical outcome regarding clinical progression of knee or 
hip or lower limb OA is available at this moment, our choice of outcome could be 
considered to be used in observational studies. 
It should be noted that our study population consists mainly of female. OA is 
known to be more common in female. The phenomenon that female tend to be 
overrepresented in OA studies is well known, such as in the large Bristol ‘OA 500 
study’ mentioned above.9 In the present study, effort has been taken to adjust for 
this possible confounder.
In summary, over a period of 6 years, more than half of the patients showed 
progression of lower limb OA, based on total joint replacement or change in self-
reported pain or function above the MPCI. Performing combination of clinical and 
radiological assessment in clinical practice could evaluate the sub-group of patients 
with progression of lower limb OA. These findings would help doctors in patient 
information regarding progression of lower limb OA.
Acknowledgements
The authors would like to thank Dr. Naghmeh Riyazi and Dr. Stella Botha-Scheepers 
for performing clinical assessments. The author would also like to acknowledge 
support of the cooperating hospitals (Bronovo Hospital, The Hague: dr. ML Westedt; 
Jan van Breemen Instituut, Amsterdam: dr. D van Schaardenburg; Leyenburg 
Hospital, The Hague: dr. HK Ronday and dr. LN Coene; Reinier de Graaf Gasthuis, 
Delft: dr. AJ Peeters; Rijnland Hospital, Leiderdorp: dr. EJ van Langelaan) and referring 







































 (1)  Lawrence RC, Helmick CG, Arnett 
FC, Deyo RA, Felson DT, Giannini EH, 
et al. Estimates of the prevalence of 
arthritis and selected musculoskeletal 
disorders in the United States. 
Arthritis Rheum 1998 May;41(5):778-
99.
 (2)  Felson DT. Developments in 
the clinical understanding of 
osteoarthritis. Arthritis Res Ther 
2009;11(1):203.
 (3)  Cooper C, Snow S, McAlindon TE, 
Kellingray S, Stuart B, Coggon D, et 
al. Risk factors for the incidence and 
progression of radiographic knee 
osteoarthritis. Arthritis Rheum 2000 
May;43(5):995-1000.
 (4)  Lane NE, Nevitt MC, Hochberg MC, 
Hung YY, Palermo L. Progression of 
radiographic hip osteoarthritis over 
eight years in a community sample 
of elderly white women. Arthritis 
Rheum 2004 May;50(5):1477-86.
 (5)  Roos EM, Bremander AB, Englund 
M, Lohmander LS. Change in self-
reported outcomes and objective 
physical function over 7 years in 
middle-aged subjects with or at 
high risk of knee osteoarthritis. Ann 
Rheum Dis 2008 Apr;67(4):505-10.
 (6)  O’Reilly SC, Muir KR, Doherty 
M. Occupation and knee pain: a 
community study. Osteoarthritis 
Cartilage 2000 Mar;8(2):78-81.
 (7)  Lacey RJ, Thomas E, Duncan RC, Peat 
G. Gender difference in symptomatic 
radiographic knee osteoarthritis in 
the Knee Clinical Assessment--CAS(K): 
a prospective study in the general 
population. BMC Musculoskelet 
Disord 2008;9:82.
 (8)  Ehrich EW, Davies GM, Watson DJ, 
Bolognese JA, Seidenberg BC, Bellamy 
N. Minimal perceptible clinical 
improvement with the Western 
  Ontario and McMaster Universities 
osteoarthritis index questionnaire 
and global assessments in patients 
with osteoarthritis. J Rheumatol 2000 
Nov;27(11):2635-41.
 (9)  Dieppe P, Cushnaghan J, Tucker 
M, Browning S, Shepstone L. The 
Bristol ‘OA500 study’: progression 
and impact of the disease after 8 
years. Osteoarthritis Cartilage 2000 
Mar;8(2):63-8.
 (10)  Belo JN, Berger MY, Reijman M, 
Koes BW, Bierma-Zeinstra SM. 
Prognostic factors of progression 
of osteoarthritis of the knee: a 
systematic review of observational 
studies. Arthritis Rheum 2007 Feb 
15;57(1):13-26.
 (11)  Wright AA, Cook C, Abbott JH. 
Variables associated with the 
progression of hip osteoarthritis: a 
systematic review. Arthritis Rheum 
2009 Jul 15;61(7):925-36.
 (12)  Riyazi N, Meulenbelt I, Kroon HM, 
Ronday KH, Hellio le Graverand MP, 
Rosendaal FR, et al. Evidence for 
familial aggregation of hand, hip, 
and spine but not knee osteoarthritis 
in siblings with multiple joint 
involvement: the GARP study. Ann 
Rheum Dis 2005 Mar;64(3):438-43.
 (13)  Altman R, Asch E, Bloch D, Bole 
G, Borenstein D, Brandt K, et al. 
Development of criteria for the 
classification and reporting of 
osteoarthritis. Classification of 
osteoarthritis of the knee. Diagnostic 
and Therapeutic Criteria Committee 
of the American Rheumatism 
Association. Arthritis Rheum 1986 
Aug;29(8):1039-49.
 (14)  Altman R, Alarcon G, Appelrouth 
D, Bloch D, Borenstein D, Brandt 
K, et al. The American College 
of Rheumatology criteria for the 
classification and reporting of 






































 (15)  Ware JE, Jr., Sherbourne CD. The MOS 
36-item short-form health survey 
(SF-36). I. Conceptual framework 
and item selection. Med Care 1992 
Jun;30(6):473-83.
 (16)  Aaronson NK, Muller M, Cohen PD, 
Essink-Bot ML, Fekkes M, Sanderman 
R, et al. Translation, validation, and 
norming of the Dutch language 
version of the SF-36 Health Survey 
in community and chronic disease 
populations. J Clin Epidemiol 1998 
Nov;51(11):1055-68.
 (17)  Doyle DV, Dieppe PA, Scott J, 
Huskisson EC. An articular index for 
the assessment of osteoarthritis. Ann 
Rheum Dis 1981 Feb;40(1):75-8.
 (18)  Altman RD, Gold GE. Atlas of 
individual radiographic features in 
osteoarthritis, revised. Osteoarthritis 
Cartilage 2007;15 Suppl A:A1-56.
 (19)  Zhang J, Yu KF. What’s the relative 
risk? A method of correcting the 
odds ratio in cohort studies of 
common outcomes. JAMA 1998 Nov 
18;280(19):1690-1.
 (20)  Nilsdotter AK, Toksvig-Larsen S, Roos 
EM. Knee arthroplasty: are patients’ 
expectations fulfilled? A prospective 
study of pain and function in 102 
patients with 5-year follow-up. Acta 
Orthop 2009 Feb;80(1):55-61.
 (21)  Bykerk V. Anti-cyclic citrullinated 
peptide antibody versus HAQ/
MDHAQ: comparing apples and 
oranges? J Rheumatol 2009 
Aug;36(8):1565-7.
 (22)  Bijsterbosch J, Wassenaar MJ, le 
CS, Slagboom PE, Rosendaal FR, 
Huizinga TW, et al. Doyle Index is a 
valuable additional pain measure 
in osteoarthritis. Osteoarthritis 
Cartilage 2010 May 14.
 (23)  Zhang W, Doherty M, Peat G, Bierma-
Zeinstra MA, Arden NK, Bresnihan 
B, et al. EULAR evidence-based 
recommendations for the diagnosis 
of knee osteoarthritis. Ann Rheum 
Dis 2010 Mar;69(3):483-9.
 (24)  Zhang Y, Niu J, Felson DT, Choi HK, 
Nevitt M, Neogi T. Methodologic 
challenges in studying risk factors for 
progression of knee osteoarthritis. 
Arthritis Care Res (Hoboken ) 2010 
Nov;62(11):1527-32.
 (25)  Ledingham J, Regan M, Jones 
A, Doherty M. Factors affecting 
radiographic progression of knee 
osteoarthritis. Ann Rheum Dis 1995 
Jan;54(1):53-8.
Chapter 4
Repeated measurements of uCTX-II, sCOMP, sPIIANP, 
uCTX-I, and hsCRP as biomarkers of progression or efficacy 
of intervention 
Erlangga Yusuf1, Ingrid Meulenbelt2, 
Benno van El3, Marie-Pierre Hellio Le 
Graverand4, Jessica Bijsterbosch1, 
Evert J van Langelaan5, 
Frits R Rosendaal6, P. Eline Slagboom2, 
Tom W J Huizinga1, Margreet Kloppenburg1
From: 
1 Department of Rheumatology, 
Leiden University Medical Center (LUMC), 
Leiden, The Netherlands
2 Department of Molecular Epidemiology, 
LUMC
3 TNO Earth, Environmental and Life 
Sciences (EELS), Leiden, The Netherlands
4 Pfizer Inc, Primary Care, Groton, CT, USA
5 Department of Orthopaedic Surgery, 
Rijnland Hospital, Leiderdorp









































To investigate the association between repeated measurements of biomarkers: uCTX-
II, sCOMP, sPIIANP, uCTX-I and hsCRP, and radiographic progression of osteoarthritis 
(OA).
Methods
One hundred and twenty-five patients with OA at multiple sites (mean age 59.6 
years, 79% female) who participated in GARP (Genetics ARthrosis Progression) study 
were followed-up at 6-month, 1-year, 2-years, and 6-years. Time-integrated areas 
under the curve (AUCs) were selected to summarize longitudinal data. Radiographs 
of these patients were scored in two pairs: baseline and 2-years, baseline and 
6-years, using the OARSI atlas for joint space narrowing (JSN) of knee, hip and hand 
joints. We calculated the risk ratios (RRs with (95% CI)) of OA progression (defined as 
JSN score changes above smallest detectable change) at 2- and 6-years for patients 
in the second and third AUC tertile relative to the first AUC tertile of biomarkers. 
Adjustments were made for age and sex.
Results
Patients in the highest AUC tertile of uCTX-II at 6, 12 and 24 months had a RRs of 2.9 
(1.6 to 4.1), 1.8 (1.1 to 2.5) and 1.9 (1.1 to 2.7) to have OA progression at 2- years, 
respectively. Patients in the highest AUC tertile of uCTX-II at 6, 12 and 24 months had 
a RRs of 1.6 (1.1 to 2.0), 1.5 (0.9 to 1.9) and 1.8 (1.2 to 2.2) to have OA progression 
at 6-years, respectively. Other biomarkers were not associated with OA progression.
Conclusion
AUCs of uCTX-II are associated with progression of OA. The predictive power of 
uCTX-II levels at 0-6 months for OA progression at 2 years was highly promising and 
warrants further studies to investigate the value of this marker, that might also serve 







































Osteoarthritis (OA) is a slowly progressive disease. Due to this nature, an objective 
indicator (biomarker) of the OA disease process that could predict and measure the 
therapeutic response of drugs in OA is needed.1,2 As proposed by the Osteoarthritis 
Biomarkers Network, a biomarker could be categorized into Burden of disease, 
Investigative, Prognostic, Efficacy of intervention and Diagnostic (BIPED).3 
Compared to radiograph, there are several possible advantages in using biomarkers 
in the studies on OA. Firstly, biomarkers could be more sensitive to change in the 
disease process. For example, it is not necessary to wait until cumulative effect of 
cartilage damage is seen on radiographs to get an information about the actual OA 
state. Secondly, biomarkers may provide more information about tissues involved 
in OA.4 From imaging studies, it is now shown that OA is not merely a disorder 
characterized by cartilage loss 5 but also involve other tissues such as bone and 
synovium.6,7
Several biomarkers have been developed and studied for OA 8-10 and several remarks 
can be made on those studies. Firstly, published studies used mostly single-time 
measurement of the biomarker, while multiple measurements of biomarkers might 
be more informative. Secondly, most studies used knee and hip OA phenotypes 
separately, unaware of radiographic OA occurring in other sites such as the hand. 
Lastly, the studies were often performed in small study populations. 
Therefore, we investigated the association between repeated measurements of 
uCTX-II, sCOMP, sPIIANP, uCTX-I, and hsCRP and the progression of OA at multiple 
sites over 2 and 6 years. These biomarkers have been selected to represent three 
components: cartilage, bone and synovium.4 uCTX-II is a marker that was developed 
for measuring cartilage degradation, sCOMP for cartilage turnover, sPIIANP for 





































4.2. PATIENTS AND METHODS
4.2.1. Study design and patient population
Patients were participants of the Genetics, ARthrosis and Progression (GARP) study. 
GARP was a prospective cohort study that aimed at identifying determinants of 
OA susceptibility and progression. The recruitment criteria have been described 
elsewhere.11 Briefly, 192 Caucasian sib-pairs (aged 40 to 70 years) were included 
with symptomatic OA at multiple joint sites in the hands or OA in two or more of 
the following joint sites: hand, spine, knee, or hip. Patients were recruited from 
the rheumatologic, orthopedic and general practice clinics around Leiden, The 
Netherlands. Patients with secondary OA, familial syndromes with a clear Mendelian 
inheritance, and a short life expectancy (<1 yr) were excluded. 
Sib-pairs with at least one subject with knee or hip OA at baseline who were not in a 
radiological end stage (Kellgren and Lawrence score of 4, appendix C.1) were invited 
to attend 6-month, 1-year, 2-years, and 6-years follow up visit.11 At each follow-up 
visits, 125 patients were seen. Demographic data and data on joint replacement 
surgery of these 125 patients were obtained during every visit. The GARP study was 
approved by the Medical Ethics Committee of the Leiden University Medical Center.
4.2.2. Radiographs
Standardized protocols were used to obtain the radiographs of the knees (posterior-
anterior (PA); weight-bearing, non-fluoroscopic fixed-flexion protocol), hips (PA; 
weight-bearing) and hands (dorsal-volar) at baseline, at 2-years, and at 6-years. 
Baseline and radiographs at 2-years were analogue films and were digitized using a 
film digitizer at a resolution corresponding to a pixel size of 100 mu. Radiographs at 
6-years follow-up were obtained digitally.
Two experienced readers scored radiographs in two pairs: baseline and 2-years, 
baseline and 6-years using the Osteoarthritis Research Society International (OARSI) 
atlas (appendix C.2).12 The readers were blinded for patient characteristics. Joint 



































Repeated measurements of biomarkers and OA progression
79
4
(distal interphalangeal (DIP), proximal interphalangeal (PIP), first interphalangeal 
(IP-1), first carpometacarpal (CMC-1), metacarpophalangeal (MCP) and 
scaphotrapezotrapezoidal (STT) joints), leading to a sum score of JSN, ranging from 0 
to 114. Intraclass correlation coefficients (ICC) for intrareader reproducibility based 
on random samples of 20 radiographs at 2- and 6-years follow-up were very good (at 
least 0.88 in the tibiofemoral knee joints, 1.00 in the hips and 0.92 in the hands). New 
knee or hip prosthesis on radiograph was scored as having increase in JSN score of 1. 
4.2.3. Definition of progression
Progression was defined as difference between the sum of JSN’s at follow-up and 
at baseline above the smallest detectable change (SDC). SDC reflects change above 
measurement error.13 After calculating the SDC, increase in sum JSN score of ≥1 and 
≥2 at 2- and 6-years respectively, was defined as progression. 
4.2.4. Biochemical analysis
Serum and second void morning urine samples were collected from the study 
patients at baseline, at 6-months, at 1-year, 2-years and 6-years follow-up. All 
samples were stored within four hours at -80 °C until measurements of biomarkers 
were undertaken. Baseline biomarkers were measured by Synarc (Lyon, France) and 
the measurements at other time points were performed by TNO EELS (Leiden, The 
Netherlands). 
CTX-II in the urine (uCTX-II) was measured using an enzyme linked immunosorbent 
assay (ELISA) based on a monoclonal antibody raised against the EKGPDP linear 
6-amino acid epitope of the CII C-telopeptide (CartiLaps, Nordic Bioscience, Herlev, 
Denmark). Intra-assay and inter-assay variation (CV, %) was less than 9% and 
12%, respectively. The ICC for uCTX-II measurements in two different laboratories 
was excellent (0.97) based on the re-measurement of 18 baseline samples. The 
concentration of uCTX-II (in ng/liter) was standardized to the total urine creatinine 





































Serum COMP (sCOMP) was measured by a two-site immunoassay (COMP™ ELISA 
kit, AnaMar Medical, Lund, Sweden). Intra- and inter-assay CVs were below 7% and 
8%, respectively. The ICC for COMP measurements in two different laboratories was 
excellent (0.97).
sPIIANP was measured using a polyclonal antibody specific for the type IIA of the 
N-propeptide of type II collagen.4 Due to a very low ICC measurements in two 
laboratories, we only performed analysis on baseline and not on repeated data of 
sPIIANP.
uCTX-I was measured in the urine by the Crosslaps ELISA (Nordic Biosciences, Herlev, 
Denmark) that used a polyclonal antiserum raised against the β isomerized EKAH 
β DGGR sequence of the C-telopeptide of α1 chains of human type I collagen. 
Intra- and inter-assay CV were below 3% and 10 %, respectively. The ICC for uCTX-I 
measurements in two different laboratories was excellent (0.99).
High sensitivity CRP (hsCRP) was measured in the serum using ultrasensitive 
immunonephelometry method (N Latex CRP mono, Behringwerke, AG, Marburg, 
Germany) on a BNA Behring nephelometer. The intra- and inter-assay CVs were lower 
than 5%. The ICC for hsCRP measurements in two laboratories was 0.99.
4.2.5. Statistical analysis
To assess normality of their distributions and to visualize the course of biomarkers 
level within the group during the follow-up, we drew boxplots using GraphPad Prism 
(Graphpad Software Inc., La Jolla, USA). 
Generalized Estimating Equations (GEE) with robust variance estimators to account 
for family effect was used to calculate the β- regression coefficients for the association 
between the baseline biomarkers levels (independent variable) and the increase in 
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To incorporate measurements at multiple time-points, we calculated the area under 
the curve (AUC) baseline to 6-months follow-up (AUC 0-6), baseline to 1-year (AUC 
0-12), baseline to 2-year (AUC 0-24), and baseline to 6-year (AUC 0-72) using the 
formula which has been used previously in rheumatology research.14 For example, to 
calculate AUC uCTX-II 0-24: 
AUC uCTX-II (ng/mmol creatinine)*month) =
((uCTX-II at baseline + uCTX-II at 6 months)/2)*6 +((uCTX-II at 6 months + uCTX-II at 1 
year)/2)*6 + ((uCTX-II at 1 year + uCTX-II at 2 years)/2)*12.
Every AUC was calculated after excluding patients who received a joint prosthesis 
during that AUC follow-up. For example, a patient who received knee prosthesis after 
11 months follow-up was excluded for the calculation of AUC 0-12. Consequently, 
this patient was also excluded for analyses with AUC 0-24 and 0-72. This was done 
because the replaced joint did not contribute to the amount of measured biomarkers. 
To investigate the association between AUCs at different time points and OA 
progression, two types of statistical analyses were used. Firstly, mean difference (95% 
CI) in AUCs between patients with and without progression was estimated using GEE. 
Secondly, logistic regression analysis in GEE was used. In this analysis, patients were 
divided into their biomarkers AUC tertiles. Then, we calculated the odds ratio’s (ORs 
with 95% CI) of radiographic OA progression for participants in the second and third 
AUC tertiles relative to the first tertile. All ORs were transformed to risk ratio (RRs 
with 95% CI) using the approximation formula of Zhang because ORs of common 
outcomes in a fixed cohort are not a good approximation of RRs.15 
All analyses were performed on PASW Statistics 17 (SPSS Inc., Chicago, USA) and 
adjustment was made for age, sex, and BMI.
4.3. RESULTS
4.3.1. Study population
The characteristics of the 125 patients in the present study are shown in table 4.1. 





































During 2- and 6-years follow-up, 45 and 67 patients respectively showed radiographic 
OA progression. No patients received joint prosthesis during 6-months follow-
up. Between 6 and 12 months, between 12 months and 24 months, and between 
24 months and 72 months, one, five and 16 patients, received joint prosthesis, 
respectively. 
Table 4.1 Characteristics of the study sample (n=125).
Characteristics
Age, mean (SD) years 59.6 (6.9)
Female sex, % 99 (79)
Body Mass Index, mean (SD), kg/m2 26.7 (3.9)
Sites with osteoarthritis
     Knee
     Hip




Baseline level, mean (SD); median (IQR)
     uCTX-II, ng/ mmol creatinine 
     sCOMP, U/L
     sPIIANP, ng/ ml
     uCTXI, μg/ mmol creatinine
     hsCRP, mg/ L
266.2 (152.8); 229.7 (153.2 to 330.3)
11.5 (3.1); 11.3 (9.5 to 13.2)
219.5 (106.7); 182.7 (137.4 to 275.1)
178.1 (105.1); 154.8 (101.7 to 233.4)
3.3 (6.1); 1.7 (0.9 to 3.7)
4.3.2. The course of biomarkers level
The mean (SD) and median (IQR) of baseline levels of all biomarkers are presented in 
table 4.1. The course of biomarker levels over time is presented in figure 4.1.
4.3.3. Association between biomarkers levels at baseline and increase in JSN scores
At baseline, uCTX-II, sCOMP, and sPIIANP showed some correlation with age 
(respective Pearson’s correlations 0.2 (p-value=0.03), 0.2 (p-value=0.05), and 0.2 
(p-value=0.01). hsCRP and uCTX-I were not correlated with age. None of the baseline 
level of biomarkers differed across sexes. Although not significant, all baseline levels 
showed positive association with OA progression over 2 and/or 6 years, except for 
hsCRP over 6 years (table 4.2). None of the baseline biomarkers levels were associated 
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Figure 4.1 The course of the biomarkers level within the patient group during the follow-up 
presented using box-plots. The top and bottom of each box indicates the upper and the lower 
quartiles, and the thick black lines across the boxes represents the median of each group. 
Table 4.2 Mean difference in baseline levels and Area Under the Curve’s (AUC’s) between 
patients with OA progression and patients without OA progression. 
2-years progression 
(45 patients with vs. 80 
without progression)
6-years progression
(67 patients with vs. 58 
without progression)
uCTX-II
     baseline (ng/ mmol creat)
     AUC 6 month
     AUC 1 year
     AUC 2 years
     AUC 6 years
33.1 (-18.9 to 85.2)
183.3 (-90.3 to 457.0)
335.4 (-161.8 to 832.6)
864.1 (32.6 to 1760.8)‡
n.a.
32.9 (-24.6 to 90.4)
118.2 (-184.0 to 420.3)
145.3 (-409.5 to 700.0)
272.9 (-691.6 to 1237.4)
-867.6 (-6013.0 to 4277.9)





































4.3.4. Association between AUC’s of the biomarkers and 2-years OA progression.
AUCs (reflecting total change in biomarker level over time) were calculated over the 
follow-up time intervals in patients with and without progression over 2 years. Only 
AUC of uCTX-II was shown to be significantly higher (mean difference of 864.1 (95% 
CI 32.6 to 1760.8) in progressors of JSN over 2 years compared to non-progressors 
(table 4.2). The mean difference of other biomarkers that were not significant.
 
We explored the AUCs of uCTX-II (table 4.3). Patients with the highest AUC uCTX-
II at consecutive time-intervals had a significantly increased risk to have 2-years 
progression as compared to the lowest AUC tertile uCTX-II (table 4.3). Especially 
patients with the highest AUC levels of uCTX-II in the first 6 months after baseline 
had a significant risk increase (RR 2.9 (1.6 to 4.1)) to have progression at 2-years. 
Table 4.3 Associations between tertiles of Area Under the Curve’s (AUC’s) of biomarkers with 
2- and 6-years progression of OA.
Biomarkers 
in tertiles
Association with 2-years OA progression Association with 6-years OA progression
Number of 
patients




+ - + -
AUC uCTX-II ((ng/mmol creatinine) month)
0-6 (n=125)
     1st
     2nd








2.4 (1.2 to 3.6)‡








1.4 (0.8 to 1.9)
1.6 (1.1 to 2.0)‡
0-12 (n=124)
     1st
     2nd








1.7 (0.9 to 2.5)








1.2 (0.7 to 1.7)
1.5 (0.9 to 1.9)
0-24 (n=117)
     1st
     2nd








1.2 (0.5 to 2.1) 








1.2 (0.7 to 1.8)
1.8 (1.2 to 2.2)‡
0-72 (n=100)
     1st
     2nd








1.1 (0.6 to 1.6)
1.8 (0.8 to 1.8)
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4.3.5. Association between AUC’s of biomarkers and 6-years OA progression.
AUC of uCTX-II was not associated with 6-years progression (table 4.2). AUC´s of 
other biomarkers were also not associated with 6-years progression.
Examining uCTX-II further, we found that patients with the highest AUC uCTX-
II at consecutive time-intervals (up to AUC uCTX-II over 2-years) had a consistent 
increased risk to have progression after 6-years when compared with patient with 
the lowest AUC tertiles (table 4.3). For example patients in the highest uCTX-II tertiles 
of AUC 0-6 had an RRs (95% CI) of 1.6 (1.1 to 2.0) to have 6- years progression relative 
to patients in the lowest AUC tertile. 
4.3.6. Association between AUC over 6 years (0-72) with 6-years OA progression
The AUCs over 6 years (0-72) of uCTX-II were not associated with 6-years OA 
progression (table 4.3). 
4.4. DISCUSSION
The present study is the largest study investigating repeated measurements of 
biomarkers that might be involved in OA progression. While baseline levels of 
biomarkers are not informative for OA progression, multiple measurements of uCTX-
II (summarized as AUCs at various time points) are shown to be associated with 2- 
and 6-years OA progression.
The published studies on multiple measurements of biomarkers mostly used knee OA 
as phenotype. Direct comparison is therefore difficult since we also take into account 
other joints (hands and hips) that might have OA but do not come to attention in the 
other studies. Differences between our results and results from other studies could 
be explained by the difference in the presence of OA in the other joints; other joints 
could contribute to the measured biomarker. In our study the presence of OA in the 





































Our results showed the association between summary of multiple measurements of 
uCTX-II with OA progression and this is in line with several other studies. In a study 
of 62 knee OA patients (79% woman), it was shown that while baseline uCTX-II levels 
were not associated, an increase in uCTX-II over 3 months was associated with 1-year 
cartilage loss in the knee joints measured on MRI.8 In another study in 84 patients 
with OA, Sharif, et.al. showed that patients with biomarkers level above the median 
of the 5-years mean of uCTX-II levels had a RR of 3.4 (95% CI 1.2 to 9.4) to have knee 
OA progression.16 In the same study, patients in the highest quartile of the 5-years 
mean of sPIIANP levels had RR of 3.2 relative to patients in the lowest quartile, to 
have knee OA progression. Regarding sCOMP, our results differ with the results from 
a study in 115 knee OA patients.17 In that study, the mean AUC sCOMP (summary of 
measurements at baseline, 6, 12, 18, 24, 30, 36, 42, 48 and 60 months) was higher 
in patients with progression (n=37, of which 22 had total knee replacement) than 
without knee OA progression (n=78) during 5-year follow-up. Concerning uCTX-I and 
hsCRP, data are only available from studies using single measurement. Our results 
support the notion that uCTX-I is not associated with OA progression.8 Our study 
showing an indication of the association between CRP and 2-years OA progression is 
in line with several studies that showed the association between baseline hsCRP and 
incidence 18 and progression of OA.19
The consequence of our finding is that the AUC of uCTX-II could be tested in the 
clinical setting as a prognostic marker of OA progression since for example AUC 
uCTX-II of 6 months was shown to be associated with radiographic OA progression 
in mid- (2-years) and long- term (6 years). Another consequence is that uCTX-II could 
be used as a surrogate, or as an addition to radiograph to investigate the efficacy 
of intervention biomarkers. Potentially, it would lead to more sensitive detection of 
the effect of disease modifying anti osteoarthritic drugs, since the possible range of 
uCTX-II is broad. uCTX-II has indeed been used in several clinical studies. Garnero 
et. al. showed that uCTX-II decreased in knee OA patients who received risedronate 
and the level of decrease was related to the dose of risedronate.20 Finally, our study 
adds to the knowledge on cartilage pathophysiology in OA by suggesting that OA 
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and less associated with cartilage turnover (as measured as sPIIANP) or cartilage 
synthesis (as measured by sPIIANP). However the data are on the association with 
cartilage loss as seen on the radiograph, thus it is possible that JSN on radiograph 
do not reflect comprehensive cartilage defects in OA. It is also possible that other 
biomarkers such as uCTX-I and hsCRP are associated with other structure in the joint 
such as bone marrow lesion and synovium, structures that are not investigated in the 
present study.
Our study has several strengths. Firstly, we used a simple method to summarize the 
multiple biomarkers measurements instead of using complicated statistical method. 
Secondly, our study used a patient population. Practically, expensive prognostic tools 
in OA should concentrate on use in patient’s rather than in the general population.21 
Thirdly, we assessed the presence of OA at multiple sites. Arguably, OA often presents 
at multiples sites, where only the site with the most severe pain attracts attention. 
Biomarkers measured in body fluid originate from every joint and not only from knee 
or hip alone. However, using OA at multiple sites as a phenotype has drawbacks too, 
such as the summarization of the JSN scores and how to deal with joint replacement 
during the follow-up.17 In our study, having a joint prosthesis during follow-up was 
scored as increase in JSN score of 1. In a sensitivity analysis, where every patient 
who underwent a joint replacement during follow-up was defined as progression, no 
differences in effect sizes were seen (data are not shown).
In summary, AUCs uCTX-II were associated with the 2- and 6-years progression of 
OA. It is highly promising to use this biomarker as biomarker for prediction and to 
measure the efficacy of intervention.
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To investigate the association between weight or body mass index (BMI) and the 
development of hand osteoarthritis.
Methods
Systematic review of observational studies. Medical databases were searched up to 
April 2008. Articles that presented data on the association between weight and hand 
osteoarthritis were selected. The qualities of these studies were then assessed by 
two independent reviewers using a 19 criteria scoring system. Using the mean scores 
of all studies as a cut-off value, the studies were deemed as high or low quality. Study 
quality and study designs were combined to determine the level of evidence using 
best-evidence synthesis, which consisted of five levels of evidence.
Results 
From the 25 studies included, two had cohort, three case–control and 20 cross-
sectional study designs. Fifteen studies were considered high-quality studies. Of these 
high-quality studies, one cohort, two case–control and seven cross-sectional studies 
showed a positive association between weight or BMI and hand osteoarthritis. Based 
on three high-quality studies with preferred study designs (one cohort and two case–
control) with a positive association, the level of evidence of the association between 
overweight and developing hand osteoarthritis is moderate. The approximate risk 
ratio of this association is 1.9.
Conclusion 
Weight or BMI is associated with the development of hand osteoarthritis. The level 
of evidence of published studies is moderate according to best-evidence synthesis. 
Further high-quality cohort or case–control studies are needed to elucidate the role 







































Osteoarthritis is the most common joint disease. Its aetiology is largely unknown 
and no disease-modifying treatment exists.1 Overweight is recognised as a risk factor 
for developing knee osteoarthritis. Being overweight increases the mechanical 
forces across weight-bearing joints and leads to osteoarthritis.2 Whether this is the 
sole explanation is challenged by some studies that showed that overweight is also 
associated with osteoarthritis of non-weight-bearing joints, such as hand joints.
In a recommendation for the diagnosis of hand osteoarthritis by a task force of the 
European League Against Rheumatism, obesity was described as a risk factor for 
hand osteoarthritis.3 This was based on only four studies. However, in two narrative 
reviews 1,4 the association of overweight and hand osteoarthritis was inconsistent, 
but narrative reviews have some shortcomings such as the potential selective 
inclusion of papers without systematic quality assessment of selected studies.5 
Furthermore, since the latest narrative review, several new studies on this topic have 
been published. 
To summarize data on the association between weight and the development of hand 
osteoarthritis, which would give more insight into the etiology of osteoarthritis and 
give consideration as to whether prevention of overweight and losing weight could 
be a preventive treatment of hand osteoarthritis, we performed a systematic review 
of available studies.
5.2. MATERIALS AND METHODS
5.2.1. Identification of studies
Together with a medical librarian we searched medical databases up to April 2008 for 
studies with data on the association between weight or body mass index (BMI) and 
hand osteoarthritis. No language restriction was applied. Additional articles were 






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































5.2.2. Inclusion and exclusion criteria
Two reviewers, EY, a PhD student, and MK, a senior rheumatologist, independently 
read abstracts of all retrieved references for obvious exclusions and subsequently read 
the full text of remaining references. Studies with data on the association between 
weight or BMI and hand osteoarthritis, participants with clinical, radiographic or 
self-reported hand osteoarthritis, were included. Hand osteoarthritis was defined 
as involvement of at least one hand joint. Reviews, abstracts, letters to the editor, 
case reports, case series and studies investigating other musculoskeletal disease 
than osteoarthritis, were excluded. In the case of multiple publications of the same 
patient population, the publication with the largest study population was selected.
5.2.3. Data extraction
The following data were extracted: (i) study population (patient characteristics, 
population size, gender and age); (ii) exposure (weight (kg) or BMI (kg/m2) or 
other methods); (iii) outcome (methods of assessment of hand osteoarthritis, 
reproducibility, blinding); (iv) potential confounders (age, gender, smoking, hormone 
therapy, workload) and (v) association size (relative risk (RR) or odds ratio (OR)).
5.2.4. Assessment of study quality
The same reviewers independently evaluated the quality of the studies using 19 
criteria based on previous systematic reviews in the area of musculoskeletal disorders 
6,7 with a modification to evaluate studies on the association between weight and 
hand osteoarthritis (table 5.1). When the criterion was met in the article, ‘1’ was 
given, otherwise ‘0’. A ‘0’ was also given when no information was given about the 
specific criterion mentioned in the article. Differences were solved by discussion. 
Maximum scores obtainable were 16 for cohort and case–control studies and 13 for 
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5.2.5. Rating the level of evidence
We generated a Forest plot and summarised the evidence using the best-evidence 
synthesis based on the guidelines on systematic review of the Cochrane Collaboration 
Back Review Group.8 This system is a method to summarise evidence in observational 
studies in which the study population, the assessment of exposure and outcomes 
and the data analyses are heterogenic.7 It has five levels of evidence (table 5.2). It 
puts more weight on studies with a prospective cohort design in which exposure 
truly precedes outcomes. The next preferred designs are case–control and cross-
sectional, respectively.
The mean of the quality scores of all studies was used to classify studies as high or 
low quality.
Table 5.2 Best-evidence synthesis used in this review.8
Strong General consistent findings were presented in multiple high-quality cohort 
studies.
Moderate One high-quality cohort study and at least two high-quality case-control 
studies, or when at least three high-quality case-control studies show 
general consistent findings.
Limited General consistent findings were found in a single cohort study, or in 
maximum two case-control studies, or in multiple cross-sectional studies.
Conflicting Less than 75% of the studies reported consistent findings.
No evidence No study could be found.
5.2.6. Publication bias
Publication bias was investigated by generating a funnel plot. The association size of 
weight or BMI and developing hand osteoarthritis on the horizontal axis was plotted 
against study population size on the vertical axis. Asymmetry in the funnel plot 







































From 472 identified references 27 were selected based on inclusion and exclusion 
criteria (figure 5.1).10-36 An additional search resulted in another six articles.37-42 Seven 
articles were excluded 11,17,25,27,32,35,41 as a result of overlap in the study population. 
One study was represented by two publications, 20,21 further referred to as reference 
20. In total, 25 studies were included: two cohort, 13,36 one case–control 30 and 20 
cross- sectional studies.10,12,15,16,18-20,22-24,26,28,31,33,34,37-40,42 Two studies 14,29 resembled a 
case–control design.
Identified references,
titles and abstracts reviewed
472
Possibly relevant references,
full text articles obtained
41
Full text articles fullfiled in-
and exclusion criteria
27
No original data or
not relevant
14
Full text articles excluded





Full text articles fullfilled in- and
exclusion criteria after hand search
6
Full text articles excluded
due to multiple publications
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5.3.2. Characteristics of included studies
The characteristics of the included studies can be seen in table 5.3. Eight studies
investigated only women 13,14,18,23,30,34,37,38 and one 22 only men.
Hand osteoarthritis was diagnosed using radiographic criteria in 21 studies 12-16,18,20,22-
24,26,28,30,33,34,36-40,42 ; 18 of them used radiographic criteria only and three 18,30,39 used 
radiographic and clinical criteria. Clinical criteria only were used in two studies; 10,31 one 
of them 10 used the American College of Rheumatism criteria for hand osteoarthritis. 
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5.3.3. Study quality assessment
The two reviewers agreed on 305 (90%) of 340 criteria. The disagreements
were solved in a single meeting and mostly concerned the assessment of hand 
osteoarthritis (criteria 9 and 10). The mean of quality scores was 63%.
The participation rates in most studies were lower than 80% (criterion 5). One cohort 
study had limitations in the assessment of hand osteoarthritis (criteria 9 and 10) 
and the follow-up (criteria 14 and 15). Two case–control studies had limitations in 
the assessment of hand osteoarthritis (criterion 10). Moreover, two of three case–
control studies had potential selection bias, being sampling bias (items 2 and 5). This 
bias was also commonly seen in cross-sectional studies.
5.3.4. Associations shown in included studies
Hand osteoarthritis in at least one joint showed a statistically significant positive 
association with weight in 16 of 25 (64%) studies.12-16,18,20,26,30,31,33,34,37,38,40,42 The other 
nine studies showed a non-significant or no association. Fourteen of 25 studies 
10,13,14,16,18-20,24,28,30,31,34,36,39 presented association sizes as OR and RR values (figure 5.2) 
giving an estimated pooled risk ratio of 1.9 for the positive association between 
(over)weight and the development of hand osteoarthritis. Three 15,31,37 of these 16 
studies showed a significant positive association in one gender, but a non-significant 





































Figure 5.2 Forest plot showing the association sizes (odds ratios (OR) or relative risks (RR)) 
between (over)weight or body mass index (BMI) with hand osteoarthritis of the studies 
included, arranged by study design and quality scores (from high to low). The numbers in 
parentheses represent the references. n represents number of study population. For 
information on the actual association sizes concerning used hand osteoarthritis phenotype 
and BMI category see table 5.3. Studies labeled with an asterisk are those that presented OR 
or RR as an increase per unit BMI.
Six of nine studies 12,14-16,18,24,39,40,42 investigating distal interphalangeal joints, two of 
eight 12,14-16,36,39,40,42 studies investigating proximal interphalangeal joints, one of four 
studies 12,22,40,42 investigating metacarpophalangeal joints and four of 12 studies 
12,14-16,20,24,28,33,36,39,40,42 investigating first carpometacarpal joints showed a positive 
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5.3.5. Levels of evidence
The level of evidence for a positive association between weight or BMI and hand 
osteoarthritis is moderate. Fifteen of 25 included studies 10,13-16,18,20,24,28,30,31,34,36,39,42 
were considered to be of high quality. Of two high-quality cohort studies 13,36 one 13 
showed an RR of 3.12 (1.65 to 5.88); the second showed no association.
Both high-quality case–control studies 14,30 reported a positive significant association, 
with an OR of 1.30 (1.06 to 1.59)14 and 8.3 (1.2 to 56.5).30 Of 11 10,15,16,18,20,24,28,31,34,39,4
2 high-quality cross-sectional studies, seven studies 15,16,18,20,31,34,42 reported a positive 
association.
In a subgroup of studies that used radiographic criteria with or without clinical 
criteria for hand osteoarthritis, 13 of 21 studies were deemed to be high quality. 
Ten 13-16,18,20,30,31,34,42 of these 13 studies showed a positive association and the level of 
evidence remained moderate. In the subgroup of studies using radiographic criteria 
only (18 studies; of which 10 were high quality), seven 13-16,20,34,42 studies showed a 
positive association, but because of the lack of a sufficient number of high-quality 
cohort (only one study) and case–control (only one study) studies, the level was 
limited. The subgroup of clinical studies 10,31 showed conflicting levels of evidence.
Using alternative cut-offs for methodological quality assessment (median or 25th 
percentile) did not change the results. When using the 75th percentile as the cut-off, 
few studies were retained, leading to limited level of evidence.
5.3.6. Publication bias
We plotted the association sizes (OR and RR) against the sample sizes of 14 studies to 





































Figure 5.3 Funnel plot showing the relationship between association sizes (odds ratios (OR) 
or relative risks (RR)) and sample size. The numbers represent the references of the studies. 
When studies presented multiple association sizes, the largest RR or OR concerning a cut-off 
at body mass index (BMI) 25 kg/m2 was denoted. If this information was not available, the 
association size of a cut-off at a higher BMI level was used. Preferentially, association sizes for 
radiographic hand osteoarthritis and for men and women combined were presented.
5.4. DISCUSSION
This systematic review showed that the evidence for a positive association between 
weight or BMI and hand osteoarthritis is moderate. This conclusion is based on three 
high-quality studies with preferred study designs. A moderate level of evidence did
not change for the subgroup of studies investigating hand osteoarthritis using 
radiographic criteria. When no best-evidence synthesis was performed, a pooled risk 
ratio was approximately 1.9, in which 64% of published studies showed a positive 
association between (over)weight and hand osteoarthritis. 
The strength of a systematic review is the use of a focused research question, 
an extended search strategy and a predefined system to evaluate the quality of 
evidence. Here, we also use qualitative levels of evidence to give a conclusion when 
a summary of quantity statistic was not appropriate. Yet, this systematic review has 



































Systematic review: overweight and hand OA
109
5
The first caveat is the heterogeneities in multiple aspects of the studies, such as the 
definition of BMI, hand osteoarthritis and study population. Studies categorised BMI 
in various ways, mainly based on the distribution of the study population, such as 
tertiles and median or BMI as a continuous variable. Preferentially, the cutoff of BMI 
is 25 kg/m2, as the World Health Organization definition for overweight could be 
used.43 However, this was the case in only a minority of studies. Included studies also 
defined hand osteoarthritis in various ways, using radiographic and clinical criteria. 
Subgroup analysis of studies that used radiography to make a diagnosis of hand 
osteoarthritis, however, did not change the level of evidence. The level of evidence 
became conflicting when we performed a subgroup analysis in only two studies 
defining hand osteoarthritis using clinical criteria. The lack of clinical studies might 
reflect the available evidence, which suggests that radiography is a better method of 
defining hand osteoarthritis in epidemiology studies.4 Another heterogeneity that 
should be mentioned here is the study population. Although most studies used a 
mixed sex population, a third of the included studies concerned only women. These 
heterogeneities lead to difficulties in comparing studies and in summarizing studies 
quantitatively. The second caveat of this review is the possibility of publication bias. 
However, when we examine the funnel plot carefully, the asymmetry is caused by one 
study with a large effect.30 That study also differs from other studies in that it used 
hand osteoarthritis based on clinical criteria supported by radiographic findings. The 
third caveat of this review is that theoretically the criteria we used can influence the 
outcomes of the review. We used and modified criteria that were previously used in 
systematic reviews of the musculoskeletal field, because no generally accepted set of 
criteria exist for methodological quality assessment in observational studies.
The consequence of the moderate level of evidence of an association is that further 
research is likely to have an important impact.44 Therefore, future studies, especially 
well-designed prospective cohort or case–control studies, are called for, which 
should also investigate the aetiological mechanisms of the association and temporal 





































The pathogenesis of osteoarthritis is largely unknown and no disease-modifying 
treatment exists, therefore knowledge of the role of overweight in hand osteoarthritis 
is of importance for understanding and treating (hand) osteoarthritis. The association 
between overweight and hand osteoarthritis suggests that factors other than 
mechanical forces also play a role. Some possible links between overweight and 
osteoarthritis have been proposed, such as metabolic alteration, atherosclerosis and 
diabetes mellitus.45 Fat tissues secrete pro and anti-inflammatory adipo(cyto)kines, 
such as leptin, which was observed in synovial fluid obtained from osteoarthritic 
joints.46 The concentration of leptin in advanced osteoarthritic cartilage is significantly 
correlated with the BMI of the patients, and its level and pattern of expression were 
related to the grade of cartilage destruction. Obesity-associated atherosclerosis can 
also accelerated the osteoarthritis process by vascular disease in subchondral bone.47 
Finally, in diabetes mellitus, advanced glycation end-products (AGE) are formed and 
accumulated. AGE cross-links the damaged collagen network and leads to cartilage 
changes associated with osteoarthritis. This AGE formation is initiated by sugars and 
by lipids.48
In summary, this is the first systematic review to investigate the association between 
weight and BMI and hand osteoarthritis. The association is positive and the level of 
evidence is moderate. This calls for well-designed studies that further estimate the 
association as well as its underlying mechanisms.
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To investigate the association between baseline serum adipokines levels—leptin, 
adiponectin and resistin—and long-term progression of hand osteoarthritis (HOA).
Methods 
Baseline and 6-year radiographs of 164 patients (mean age 60 years, 81% women) 
with HOA (defined as a Kellgren and Lawrence score ≥2 in at least two hand joints) 
were assessed for joint space narrowing (JSN) in 32 hand joints using the Osteoarthritis 
Research Society International atlas. Progression was defined as a change in the sum 
of the JSN score above the smallest detectable change of 2, reflecting change above 
measurement error. Serum adipokines were measured at baseline and patients were 
categorised by adipokine tertiles. RRs (and 95% CI) of HOA progression for patients 
in the second and third tertiles were calculated relative to the first tertile, using 
generalised estimating equations. Adjustments were made for age, sex and body 
mass index.
Results 
Patients in the two highest tertiles of adiponectin had a decreased risk of 70% (RR=0.3 
(0.2 to 0.7)) for HOA progression in comparison with patients in the lowest tertile. 
Leptin and resistin levels were not associated with progression.
Conclusion 







































Obesity is a well-known risk factor for osteoarthritis (OA).1 The link between being 
overweight and OA may be explained by the increased joint stress accompanying 
obesity. However, the mechanical burden does not explain the observation that 
being obese is also associated with OA of non-weight bearing joints such as hand 
joints.2 This observation suggests that systemic factors associated with obesity play a 
role in the pathophysiology of OA.3 
Leptin, adiponectin and resistin are among the systemic factors implicated in obesity. 
These adipokines are produced by adipocytes but may also be synthesised at other 
sites.4,5 Adipokines are involved in a wide range of physiological processes in the 
human body, including immunity, bone mass function and glucose homoeostasis.4,6 
In OA, studies on the role of adipokines are emerging. However, data mostly originate 
from experimental or cross-sectional studies which use knee OA as phenotype.3 
Arguably, knee OA is less suitable for studies on metabolic factors associated with 
obesity in OA because the knee is also influenced by mechanical force associated 
with obesity. 
Therefore, it is difficult to differentiate between metabolic and mechanical factors in 
obese subjects. Therefore, we investigated the association between baseline serum 
levels of leptin, adiponectin and resistin and radiographic progression of hand OA 
over 6 years.
6.2. PATIENTS AND METHODS
6.2.1. Study design and patient population
The study was conducted in 248 participants of the Genetics, ARthrosis and 
Progression (GARP) study with hand OA. The GARP study included 192 Caucasian 
sib pairs (aged 40 to 70 years) from primary or secondary care; all had symptomatic 
OA at multiple joint sites in the hands or in two or more of the following joint sites: 





































Lawrence score ≥2 (appendix C.1) in at least two hand joints. The GARP study was 
approved by the medical ethics committee of the Leiden University Medical Center.
6.2.2. Radiographs and definition of progression
Standardised protocols were used to obtain the radiographs of hands (dorsal-volar) 
at baseline (August 2000 to March 2003) and at follow-up (April 2007 to June 2008).
Two experienced readers (EY, JB) who were blinded for patient characteristics 
scored the radiographs paired in chronological order by using the Osteoarthritis 
Research Society International (OARSI) atlas (appendix C.2).8 Joint space narrowing 
(JSN) was graded 0 to 3 in 32 joints of both hands: distal interphalangeal, proximal 
interphalangeal, first interphalangeal, first carpometacarpal, metacarpophalangeal 
and scaphotrapezotrapezoidal joints, leading to a sum score of JSN, ranging from 0 
to 96. The intraclass correlation coefficient for intrareader reproducibility based on 
a random sample of 25 radiographs was very good: 0.87. Progression was defined as 
the difference between the sum of the JSN scores at follow-up and at baseline above 
the smallest detectable change (SDC). The SDC reflects change above measurement 
error.9 We chose JSN as the outcome since it reflects articular cartilage damage.10 
Since the SDC was 1.5, a JSN score change ≥2 was defined as progression.
6.2.3. Assays
Baseline serum adipokine concentration was measured using the Bio-Plex Pro Human 
Diabetes kit (Bio-Rad, Hercules, CA, USA), the Bio-Plex array reader and Bio-Plex 
software, following the manufacturer’s instruction. The intra-assay and interassay 
variations for leptin are 3% and 4%, respectively; for adiponectin 4% and 2% and for 
resistin 3% and 4%. All blood samples were obtained in the morning.
6.2.4. Statistical analysis
All analysis was performed using PASW Statistics 17 (SPSS Inc, Chicago, Illinois, USA). 
Means (SD) were used to describe baseline characteristics. The association between 
body mass index (BMI) and progression of hand OA was evaluated using logistic 
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BMI and adipokines were evaluated using Pearson’s correlation coefficient (with p 
values). 
The geometric mean difference (95% CI) in adipokine levels between patients with 
and without progression was estimated using generalised estimating equations with 
robust variance estimators to account for family effects and corrected for age, sex 
and BMI. Geometric mean was calculated because in this analysis, the adipokine 
levels were log-transformed owing to the skewed distributions. 
In the absence of established cut-off points and in order to retain adequate statistical 
power, we categorised patients by adipokine tertiles. ORs of hand OA progression for 
patients in the second and third tertiles were calculated relative to the first tertile, 
using generalised estimating equations. ORs were subsequently transformed to 
RRs (95% CI) because ORs for common outcomes in a fixed cohort are not a good 
approximations of RRs.11 Adjustments were made for age, sex and BMI. RRs >1 
indicate a higher risk for progression.
6.3. RESULTS
6.3.1. Study population
Of the 248 patients with hand OA, 208 (83.9%) gave consent for follow-up. Nine 
patients had died and 31 did not give consent. The most common reasons for lack of 
consent were loss of interest, health problems not related to OA and unavailability 
of transport. From patients who gave consent, complete radiographs at baseline and 
follow-up were available from 164 patients. 
The mean follow-up time was 6.0 years (SD 0.6 years). Baseline characteristics are 
shown in table 6.1. Patients without complete radiographs were somewhat older. 
Other demographic and disease characteristics did not differ between these groups 





































Fifty-five of the 164 patients showed progression of hand OA. BMI was not 
associated with progression (OR=1.003 (95% CI 0.9 to 1.1)). Leptin, adiponectin and 
resistin levels did not correlate with each other. BMI was positively correlated with 
leptin (Pearson’s correlation coefficient: 0.3, p=0.00) and resistin (0.2, p=0.04), and 
negatively correlated with adiponectin (−0.2, p= 0.005).
Table 6.1 Baseline characteristics (n=164).
Characteristics
Mean age, years (SD)
Number of female, %
Mean BMI, kg/m2 (SD)
Number of patients with Osteoarthritis on other sites1 (%)
    Knee
    Hip
Mean baseline serum level (SD)
    Leptin, ng/mL
    Adiponectin, μg/mL









1 defined on radiograph as knee or hip with Kellgren and Lawrence score.
6.3.2. Association between adipokines and hand OA progression
The mean leptin level in patients with hand OA progression was slightly higher 
than in patients without progression: 3.0 ng/ ml (95% CI −0.3 to 6.3), p=0.08. The 
mean adiponectin level was significantly lower (−6.0 μg/ml (−11.3 to −0.8), p=0.02) 
in patients with progression compared with those without progression. The mean 
resistin levels did not differ across hand OA progression groups: −0.04 ng/ml (−0.3 
to 0.2), p=0.8. 
After adjusting for age, sex and BMI, patients in two highest tertiles of adiponectin 
had a 70% decrease in risk (RR (95% CI) 0.3 (0.2 to 0.7)) for hand OA progression in 
comparisonto patients in the lowest tertile (table 6.2). The RRs were similar when 
leptin and resistin levels were added to the model. Leptin and resistin levels were 
not associated with progression. Patients in the highest tertile of leptin and resistin 
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Table 6.2 The association between adipokines and progression of hand osteoarthritis. 
Serum level of 
adipokines
Number of patients Crude RR 
(95% CI)
RR after adjusting 









   < 4.4
   4.4 to 8.2
   > 8.2
Adiponectin (μg/mL)
   < 16.6
   16.6 to 28.4
   > 28.4
Resistin (ng/mL)
   < 0.8
   0.8 to 1.4




















0.9 (0.4 to 1.5)
1.2 (0.7 to 1.9)
1 (reference)
0.3 (0.1 to 0.6)‡
0.3 (0.1 to 0.6)‡
1 (reference)
0.9 (0.5 to 1.5)
0.9 (0.4 to 1.5)
1 (reference)
0.8 (0.4 to 1.4)
1.1 (0.5 to 1.9)
1 (reference)
0.3 (0.2 to 0.7)‡
0.3 (0.2 to 0.7)‡
1 (reference)
0.9 (0.5 to 1.5)
0.8 (0.3 to 1.4)
6.4. DISCUSSION
As far as we know, this is the first report that shows that a higher level of adiponectin 
is associated with a lower risk for hand OA progression. Adiponectin appears to be 
protective against cartilage damage. The other adipokines we investigated showed 
no association with hand OA progression. 
Our result differs from the only other clinical study investigating adiponectin and 
hand OA, where it was shown that the mean serum level of adiponectin was higher 
in 48 women with, than in 27 women without, erosive hand OA in a cross-sectional 
analysis.12 The discrepancy might be caused by the difference in the research 
questions, in case definitions and in study designs. In a cross-sectional study, it is 
not possible to draw any conclusion about causation. Our result is also contradictory 
to the result from a study in patients with rheumatoid arthritis (RA), where higher 
adiponectin levels were shown to be associated with more radiographic damage 
in a cross-sectional analysis.13 This difference can be explained by the difference 
in the radiological scoring system, where in RA bone erosion was assessed next to 
JSN. Moreover, the difference might also caused by the difference in the underlying 





































The mechanisms that may explain the protective role of adiponectin may be direct 
and indirect. A possible direct mechanism is the induction of tissue inhibitor of 
metalloproteinase-2, which consequently reduced the cartilage defect induced 
by matrix metalloproteinase.14 A putative indirect mechanism is by mediation of 
atherosclerosis. It is speculated that atherosclerotic plaques might obstruct the 
subchondral vasculature and subsequently impair cartilage nutrition, leading to 
its deterioration.15 Since adiponectin is protective against atherosclerosis, 16 the 
presence of a high level of adiponectin might prevent cartilage deterioration. 
Our results showed no association between leptin and resistin levels and hand 
OA progression. Filkova and colleagues also showed previously that there was no 
difference in serum level of resistin between patients with and without erosive hand 
OA.12 The association between leptin levels and hand OA, to our knowledge has not 
been investigated previously. Experimental data on the role of leptin on cartilage 
are also inconclusive. Catabolic 4,17 and anabolic 18 effects have been reported. In our 
study, the effect of adiponectin on hand OA progression remains after adjustment 
for BMI, and BMI itself is not associated with progression. This is not surprising if 
we consider that BMI is simply an algorithm of the weight of a person corrected for 
height. It does not differentiate total body fat from lean body mass.19 BMI might be 
not as informative as measurement of fat tissue products in evaluating the effect of 
fat tissue.
In conclusion, our findings might provide insight into the potential importance of 
adiponectin in OA. Although our results should first be confirmed in other studies, 
they indicate that adiponectin is an attractive target for prevention of hand OA 
progression since adiponectin levels can be increased through pharmaceutical and 
lifestyle intervention.5
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To investigate: (i) the association between body mass index (BMI) and pain, (ii) the 
role of radiographic severity on this association, and (iii) the association between 
BMI and indication to perform total hip (THR) or knee replacement (TKR). 
Methods
Cross-sectional study on 632 and 870 patients with hip and knee OA who visited 
orthopedic surgeons in 11 countries. Two types of self-reported pain were used: pain 
with activity (WOMAC pain subscale) and pain experience (ICOAP). Recommendation 
for THR/ TKR was defined by the surgeon. Association between BMI and pain 
index were investigated using linear regression. The role of radiographic severity 
was analyzed using method of Baron and Kenny. The odds ratios (ORs) with (95% 
confidence interval) for having indication for THR/ TKR were calculated for BMI 
categories: overweight, obese and very obese relative to normal BMI category using 
logistic regression analysis. All analyses were adjusted for age and sex in knee and 
hip OA population.
Results
The mean age, BMI (SD) and percentage of women in hip OA population were: 65 (12) 
years, 28 (5) kg/m2, and 56%. These numbers were: 68 (10) years and 31 (7) kg/m2 
and 8% in knee OA. In hip OA participants, beta-regression coefficient with WOMAC 
and ICOAP respectively were the same: 0.5 (0.2 to 0.9). In knee OA, beta-regression 
coefficient with WOMAC was 0.5 (0.3 to 0.7) and with ICOAP pain (0.1 (-0.1 to 0.4)). 
Radiographic severity acts as mediator in the association between obesity and pain 
in knee but not in hip OA. ORs of having TJR indication for obese compared with 
normal weight patients for hip and knee OA were respectively 1.8 (1.03 to 3.2) and 
2.3 (1.4 to 3.7).
Conclusion
BMI is associated with pain and TJR. The effect of BMI pain differs in hip and in knee 








































Patients with OA seek medical attention mostly because of pain.1,2 In OA, pain and 
structural damage are not always concordant.2 Some patients with severe pain have 
only mild joint space narrowing (JSN) or osteophytes while many others with mild 
pain have extensive signs of OA on radiograph.3 OA patients are often obese.4,5 
Obesity, measured as Body Mass Index (BMI) has been shown to be associated with 
structural incidence and progression of OA, mainly for knee OA.4 Whether obesity is 
also associated with joint pain itself, is less known.
In several diseases such as: chronic pain, fibromyalgia, abdominal pain and migraine, 
obesity has been shown to be linked with pain.6 It is reasonable to think that obesity 
could also cause joint pain in OA. This can happen through the increased weight-
bearing effect on already damage OA joint such as knee. Alternatively, this happens 
independent of structural damage associated with OA. To investigate the effect of 
obesity on pain in OA, hip and knee OA can be compared since hip is considered as 
less weight-bearing than the knee joint.7 If the difference in the effect of BMI on pain 
in knee and hip OA patients indeed exists, it will lead to more insight in the etiology 
of pain in OA and could also have consequence in treatment aimed at reducing pain 
in knee and hip OA.
The joint damage in OA could eventually progress into total joint failure needing joint 
prosthesis. Several studies have investigated the association between obesity and 
total joint replacement (TJR).8-11 In these studies, joint replacements were defined 
as the actual performed surgery. However, performance of total joint replacement 
(TJR) is influenced by numerous non-health related factors such as patient race, 
ethnicity, income and non-musculoskeletal health factors such as co-morbidity.12 
Another remark is that in these studies, severe obesity (i.e. BMI larger than 35 kg/
m2) is not studied separately from obesity patients (i.e. BMI larger than 30 kg/ m2). 
Yet, in clinical practice, it is still the matter of debate whether severe obesity is a 
contraindication to TJR. A better alternative in defining joint failure in OA would be 





































association of severe obesity with TJR should be investigated too. To our knowledge, 
no studies have investigated the association between obesity and indication for TJR.
This study had several aims. Firstly, to investigate the association between obesity 
and pain level in knee and hip OA. We used two types of self-reported pain scores: 
pain on activity (as measured with WOMAC pain subscale (appendix B.1)) and pain 
experience (as measured with ICOAP score (appendix B.2 and B.3)). Secondly to 
investigate in which way structural damage influences this association. Thirdly, to 
investigate the association between BMI and the indication for TJR.
7.2. PATIENTS AND METHODS 
7.2.1. Study design and subjects 
The present study was a part of an observational cross-sectional study conducted 
by OARSI-OMERACT Task Force on total joint replacement in the orthopaedics 
departments of tertiary-care and secondary-care centers in 11 countries (12 centers, 
one per country in the Czech Republic, Italy, Spain, Sweden, and the United Kingdom; 
two per country in France and The Netherlands; three in Germany), Canada (two 
centers), the United States of America (two centers), and Australia (two centers). 
The main aim of the task force was to elaborate a set of criteria in defining a non-
acceptable symptom and structural state in knee/hip OA that could be used as an 
endpoint in clinical trials evaluating potential disease modifying drugs in OA.12,13 
Ethical approval was obtained from all participating centers.
Participant inclusion and exclusion criteria have been described in detail elsewhere.12 
In short, consecutive patients with knee or hip OA, who consulted an orthopedic 
surgeon to discuss the possibility of a joint replacement, were included. The 
diagnosis of OA was made by the consulted surgeon based on clinical judgment 
and the presence of radiographic signs of OA. Only patients for whom the surgeon 
answered ‘There are definite radiographic signs of OA of the target joint’ were 
included. Excluded were patients with prior joint replacement or prior osteotomy in 
the target joint, patients with concomitant inflammatory joint disease and patients 
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7.2.2. Demographic data 
Demographic data (i.e. age, sex, height and weight) were collected using standardized 
questionnaires. BMI was calculated as weight (in kilograms) divided by the square of 
height (in meters). Complete demographic data were available from 632 and 870 
patients with hip and knee OA, respectively.
7.2.3. Pain assessment
Self-reported pain was assessed using the intermittent and constant osteoarthritis 
pain (ICOAP) score (appendix B.2 and B.3).14 It assessed continuous pain (five items) 
and pain that comes and goes (six items). The ICOAP questionnaire had previously 
undergone translation and cross-cultural adaptation into each of the participating 
countries languages.15 In addition, self-reported pain (five items) was evaluated by 
using the Western Ontario and McMaster Universities Osteoarthritis (WOMAC) Index 
(appendix B.1)16 The ICOAP and WOMAC pain subscale were assessed with Likert 
response options and transformed to 0 to 100 score, where higher scores indicated 
greater pain.
7.2.4. Indication for TJR
Indication for TJR was defined by the orthopedic surgeon’s opinion, stating that: 
(i) TJR was recommended for the patient; or (ii) the patient’s pain and functional 
disability were severe enough to indicate TJR but surgery was not indicated because 
of comorbidity or patient declining surgery. This was irrespective of whether the TJR 
was performed or not. 
7.2.5. Radiographic severity
The local investigator assessed the joint space narrowing (JSN) of the knees or the 
hips. The JSN was categorized as: none, < 25%, 25 to 50%, > 75%. Only JSN data 
for 418 knees and 322 hips were available since not all centers participated in the 





































7.2.6. Statistical analysis 
Data were analyzed using PASW Statistics 17 (SPSS Inc., Chicago, Ill, USA). Means with 
standard deviation (SD) were used to describe the hip and knee study population. 
Distributions of patient characteristics were evaluated for the presence of marked 
deviation from normal distribution. All analyses described below were performed 
separately in hip and knee OA population and adjusted for age and sex. An association 
was considered significant when p<0.05.
To investigate the association between BMI and pain scores, linear regression analysis 
was used to calculate the beta-regression coefficients with its 95% confidence 
interval (CI). 
To investigate whether structural damage (JSN) acts as mediator in the association 
between BMI and pain, the method described by Baron and Kenny to asses 
mediation was used.17 This method described that to be determined as a mediator, 
a variable (in this case radiographic severity measured as JSN) needs to meet all the 
following conditions: (i) independent variable (in this case BMI) was associated with 
presumed mediator (JSN), (ii) presumed mediator (JSN) is associated with dependent 
variable (in this case pain), and (iii) when the association between BMI and pain 
was controlled for JSN, the previous significant association between BMI and pain 
became not significant. 
  
To investigate the association between BMI and indication for joint replacement, 
BMI was first categorized into four categories: < 25 (normal, referent), 25 to 30 
(overweight), 30 to 35 (obese) and > 35 kg/m2 (very obese). Patients with BMI > 30 
kg/m2 were divided into obese and very obese to examine dose-response relationship 
and to examine whether very obese patients were less likely to have TJR. The odds 
ratios (ORs) of total hip replacement (THR) or total knee replacement (TKR) with 







































7.3.1. Characteristic of the study population
The mean age (SD) and BMI (SD) of the study population with hip OA (n=632) were 
65 (12) years and 28 (5) kg/m2, respectively; 56% were women. The mean age (SD) 
and BMI (SD) of the study population with knee OA (n=870) were 68 (10) years and 
31 (7) kg/m2, respectively; 58% were women (table 7.1). Study population with hip 
OA had slightly higher scores of WOMAC pain and ICOAP than study population with 
knee OA. In both populations, both scores were normally distributed.
Table 7.1 Characteristics of study population. 
Hip OA (n=632) Knee OA (n=870)





















Mean BMI, kg/m2 
Pain scores
   WOMAC pain subscale
   ICOAP
Radiographic scores, n (%)*
   None
   < 25%
   25 to 50%
   50 to 75%
   > 75%
Abbreviations: TKR: total knee replacement, THR: total hip replacement, n=number of study 
population.
Results are presented as mean (standard deviation) unless otherwise mentioned. 
* of available data (417 for the knee and 322 for the hip).
7.3.2. Association between BMI and pain scores 
In hip OA participants, BMI was positively associated with both pain measures before 
and after additional adjustment for radiographic severity. Adjusting for age and sex, 
the beta-regression coefficients for the association between BMI and WOMAC pain 
and ICOAP were the same: 0.5 (0.2 to 0.9). Adjusting for age, sex, and radiographic 
severity the beta-regression coefficients for the association between BMI and 





































In the study population with knee OA, BMI was associated with WOMAC pain 
subscale (beta-regression coefficient: 0.5 (0.3 to 0.7) but not with ICOAP pain (beta-
regression coefficient 0.1 (-0.1 to 0.4)). After further adjustment for radiographic 
severity, this association between BMI with WOMAC pain was no longer significant 
(beta-regression coefficient was 0.3 (-0.1 to 0.7). 
7.3.3. Investigating radiographic scores as a possible mediator in the association 
between BMI and pain score
In hip OA population, radiographic severity, measured as JSN did not act as mediator. 
It fulfilled these two criteria: (i) BMI was associated with JSN (beta-regression 
coefficient was -0.02 (-0.04 to -0.001) and (ii) JSN was associated with WOMAC pain 
subscale and ICOAP pain. Beta-regression coefficients were respectively 5.8 (3.7 to 
8.4) and 4.3 (1.4 to 7.2). Yet, it did not fulfill the last criteria. When JSN was used in 
the analysis to control the previous significant association between BMI and WOMAC 
pain scores and ICOAP, these associations remained significant. The beta-regression 
coefficients were 0.5 (0.05 to 1.0) and 0.2 (0.1 to 1.0), respectively.
In knee OA population, JSN acted as mediator. It fulfilled all criteria to be considered 
as a mediator. Firstly, BMI was associated with JSN (beta- regression coefficient was 
0.03 (0.01 to 0.05). Secondly, JSN was associated with WOMAC pain subscale (beta-
regression coefficient: 5.3 (3.3 to 7.3)) and ICOAP (beta-regression coefficient: 4.0 
(1.8 to 6.3)). Lastly, when JSN was used to control the previous significant association 
between BMI and WOMAC pain and ICOAP, these associations were no longer 
significant. Beta-regression coefficients were 0.3 (-0.01 to 0.7) and -0.1 (-0.5 to 0.4).
7.3.4. Association between BMI and indication for joint replacement
Greater BMI were associated with surgeon’s indication for THR. ORs of receiving a THR 
indication for obese and overweight patients compared with normal weight patients 
were respectively 1.8 (1.03 to 3.2) and 1.7 (1.04 to 2.6) (table 7.2). Yet, being very 
obese was not associated with indication for THR (OR: 1.3 (0.7 to 2.6)), compared to 
normal weight patients. The association between BMI and surgeon’s indication for 






































































































































































































































































































































































































































































































































































































































































































Greater BMI was associated with greater likelihood of receiving an indication for TKR. 
Patients with BMI > 35 kg/m2 (very obese) were 2.5 (1.5 to 4.1) times more likely to 
be recommended TKR compared with normal weight patients (table 7.2). Patients 
with BMI 30 to 35 kg/m2 (obese) and in 25 to 30 kg/m2 (overweight) were 2.3 (1.4 to 
3.7) and 1.2 (1.02 to 2.4) times more likely to be recommended for TKR compared 
with normal weight patients, respectively. These associations remained significant 
after adjustment for pain (either WOMAC pain subscale or ICOAP pain). However, the 
association was no longer significant when adjustment was made for radiographic 
severity. ORs (95% CI) for very obese, obese and overweight, were 0.5 (0.2 to 1.1), 1.3 
(0.6 to 2.8) and 0.9 (0.4 to 32.0) compared with normal weight patients, respectively.
7.4. DISCUSSION 
The present study shows that obesity is associated with pain in hip and knee OA. 
Yet, this association differs in hip and knee OA. Radiographic severity, measured as 
JSN, acts as mediator in the association between obesity and pain in knee, but not 
in hip OA. Furthermore, obesity is associated with the indication for THR and TKR. 
However, the association is no longer significant after adjustment with pain score in 
knee OA. In hip OA, the association remains significant. 
Obesity and pain has been link with several diseases characterized by pain such 
as chronic pain, fibromyalgia, abdominal pain and migraine.6 Studies on the link 
obesity and pain in OA are limited. In general, these studies in OA showed that 
obesity is associated with pain but they did not explore the aspects such as the role 
of radiographic severity in the association, and the types of pain (pain on activity 
or pain experience). Anandacoomarasamy et al. showed that the bodily pain scores 
measured by SF-36 were more severe in patients with knee OA.18 In another study, 
Desmueles et.al. showed that one-point increase in BMI was associated with 0.46 
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In our study, we add more dimension on the association between BMI and pain. We 
compare hip and knee OA, investigate the role of radiographic severity and use two 
types of pain scores: pain with activity (WOMAC pain score) and pain experience 
(ICOAP). While in hip OA, BMI is associated with both type of pain, in knee OA BMI is 
only associated with pain with activity. To explain this, we need to take into account 
the observation that the association between BMI and hip OA is weaker than that 
with knee OA 20 that might suggest that hip is less weight-bearing than knee. In hip, 
obesity alone could lead to pain experience, as observed by its association with pain 
experience (ICOAP). On the other hand, in knee OA, obesity alone does not give 
pain, but it is the additional factor to the damaged knee that consequently leads 
to pain on activity (WOMAC). This explanation is supported by two other results in 
the present study. Firstly, the association between obesity and WOMAC is no longer 
significant after adjustment with radiographic severity in knee OA while in hip OA 
the association remains significant. Secondly, using a widely-used statistical method 
to define a mediator, it is shown that radiographic severity acts as mediator in the 
association between obesity and pain in knee but not in hip OA. 
The joint damage in OA could eventually progress into total joint failure needing 
total joint replacement (TJR).Many studies have been shown the positive association 
between BMI and TJR.8,10-11 In those studies, joint replacements were defined as the 
actual performed surgery. However, performance of total joint replacement (TJR) is 
influenced by numerous non-health related factors such as patient race, ethnicity, 
income and non-musculoskeletal health factors such as co-morbidities. It is a well 
known clinical practice that obesity is considered as one of the co-morbidities. Many 
surgeons hesitate to perform surgery on an obese patient with OA who actually need 
TJR because a very obese patient is expected to have more surgical complications.12
An indication for TJR would be a better alternative in defining joint failure in OA.12 
Using this outcome definition, our study supports the evidence that higher BMI is 
associated with higher risk to have TJR. Interestingly, using this outcome definition, 
the pattern of the association between BMI and TJR differs in hip and knee OA 





































response relationship, while in hip OA the highest BMI category (BMI > 35 kg/m2) did 
not shown an association with THR. This suggests that in the highest BMI category, 
another factor than OA play a role in consulting a surgeon. This could be pain or 
disability related to obesity.
Another interesting observation is that the association BMI and TJR in knee OA 
remains after adjusting for pain score but not after adjusting for radiographic 
severity. In hip OA, the association disappeared after adjusting with pain score or 
for radiographic severity. It is possible that in hip OA the decision in performing TJR 
is influenced by pain score or by radiographic severity. In knee OA, the decision in 
performing TJR in knee OA is merely influenced by radiographic severity as has been 
shown in an earlier study.21 
The results of the present study show that the relation between BMI and TJR 
is complex. It is not merely the sequence: obesity leads to structural damage, 
consequently structural damage leads to pain, and consequently pain leads to TJR. 
Yet, our findings add to the body of evidence that the effect of obesity in hip and 
knee OA is different. In hip OA, the effect of BMI seems to be directly associated with 
pain experience, while in knee OA the effect of BMI on pain is mediated by structural 
damage. This could have a consequence in treatment. In hip OA, losing weight might 
not reverse the damage already done to joints, but it might be enough to lessen the 
pain. In contrast, in knee OA, influencing structural damage might be as important 
as losing weight.
Several limitations of our study need to be considered. Firstly, data on radiographic 
severity are not available from every patient. Yet, since the data omission happen at 
random (not all centers were participating with evaluation of radiographic severity), 
the results could be considered as valid. Secondly, height and weight were self-
reported. People tend to overestimate their height and underestimate their length, 
this lead to underestimation of BMI and consequently lead to underestimation of the 
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In conclusion, the effect of obesity in pain differs in patients with hip and knee OA. 
This difference could be explain by the difference in pathophysiology and should be 
considered in the studies on the effect of obesity in OA and OA’s treatment. 
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To investigate in which way body mass index (BMI) and alignment affect the risk for 
knee osteoarthritis (OA) progression.
Methods
Radiographs of 181 knees from 155 patients (85% female, mean age 60 years) with 
radiographic signs of OA were analyzed at baseline and after 6 years. Progression 
was defined as 1-point increase in joint space narrowing score in the medial or 
lateral tibiofemoral (TF) compartment or having knee prosthesis during the follow-
up for knees with a Kellgren and Lawrence score ≥1 at baseline. BMI at baseline 
was classified as normal (< 25 kg/m2), overweight (25 to 30) and obese (> 30). Knee 
alignment on baseline radiographs was categorized as normal (TF angle between 182° 
and 184°) and malalignment (< 182° or > 184°). We estimated the risk ratio (RR) with 
95% confidence interval for knee OA progression for overweight and obese patients 
and for malaligned knees relative to normal using generalized estimating equations 
(GEE). Additionally, we estimated the added effect when BMI and malalignment were 
present together on progression of knee OA. Adjustments were made for age and sex.
Results
Seventy-six knees (42%) showed progression: 27 in lateral and 66 in medial 
compartment. Knees from overweight and obese patients had an increased risk for 
progression (RR 2.4 (1.0 to 3.6) and 2.9 (1.7 to 4.1), respectively). RRs of progression 
for malaligned, varus and valgus knee were 2.0 (1.3 to 2.8), 2.3 (1.4 to 3.1), and 1.7 
(0.97 to 2.6), respectively. When BMI and malalignment were included in one model, 
the effect of overweight, obesity and malalignment did not change. The added effect 
when overweight and malalignment were present was 17%.
Conclusion
Overweight is associated with progression of knee OA and shows a small interaction 








































Osteoarthritis (OA) develops through different pathways in which overweight plays 
a prominent role.1,2 Overweight is associated with higher mechanical load and 
exposure to systemic effects of fat, which could lead to cartilage damage. Cartilage 
damage is known to be the central pathological feature of OA.1 The knee, as a weight-
bearing joint, is affected most by obesity. Theoretically, overweight should not only be 
associated with the development of knee OA but also with its progression. However, 
according to a systematic review published in 2007 that included seven studies, the 
evidence on the association between body mass index (BMI) and progression of knee 
OA is conflicting.2 Other observational studies 3,4 published after that review also 
showed conflicting results. 
Besides overweight, another important mechanical factor that exerts its force on 
the knee is malalignment. It has been shown that malaligned knees are at higher 
risk to have knee OA progression.5-7 Arguably, when the two forces: overweight 
and malalignment are present together in one knee, the chance of having knee 
OA progression would be increased. Interestingly, a recent study showed that knee 
alignment status could modify the association between BMI and knee OA progression. 
Niu et al. showed that knees from very obese subjects were associated with higher 
risk of knee OA progression only in neutral but not in varus and valgus aligned knees.3 
Overall, they did not observe an association between BMI and knee OA progression. 
To understand the effect of overweight on knee OA progression, the influence of 
malalignment need to be taken into account. Therefore, we investigated how 
overweight and alignment affected the risk of knee OA progression. We also 
investigated the association between varus and valgus alignments with medial and 






































8.2. PATIENTS AND METHODS
8.2.1. Study design and patient population
This study is part of the Genetic ARthrosis and Progression (GARP) study, a cohort 
study aimed at identifying determinants of OA susceptibility and progression.8 In this 
study, 192 Caucasian sibpairs (aged 40 to 70 years) were included with symptomatic 
OA at multiple joint sites in the hands or OA in two or more of the following joint sites: 
hand, spine (cervical or lumbar), knee, or hip. Patients with secondary OA, familial 
syndromes with a clear Mendelian inheritance, and a shortened life expectancy (<1 
year) were excluded. Patients underwent baseline assessment between August 2000 
and March 2003. The follow-up assessment was performed between April 2007 and 
June 2008 (mean follow-up 6 years).9 This study was approved by the Medical Ethics 
Committee of the Leiden University Medical Center. 
To be eligible for the present study, a patient needed to have radiographic signs of 
OA, 10 indicated by Kellgren and Lawrence (K&L) (appendix C.1) score of 1 (possible 
osteophyte lipping) or higher, in at least one knee at baseline.
8.2.2. Radiographs
Standardized non-fluoroscopic weight-bearing/semiflexed posterior anterior (PA) 
radiographs of the knees were obtained by a single experienced radiographer at 
baseline and after 6 years using a standard protocol with a fixed film focus distance 
(1.30 m). To facilitate uniform anatomical alignment of the knee, a SynaFlex X-ray 
positioning frame (Synarc. Inc., San Francisco, CA) was used. Baseline radiographs 
were analog films and were digitized using a film digitizer at a resolution corresponding 
to a pixel size of 100 mu. Follow-up radiographs were obtained digitally.
8.2.3. Evaluation of risk factors
Demographic data were recorded using standardized questionnaires. Height and 
weight were measured to the nearest 0.1 cm and 0.1 kg, respectively (shoes, socks 
and bulky clothing removed). BMI was calculated as weight in kilograms divided by 
squared height (in meters). We categorized BMI into three categories: < 25 (normal, 
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Anatomic knee angle was measured on baseline radiographs by two trained 
examiners (AT, EY) as the medial angle formed by the femur and tibia as described 
by Moreland and colleagues.11 Two lines originating at least 10 cm from the knee 
joint margins were drawn: one passing through the middle shaft of the femur and 
the other one through the middle shaft of the tibia. The medial angle subtended at 
the meeting point of these two lines was defined as the anatomic tibiofemoral angle 
(TF angle). This measurement technique of alignment has been shown to be a valid 
alternative of alignment measurement using hip-knee-ankle (HKA) axis.12 The inter-
observer reproducibility expressed as intraclass correlation coefficient (ICC) based on 
measurement of 16 randomly selected knees was excellent. The ICC was 0.94.
The knees were categorized based on TF angle into three groups: normal (TF angle 
between 182° and 184°), varus (TF angle < 182°) and valgus alignment (TF angle > 
184°). These cutoffs were based on values for normal, varus and valgus alignment 
at full-limb radiograph as described by Moreland et al.11 with 4° adjustment for the 
offset in valgus direction when TF angle was measured on knee radiograph.5
8.2.4. Radiographic progression
Baseline and 6-year radiographs were scored paired in chronological order, by a team 
of two experienced readers (EY, JB) that was blinded for patient characteristics. Using 
the Osteoarthritis Research Society International (OARSI) atlas (appendix C.2), 13 
joint space narrowing (JSN) was graded 0 to 3 in the medial and lateral compartment 
leading to a sum score of JSN ranging from 0 to 6. Joint space was assessed because 
it reflects articular cartilage damage.6 The ICC for intra-reader reproducibility based 
on 25 randomly selected pairs of radiographs was excellent: 0.98. 
Radiological progression was defined as difference between the sum of JSN scores 
at follow-up and at baseline above the smallest detectable change (SDC). The SDC 
reflects the change above the measurement error and was calculated in the present 
study by scoring 25 randomly selected pairs of radiographs twice.14 In the present 
study, a 1-point increase in JSN score was considered as radiological progression. 






































We first examine the association between the risk factors and knee OA progression. 
The odds ratios (ORs) for knee OA progression for knees from obese and overweight 
categories and for malaligned knees were calculated relative to knees with normal 
weight and normal alignment (reference categories). The calculation was performed 
using generalized estimating equations (GEE) analysis to account for the correlations 
between two knees within a subject (PASW Statistics 17 (SPSS Inc., Chicago, USA)). 
Then, we included BMI and malalignment in one model to investigate whether the 
effect of BMI was confounded by alignment status. Additionally, we investigated 
whether varus and valgus knees were associated with a specific compartmental knee 
progression, by calculating the ORs for medial and lateral knee OA progression for 
varus and valgus knees relative to normal aligned knees. 
In all analysis, adjustment was made for age and sex. All ORs were transformed 
to risk ratios (RRs) with 95% confidence interval (95% CI) using the approximation 
formula of Zhang because ORs of common outcomes in a cohort study are not a good 
approximation of RRs.15 
The amount of interaction between BMI and malalignment on progression of knee 
OA, was calculated using a method described by Rothman for departures of additive 
effects.16 BMI and alignment were first re-categorized into two categories. BMI into: 
normal (≤ 25 kg/m2) and overweight (> 25), and alignment into: normal (TF angle 
between 182° and 184°) and malalignment (TF angle < 182° or > 184°). Then, the 
increase in RR for malalignment knees among knees with normal BMI was calculated. 
Similarly, the increase in RR was calculated for knees with overweight among knees 
with normal alignment. The sum of these increases together with the background 
effect was then compared with the RR of the combined joint effect, i.e., the RR for 
knee with malalignment and overweight relative to knee with normal alignment and 
normal BMI. The difference represents the amount of additive effect on knee OA 







































A sensitivity analysis was performed to evaluate whether the association between 
BMI and knee OA progression would change when the sub-sample of knees with 
definite OA (K&L scores of ≥2 at baseline) was used. In this sub-sample, the RR of 
knee OA progression across the BMI categories was calculated relative to normal 
BMI. A sensitivity analysis was also performed to examine the effect of obesity on 
knee OA progression across alignment status: varus, valgus and normal in patients 
with K&L scores of ≥2 at baseline.
8.3. RESULTS
8.3.1. Population
The flow of participants is shown in figure 8.1. Of 237 patients with radiographic signs 
in at least one knee at baseline, 160 patients were available for follow-up. Eleven 
patients died during follow-up, eight were lost to follow-up, two emigrated and 56 did 
not give consent to perform follow-up radiographs. Most frequent reasons for non-
consent were unavailability of transport and large distance (n = 23), loss of interest to 
participate (n = 20) and health problems not related to OA (n = 13). At baseline, mean 
age of patients with follow-up (SD) was 59.6 (7.5) years, 85.2% was female and mean 
BMI (SD) was 27.7 (5.3) kg/m2 (table 8.1). Mean age (SD) of patients without follow-
up was 63.6 (7.8) years, 77% was female, and mean BMI (SD) was 28.0 (5.5) kg/m2. 
Of the 320 knees from 160 patients with follow-up, 139 knees were excluded 
from the analysis: 107 had no signs of knee OA, 10 due to missing alignment data 
(corresponding to five patients in which analog radiographs could not be digitized), 
12 due to knee prosthesis at baseline and 10 due to maximum K&L score of 4 at 
baseline (table 8.1). 
Of the eligible 181 knees from 155 patients, 51 knees had normal, 74 varus and 56 
valgus alignments. Seventy six of 181 knees (42%) had progression, 27 had lateral, 66 





































Figure 8.1 Study flowchart.
Table 8.1 Characteristics of the study population (n=155 patients) at baseline.
Characteristics
Mean age (SD), years 59.6 (7.4)
Number of female, % 132 (85.2)
Mean BMI (SD), kg/m2 27.7 (5.3)
   Normal (< 25), %
   Overweight (25-30), %
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8.3.2. Association between BMI, malalignment, BMI and malalignment with 
progression of knee OA
Compared to knees of patients with normal weight, the RR (95% CI) for progression 
in knees from patients with overweight was 2.4 (1.3 to 3.6) (table 8.2) and for knees 
from patients with obesity was 2.9 (1.7 to 4.1). 
Knees with malalignment had a RR of 2.0 (1.3 to 2.8) for progression compared to 
knees with normal alignment. For varus knees the RR was 2.3 (1.4 to 3.1) and for 
valgus knees the RR was 1.7 (0.97 to 2.6) for progression in comparison to normal 
aligned knees. 
When BMI and alignment were included in one model, the effect of overweight and 
obesity did not change much: the RR for knees of overweight patients was 2.3 (1.2 to 
3.5) and for knees of obese patients was 2.7 (1.5 to 3.9) compared to knees in normal 
weight patients. The effect of malalignment was also not affected by controlling for 
BMI, the RR for knee OA progression for knees with malalignment relative to knee 
with normal alignment was 1.8 (1.1 to 2.7). Finally, the effects of the two types of 
malalignment were also virtually unaffected by adjustment for BMI: compared to 
knees with normal alignment, the RR for knee OA progression for knees with varus 
alignment (TF angle < 182°) was 2.1 (1.2 to 2.9) and knees with valgus alignment (TF 
angle: > 184°) was 1.5 (0.8 to 2.5).
Table 8.2 Association between alignment, body mass index (BMI) with knee osteoarthritis 
progression (n=181 knees).





   Normal (< 25) 10 42 1 (reference) 1 (reference)
   Overweight (25 to 30) 41 44 2.4 (1.3 to 3.6)‡ 2.3 (1.2 to 3.5)‡
   Obese (> 30) 25 19 2.9 (1.7 to 4.1)‡ 2.7 (1.5 to 3.9)‡
Tibiofemoral alignment, (°)
   Normal (182 to 184) 12 39 1 (reference) 1 (reference)
   Malalignment   





2.0 (1.3 to 2.8)‡
2.3 (1.4 to 3.1)‡
1.8 (1.1 to 2.7)‡
2.1 (1.2 to 2.9)‡
      Valgus (>184) 23 33 1.7 (0.97 to 2.6) 1.5 (0.8 to 2.5)
1 adjusted for age and sex, 2 in the model: BMI, alignment, age and sex





































8.3.3. Association between malalignment and medial and lateral progression of 
knee OA
Varus alignment (TF angle < 182°) was associated with medial knee OA progression. 
The RR (95% CI) for medial progression for varus knees compared to normal aligned 
knees was 2.4 (1.5 to 3.3); no significant association was seen with lateral progression 
(RR 4.1(1.0 to 12.1)) (table 8.3). Valgus alignment (TF angle > 184°) was associated 
with lateral knee OA progression (RR 6.0, 95% CI 1.6 to 15.1) but not with medial 
progression (RR 1.2, 95% CI 0.6 to 2.2) compared to subjects with normal alignment.
Table 8.3 Association between knee alignment with medial and lateral knee osteoarthritis 
progression (n=181 knees).




















Normal 11 40 1 (reference) 2 49 1 (reference)
Varus 40 34 2.4 (1.5 to 3.3)‡ 12 62 4.1 (1.0 to 12.1)
Valgus 15 41 1.2 (0.6 to 2.2) 13 43 6.0 (1.6 to 15.1)‡
1 in the model: varus or valgus alignment, age and sex.
‡ significant at level p< 0.05.
8.3.4. Detection of interaction between BMI and alignment on progression of knee 
OA
The observed RR for knees with malalignment and overweight was 4.1 (table 8.4). 
Among knees from patients with normal BMI, malalignment had an increase in RR 
of 0.9 for progression relative to normal alignment. The increase in RR of being 
overweight in knees with normal alignment was 1.5. The sum of these components 
together with the background effect (RR = 1) was 3.4. The difference between the 
sum of these components with the observed joint RR was 0.7 (=4.1 to 3.4). The part 
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Table 8.4 Risk ratio (with 95% confidence interval) of progression by alignment status and the 
presence or absence of overweight (n=181 knees).
Tibiofemoral alignment Normal BMI
(≤25 kg/m2), n=52
Overweight 
(> 25 kg/m2), n=129
Normal (182 to 184), n=51 1 (background effect)
(n=24)
2.5 (0.7 to 5.1)
(n=27)
Malalignment (<182 or >184), n=130 1.9 (0.5 to 4.8)
(n=28)
4.1 (1.8 to 6.1) 
(n=102)
8.3.5. Sensitivity analysis
In the subgroup of knees with K&L scores of ≥2 at baseline (n = 128), the RR (95% CI) 
for OA progression in knees from obese and overweight patients relative to knees 
from normal weight patients, was 1.8 (1.1 to 2.3) and 1.4 (0.8 to 2.0) respectively 
after adjustment for age and sex. Among varus knees with K&L scores of ≥2 at 
baseline (n= 64), higher BMI was associated with knee OA progression. Varus knees 
from obese and overweight patients had a RR of 3.0 (1.2 to 2.6) and 1.7 (0.5 to 3.0), 
respectively to have progression relative to varus knee from normal weight patients. 
No significant association was shown with BMI in valgus knees (n = 35) and normal 
aligned knees (n = 29). In normal aligned knees, the RRs for progression were 1.1 (0.2 
to 2.6) and 1.7 (0.4 to 3.0) for knees from obese and overweight patients, relative to 
knees from patients with normal weight, respectively. In normal aligned knees, there 
were only seven knees in the stratum obese (BMI > 30 kg/m2).
8.4. DISCUSSION
In the present study, obesity and malalignment were associated with the progression 
of knee OA. It seemed that malalignment modified the association between obesity 
and knee OA progression in some amount. We also found that varus alignment was 
associated with medial progression and valgus alignment with lateral progression. 
Our findings do not support the results from a study by Niu et al. where no overall 
relationship between obesity and the progression of knee OA was shown.3 Probably, 





































the results. More than 80% of Niu’s study population had a BMI above 25 kg/m2 
(mean BMI ± SD was 30.4 ± 5.7), leading to less contrast between overweight or 
obese patients with normal weight patients. One might argue that the difference in 
the results could be caused by the difference in the definition of the study population. 
In the present paper, we investigated the OA progression among knees with signs of 
OA at baseline (K&L scores ≥1) because K&L grade 1 definitely does not represent 
normal knees. This definition has also been used by others to define OA, for example 
in a clinical trial on glucosamine.17 While going from K&L grade 1 to 2 is characterized 
as progression in our study, it was characterized as incidence in the study from Niu 
et al. Yet, in our study, when we performed a sensitivity analysis by selecting only 
cases with K&L scores ≥2, obesity was still shown to be associated with knee OA 
progression with smaller RR. Overweight was also still positively associated with 
progression, however, the association is no longer significant. 
In the subgroup of patients with K&L scores ≥2, we also found that higher BMI was 
associated with knee OA progression among varus knees but not among normal and 
valgus knees. The failure in showing the association in normal and valgus aligned 
knees might be caused by small numbers of knees in the obese stratum. There were 
only seven knees with normal and five knees with valgus alignment in the obese 
stratum. Our results are in contrast with the results of Niu et al. where they did 
not find the association between obesity and knee OA progression among varus 
knees.3 Niu et al. did find the association between obesity and incidence of knee 
OA (K&L scores ≥2 at 30-months follow-up) among varus knees in knees with K&L 
scores ≤1 at baseline. They hypothesized that the effect of varus alignment differed 
across different stages of OA: varus might has smaller role in incidence of OA than 
obesity, but it might drive the progression of OA more than obesity. They based their 
explanation on the observation that varus malalignment was more common in knees 
with definite OA (K&L scores ≥2) than in knees with K&L scores ≤1 at baseline (60.8% 
vs 40.6%, respectively). In our study population, we also found that varus alignment 
was more common in knees with K&L scores ≥2 (50.4%) than in knees with K&L 
scores ≤1 (29%). Yet, we still found the association between obesity and knee OA 
progression in varus aligned knees with K&L scores ≥2 at baseline. Therefore, we do 
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Re-evaluating the studies included in a systematic review by Belo and colleagues 2  on 
BMI as risk factor of knee OA progression.18-24 We notice that the studies that failed 
to observe an association between overweight or obesity and progression were 
small (study population less than 110 patients).19,21,23 However, those studies showed 
positive effect sizes with wide confidence intervals. Therefore, lack of statistical 
significance was erroneously interpreted as an absence of an association (type II 
error). In larger studies, Cooper et al., in a study in 354 subjects with K&L score ≥1 
at baseline, found an OR of 2.6 (95% CI 1.0 to 6.8) for ≥1 increase in K&L score in at 
least one of the knees, when patients within the highest BMI tertile (BMI > 25.4 kg/
m2) were compared with the lowest tertile (BMI < 22.7 kg/m2).18 Yet, the RR became 
smaller and not significant (1.3, 95% CI 0.3 to 5.0) when only subjects with K&L score 
≥2 at baseline were selected. Ledingham et al. investigated 350 OA knees and found 
an OR for an increase in JSN of 1.07 (95% CI 1.02 to 1.14).20 A population based study 
in 1507 patients showed a Hazard Ratio of 1.04 (95% CI 1.01 to 1.07). Schouten and 
colleagues investigated 422 subjects showing ORs of 3.82 (95% CI 1.2 to 12.2) and 8.8 
(2.8 to 27.8), respectively for a comparison between patients with a BMI of 26 to 27.7 
kg/m2 and a BMI > 27.8 kg/m2 to subjects with a BMI < 24.3 kg/m2.22 None of these 
studies investigated alignment. 
Concerning alignment, our study support the notion that varus alignment is associated 
with medial progression of knee OA and valgus alignment is associated with lateral 
progression of knee OA as shown for the first time by Sharma and colleagues.6 Our 
results support the biomechanical studies that varus and valgus alignment increase 
medial and lateral load, respectively, and do so with similar risk increases.6
Our study has several limitations. An important limitation is that we do not have 
full-limb radiographs, therefore preventing accurate measurement of mechanical 
alignment. Yet, we put efforts in approximating the mechanical alignment by using 
flexed knee protocol and by using a mean offset of 4° in the valgus direction in 
categorizing knees as normal, varus or valgus. This offset has been reported by Kraus 
et al. as the offset for anatomic compared to mechanic alignment.25 Although not 
optimal, the anatomical axis was shown to be correlated very well with mechanical 





































obesity on knee OA progression is not eliminated after adjustment for malalignment 
due to a possible misclassification of knee alignment status. Another limitation of the 
present study is the small sample size. The sample size is enough to detect the overall 
effect of BMI, malalignment and varus alignment on the risk for knee OA progression. 
However, to prevent type II error, we could not draw any conclusion on the effect of 
obesity on knee OA progression among normal and valgus knees. 
Our findings have implications for clinical studies and studies in the pathophysiology 
of adipose tissue in OA. Clinical trials on the effect of weight loss in preventing knee OA 
progression and studies that investigate the effects of physical therapy intervention 
which reduce the stresses on a given alignment 6 could be done in separate trials or 
simultaneously to look at synergistic effects.
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Osteoarthritis (OA) is the most common joint disease and obesity is one of the 
strongest risk factors for development and progression of OA. The main aim of this 
thesis is to give more insight on how obesity leads to OA. Gaining more insight on 
the effect of obesity on OA is important because we are losing the battle against the 
world epidemic of obesity. Simply public health measures seem not enough to lower 
the number of obese people. By understanding more about the pathophysiology of 
obesity in OA, we might be able to ‘treat’ OA by modifying the effect of obesity. This 
approach might be more effective.
After the introduction, the first three chapters of this thesis presented the results 
of the studies on the structures involved in OA and the studies on OA progression. 
Studies on OA progression investigated how to stratify OA patients at an early stage. 
Stratifying (i.e. differentiating) patients who will progress from patients who will not 
progress, is useful for the selection of the study population that will benefit most 
from OA treatment in future clinical trials.
In chapter 2, we investigated the association between joint tissue damage seen on 
magnetic resonance imaging (MRI) and pain. MRI can visualize the whole joint, not 
only cartilage but also bone and synovium. Showing which structures are associated 
with pain will lead to a rational therapeutic target. In this chapter, we summarized 
published studies to learn which tissue damage is associated with OA. We concluded 
in this systematic review that bone marrow lesion (BML) and synovitis/ effusion were 
associated with knee pain. The level of evidence of this association was moderate. 
The consequence of these findings is that bone marrow lesion and synovitis/ effusion 
have the potential to be used as target in treating OA.
In chapter 3, we changed the view for a while, from OA defined by pathology to OA 
defined by joint symptoms. In this population with clinical OA either in the knee 
or hip, we investigated the factors associated with the clinical progression and 





































patients showed progression during a 6-years period (defined as having total joint 
replacement or worsening self-reported pain or function above predefined criteria) 
and nearly one fourth had good prognosis of lower limb OA. Factors associated with 
the progression of lower limb OA in long term were: worsening of self-reported pain 
and function in one year, limited total range of motion and higher osteophytes and 
JSN scores. Factors associated with a lower chance to have good prognosis were: 
worsening in self-reported pain and function score in 1- year. The findings described 
in this chapter can be used in the clinic to inform patients with regard to their OA 
prognosis. Knowing which OA patients who will deteriorate at a very early stage is 
also very helpful in clinical trial on OA drugs or therapy: OA patients with progression 
are actually the main target in OA therapy.
In chapter 4, we investigated the use of multiple measurements of biomarkers 
to monitor the progression of OA and as a method to predict the progression of 
OA at multiple sites. The study presented in chapter 4 was unique due to several 
reasons. Firstly, we used data on multiple measurements of biomarkers. Secondly, 
we assessed OA at multiple joints. When investigating biomarkers as predictor for 
progression or as measure of OA change, not only large joint such as knee or hip 
should be considered but also smaller joints such as hand joints. All synovial joints in 
the body contribute to the measured biomarkers. Among five biomarkers, we found 
that multiple measurements of uCTX-II were associated with progression of OA. 
The predictive power of multiple measurements uCTX-II levels at 0-6 months for OA 
progression at 2 years is highly promising, implicating that this marker can be use to 
differentiate patient with and without progression at an early stage. Again, this will be 
helpful in selecting patient population to participate in clinical trials on treatment of 
OA. Moreover, since multiple measurements of this uCTX-II were associated with the 
progression of cartilage defects on radiographs, this biomarker can also be used to 
evaluate the efficacy of OA therapy. uCTX-II may also be used as one of the outcomes 






































The following three chapters in this thesis presented results of the studies that 
tried to answer several questions on how obesity influences the development and 
progression of OA. In chapter 5, we performed a systematic review and showed that 
obesity was associated with the development of hand OA. The level of evidence 
of this association was moderate. Since we do not walk on our hands (no added 
mechanical force in hands of obese people), the results presented in chapter 5 
suggest that metabolic factors associated with fat, such as adipokines might also play 
a role in OA. 
This issue was elaborated further by investigating the association between 
adipokines and the progression of radiographic hand OA in chapter 6. Among the 
adipokines investigated: leptin, adiponectin and resisitin, higher level of adiponectin 
was shown to be associated with a lower risk for hand OA progression (increased 
JSN as measured on radiographs). Patients with adiponectin  levels in the highest 
tertile had a 3 times lower risk to have hand OA progression compared to patients 
with adiponectin levels in the lowest tertile. This suggests that adiponectin is an 
attractive target for prevention of hand OA progression by increasing adiponectin 
levels through pharmaceutical or lifestyle intervention. 
In chapter 7, we investigated the association between obesity and pain in patients 
who visited orthopedic surgeons to discuss the possibility of getting hip or knee 
replacements. We found that BMI, as a measure of obesity was associated with pain. 
We also found that the effect of BMI on pain was different in hip and in knee OA. 
In hip OA, the effect of BMI was directly associated with pain experience, while in 
knee OA the effect of BMI on pain was mediated by structural damage. These results 
suggest the complexity of the relation between obesity and total joint replacement 
(TJR). It is not merely the sequence: obesity leads to structural damage, consequently 
structural damage leads to pain, and consequently pain leads to TJR. These findings 
can have a consequence in treatment of OA. In hip OA, losing weight may not reverse 
the joint damage already done, but it may be enough to lessen the pain. In contrast, 





































In chapter 8, we investigated the possible interaction between obesity and another 
strong factor of OA, i.e. malignment in their association with the progression of knee 
OA. Overweight and malalignment are mechanical factors that exert its force on the 
knee. Arguably, when these two forces: overweight and malalignment are present 
together in one knee, the risk of having knee OA progression will be increased. In 
this study, obesity, as well as malalignment was indeed shown to be associated with 
the progression of knee OA. Obesity was also shown to have small interaction with 
malalignment. These findings have the implication that clinical trials on the effect of 
weight loss, and studies on the effects of physical therapy in reducing stress due to 
malalignment in preventing knee OA progression, can be done in separate trials or 
simultaneously to look at synergistic effects.
9.2. DISCUSSION AND FUTURE DIRECTION 
9.2.1. New targets in OA treatment 
OA is a disease without pathognomonic findings. That OA has no pathognomonic 
findings is perhaps disappointing but also not surprising. Pain is caused by stimulation 
of nociceptors in areas of tissue damage. The search of the origin of pain in OA is 
actually to find which tissues are damaged. Cartilage has been thought for a long 
time as the source of pain despite the knowledge that cartilage is not innervated. This 
explains why many studies failed to show the association between structural damage 
in OA with pain. The emerging studies using MRI have shown that BML and synovitis/ 
effusion are potential targets for OA treatment because of their association with pain 
(chapter 2). Trials on medicine targeting these structures should be pursued in the 
future. 
Although it seems promising, more studies are still needed to understand how BML 
and synovitis/ effusion lead to pain in OA. The level of evidence in our study in chapter 
2 is only moderate.  The damage on subchondral bone and synovitis does not give 
a clear-cut answer on the source of pain in OA. There are several explanations and 
studies in the future should take these factors into account. Firstly, pain in OA comes 






































are studies with case-crossover design. In those studies, imaging is performed in a 
patient when he had pain, and this is compared to the imaging on the same patient 
when he does not have pain. Secondly, it is likely that pain is more complex than 
structural damage, and that psychosocial factors, such as coping mechanism might 
also be involved. These factors are much more difficult to cope in future studies. 
A possible solution is performing studies with the patient population consisted of 
patients with OA on one side and without OA on the other side (e.g. OA on right 
knee and normal left knee). The effect of OA on pain can then be compared in the 
same patients. The use of new imaging techniques such as functional MRI (fMRI) to 
investigate the pain mechanism in the brain can also be considered.
9.2.2. Stratifying OA patients 
Many clinical trials failed to show the efficacy of medicine in treating OA progression. 
One of the reasons is the mixed study population in these trials. We know that 
patients with OA have different prognosis at long term after the diagnosis. Some of 
them will progress, some will stay the same and some will be better. When patients 
from all these subgroups are included, it will lead to underestimation of the effect 
in a clinical trial. Efforts to stratify patients are needed to select patients that will 
progress at an early stage since these patients are the patients who will have benefit 
from a medicine in OA. 
Several clinical factors, such as worsening of self-reported pain and function in short 
term, limited total range of motion, and higher osteophytes and JSN scores can be 
used to identify patients who will have progression on the long term (six years in our 
study, described in chapter 3). In future clinical trials on a novel drug or treatment, 
the study population can be selected by including patients who have factors that 
increase the risk of progression. This ‘enriched’ population will increase the chance to 
show the effect of a working novel drug. Moreover, since the long-term progression 
(i.e. 6 years) can be predicted by using progression short-term progression (i.e. 1 
year), a trial can also be performed over a shorter period of time. There is no need 
to perform a long term trial when it is known that patients who will progress at the 






































The clinical factors could also be combined with the use of biomarkers such as uCTX-
II in stratifying patients who will have OA progression. To have a prediction model 
that combine clinical factors with biomarkers future studies should have a large 
number of participants. The outcome of progression in such studies can be clinical, 
radiological and combination of clinical and radiological. 
Remarks can be made on imaging as outcome in studies on progression of OA. Despite 
its widespread use, imaging as an outcome in a study has an important limitation 
that it is simply a snapshot of the end results of processes in a joint. Imaging gives no 
information about ongoing process in structures involved in OA. Measurement of a 
single level of biomarkers is also a snapshot. Therefore, multiple measurements of OA 
are likely a better option to monitor OA progression. Since multiple measurements 
of uCTX-II are associated with increasing cartilage thinning measured on radiograph 
(chapter 4), it has the potential to be used as a replacement of radiograph as an 
outcome in observational studies and clinical trials. Future studies should also 
explore the use of other structures than cartilage that involved in OA such as BML 
and synovitis/ effusion as outcome in studies. Reducing BML and synovitis/ effusion 
can be tested as a goal of a novel drug. 
9.2.3. Excess of fat affects OA in multiple ways
Based on the results presented in this thesis, we can conclude that excess of body fat 
exerts its effect not only by extra mechanical force on weight bearing joint, but also 
by producing metabolic factors (adipokines) that could damage joints. Adiponectin 
is one of the adipokines produced by fat tissue. Interestingly, obesity has an inverse 
relationship with adiponectin: more fat leads to lower level of adiponectin. Lower 
level of adiponectin seems to be bad for cartilage, as described in chapter 6. 
While adiponectin is shown to be associated with progression of OA pathology, no 
association is found between adiponectin with pain level and worsening of pain level 
(data are not shown). Probably, adipokines do not stimulate the nociceptor directly. 
Adipokines might lead to cartilage damage first and subsequently lead to pain. The 
difference of the effect of adipokines on cartilage damage progression and on pain 






































related to pain. It is still the holy grail in studies in OA to find the solution on this 
discrepancy. 
The observation that the effect of obesity in knee OA but not in hip OA is mediated by 
structural OA (chapter 7), implies that the mechanical effect of obesity on OA should 
not be totally put aside (knee is considered to be more weight bearing joint than 
hip). It should be realized in future studies on the effect of excess of fat in OA that the 
choice of which joints to be studied means investigating different effects of obesity. 
Possibly, hand joints are where metabolic effect plays the most prominent role, and 
knee joint is where mechanical effect has most important role. Considerably, the hip 
joint endures a mixed metabolic and mechanical effect.
A remark should also be made on measurement of excess of fat. BMI that is commonly 
used in epidemiological studies on OA is actually just only a proxy of human body fat. 
Therefore, the product of fat itself should be used in future epidemiological studies. 
Using the products of fat tissue as the measurements of excess of fat will bring us 
to the closer end of the causal path on the association between obesity and OA. 
Apart from adipokines, other measurement of fat products such as cholesterol and 
triglycerides should be pursued in the studies on OA. 
Future basic research should investigate the effect of adipokines on the inflammatory 
states of structures involved in OA. The structures shown on MRI that related 
with pain in OA:  BML and synovitis/ effusion are linked with inflammatory states. 
Interestingly for knee OA, more research can be done on the role of Hoffa’s fat pad. 
The knee joint is unique since it is in the approximation of a collection of fat tissue. 
This fat pad has been shown to have inflammatory characteristics.
9.3. IN SEVERAL SENTENCES
OA is a progressive disease that can be defined as pathology or symptom where 
excess of fat plays an important role in its development and progression. Whether 





































joint involved. Measurement of the fat itself or fat products should be performed 
in addition to, or instead of BMI in studies on the effect of obesity in OA. These fat 
products and its receptors are the potential therapeutic target in treating OA in the 
future.
Chapter 10 (Hoofdstuk 10)











































































Artrose is de meest voorkomende gewrichtsaandoening en obesitas is een van de 
belangrijkste risicofactoren voor de ontwikkeling (d.w.z. incidentie) en verergering 
(progressie) van artrose. Het belangrijkste doel van dit proefschrift is meer inzicht te 
geven in hoe obesitas kan leiden tot artrose. Dat is belangrijk omdat we de strijd tegen 
de obesitasepidemie aan het verliezen zijn. De maatregelen van de maatschappelijke 
gezondheidszorg lijken onvoldoende om het aantal zwaarlijvige mensen te verlagen. 
Als we de rol van de obesitas in de pathofysiologie van artrose beter begrijpen, dan 
kunnen we in de toekomst artrose ‘behandelen’ door de invloed van de obesitas te 
verminderen. Deze aanpak zou mogelijk effectief kunnen zijn.
Na de introductie, laten de eerste drie hoofdstukken van dit proefschrift de resultaten 
zien van studies over de structurele afwijkingen die worden gezien bij artrose en 
over de progressie van artrose. Studies naar de progressie van artrose onderzoeken 
hoe patiënten met artrose in een vroeg stadium gestratificeerd (m.a.w. ingedeeld) 
kunnen worden. Het onderscheiden van patiënten die zullen verergeren (m.a.w. met 
progressieve artrose) en patiënten die dat niet zullen doen (m.a.w. niet progressieve 
artrose) zal voor toekomstige klinische studies belangrijk zijn. Patiënten met een 
progressief beloop vormen namelijk de populatie die het meest zal profiteren van 
een mogelijke behandeling van artrose.
 
In hoofdstuk 2 onderzochten we de associatie tussen weefselbeschadiging door 
artrose die te zien is op Magnetic Resonance Imaging (MRI), en pijn. MRI kan het hele 
gewricht, dus niet alleen het kraakbeen, maar ook het bot en synovium visualiseren. 
Het kunnen aantonen van afwijkende structuren of weefsels in associatie met pijn 
kan leiden tot een doeltreffende behandeling van artrose. In dit hoofdstuk hebben 
we een systematisch overzicht van de literatuur uitgevoerd. We concludeerden dat 
beenmerglesies en synovitis of effusie geassocieerd waren met pijn in de knie. Het 
niveau van dit bewijs was echter matig vanwege methodologische tekortkoming in 
de gepubliceerde onderzoekingen. De consequentie van deze bevindingen is dat 






































In hoofdstuk 3, maakten we even een overstap: van artrose gedefinieerd als 
structurele afwijking naar artrose gedefinieerd als symptoom. In de populatie 
met symptomatische artrose in het been, hetzij in de knie of heup, hebben we 
zowel onderzoek gedaan naar de factoren die samenhangen met de klinische 
progressie als naar de factoren voor een goede prognose. In deze studie vonden 
we dat meer dan de helft van de patiënten progressie hadden (gedefinieerd als het 
nodig hebben van een totale  gewrichtsprothese of het verergeren van de pijn of 
afname van functie gemeten met gevalideerde criteria) tijdens een vervolgperiode 
van 6 jaar. Bijna een kwart van de groep liet een goede prognose zien. Factoren 
die samenhangen met het progressieve verloop van artrose op lange termijn 
zijn: verergering van zelfgerapporteerde pijn en functieafname binnen één jaar, 
beperkte totale bewegingsuitslag van de gewrichten en hogere osteofyten- en 
gewrichtspleetversmallingsscores. Factoren die geassocieerd zijn met een lagere 
kans op een goede prognose zijn: verslechtering van de zelfgerapporteerde pijn en 
functiescore binnen één jaar. De bevindingen die in dit hoofdstuk zijn beschreven 
kunnen worden gebruikt in de kliniek om de patiënten te informeren betreffende 
hun prognose. In klinische trials van artrosetherapie is het ook belangrijk in een zeer 
vroeg stadium te weten welke patiënten zullen verslechteren. Patiënten met een 
(snel) progressieve artrose zijn namelijk de belangrijkste doelgroep van de therapie.
In hoofdstuk 4 onderzochten we het gebruik van biomarkers gemeten op verscheidene 
tijdstippen om de progressie van artrose te bestuderen en als een methode om 
de progressie in verschillende gewrichten te voorspellen. De studie beschreven in 
hoofdstuk 4 is uniek om verschillende redenen: ten eerste wordt er gebruik gemaakt 
van biomarkers gemeten op een aantal tijdstippen. Ten tweede wordt artrose in 
verschillende gewrichten onderzocht: niet alleen de grote gewrichten, maar ook de 
kleine gewrichten zoals die van de hand. De gemeten biomarkers worden namelijk 
gemaakt door alle synoviale gewrichten van het lichaam. Van de vijf biomarkers die 
we onderzochten vonden we dat waardes van uCTX-II waren geassocieerd met de 
progressie van artrose. De concentraties in het bloed van uCTX-II over een periode van 
0-6 maanden waren voorspellend voor artroseprogressie na 2 jaar. Dit is veelbelovend 






































progressie in de toekomst te onderscheiden van patiënten zonder progressie. Dit is 
belangrijk bij het selecteren van patiënten voor deelname aan klinische studies over 
de behandeling van artrose. Aangezien  uCTX-II was geassocieerd met de progressie 
van kraakbeen beschadiging, kan deze biomarker gebruikt worden om het artrose 
ziekteproces te volgen. Hierdoor kan uCTX-II ook worden gebruikt om de effectiviteit 
van artrosebehandeling te evalueren: ze kan dienen als één van de uitkomsten in de 
klinische studies in artrose. Het verlagen van uCTX-II kan wellicht één van de doelen 
worden in toekomstige klinische trials.
De volgende drie hoofdstukken in dit proefschrift presenteren de resultaten van 
de studies die een aantal vragen proberen te beantwoorden over de invloed die 
obesitas heeft op de ontwikkeling en progressie van artrose. In hoofdstuk 5 voerden 
we een systematische literatuurstudie uit om te onderzoeken of er een verband is 
tussen obesitas en de incidentie van handartrose. We hebben dat verband kunnen 
aantonen. Het bewijsniveau van deze associatie in de gepubliceerde onderzoekingen 
was echter qua methodologie matig. Omdat we niet op onze handen lopen (geen 
extra mechanische kracht op de handen van mensen met overgewicht), suggereren 
de resultaten in hoofdstuk 5 dat metabole factoren van vet, zoals adipokinen, 
misschien ook een rol in artrose spelen.
In hoofdstuk 6 werd deze kwestie verder onderzocht door de associatie tussen 
adipokinen met de progressie van handartrose te bestuderen. De progressie van 
handartrose was op röntgenfoto’s gemeten als toename van gewrichtspleetversmalling. 
Van de onderzochte adipokinen (leptine, adiponectine en resistine), bleek dat 
verhoogde waarden van adiponectine waren geassocieerd met een verlaagd risico 
op progressie van handartrose. Patiënten met adiponectineniveaus in het hoogste 
tertiel hadden een drie keer lager risico dan patiënten met adiponectineniveaus in 
het laagste tertiel. Dit suggereert dat adiponectine een aantrekkelijk doelwit kan zijn 
voor medicamenteus onderzoek in de preventie van de verergering van handartrose. 
Dit kan ondermeer bereikt worden door het verhogen van adiponectine door 





































In hoofdstuk 7 onderzochten we het verband tussen obesitas en pijn bij patiënten 
die een orthopedisch chirurg hadden bezocht om een heup- of knieprothese operatie 
te bespreken. Wij vonden dat Body Mass Index (BMI), een maat voor obesitas, 
geassocieerd was met pijn. We vonden ook dat het effect van BMI op pijn anders 
was in de heup- dan in de knieartrose. In heupartrose was BMI direct geassocieerd 
met pijn, terwijl in knieartrose het effect van BMI op pijn werd beïnvloed door met 
artrose geassocieerde (structurele) schade. Deze resultaten tonen de complexiteit 
van het verband tussen obesitas en de noodzaak van een totale gewrichtsprothese. 
Het is niet alleen de volgorde: overgewicht leidt tot gewrichtschade, gewrichtschade 
leidt tot pijn, en pijn leidt tot een totale gewrichtsprothese. Deze bevindingen 
kunnen consequenties hebben voor de behandeling van artrose. In heupartrose 
kan gewichtsverlies de beschadiging van het gewricht niet herstellen, maar het kan 
misschien genoeg zijn om de pijn te verminderen. Daarentegen is bij knieartrose de 
poging tot herstellen van de gewrichtschade net zo belangrijk als afvallen.
In hoofdstuk 8 hebben we de interactie tussen obesitas en een andere belangrijke 
risicofactor van artrose, namelijk een veranderde mechanische belasting door een 
abnormale hoek tussen het boven- en onderbeen (malalignment), onderzocht in 
hun associatie met de progressie van knieartrose. Overgewicht en malalignment 
zijn mechanische factoren die extra krachten op de knie uitoefenen. Wanneer 
deze twee krachten in een knie samen aanwezig zijn, zal theoretisch het risico 
van knieartroseprogressie toenemen. In deze studie was obesitas in combinatie 
met malalignment  inderdaad geassocieerd met de progressie van knieartrose. 
Deze bevindingen impliceren dat de klinische trials naar het effect van afvallen en 
vermindering van malalignment in het voorkómen van artroseprogressie afzonderlijk 








































10.2. DISCUSSIE EN AANBEVELINGEN
10.2.1. Nieuwe doelwitten in de behandeling van artrose
Artrose is een ziekte zonder duidelijk onderscheidende (pathognomonische) 
kenmerken. Dat artrose geen pathognomonische kenmerken heeft is misschien 
teleurstellend, maar niet verrassend. Pijn wordt veroorzaakt door stimulatie van 
nociceptoren in het gebied van de weefselbeschadiging. Het zoeken naar de oorzaak 
van de pijn in artrose is eigenlijk zoeken naar beschadigde weefsels. Langere tijd 
werd kraakbeen beschouwd als de bron van de pijn, ondanks de kennis dat er geen 
pijnreceptoren zijn in het kraakbeen. Dit verklaart waarom veel studies het verband 
niet kunnen tonen tussen structurele of weefselschade bij artrose en pijn. Vele 
studies met MRI hebben namelijk laten zien dat beenmerglesies en synovitis of 
effusie geassocieerd zijn met pijn bij artrose (hoofdstuk 2). Deze structuren kunnen 
in de toekomst in aanmerking komen voor artrosebehandeling. Klinische trials naar 
nieuwe geneesmiddelen kunnen worden gericht op beïnvloeden van deze structuren.
Omdat deze verbanden met overgewicht enerzijds een veelbelovende benadering 
bieden, is er anderzijds nog veel onbekend, en zijn dus meer studies nodig om te 
begrijpen hoe beenmerglesies en synovitis of effusie leiden tot pijn bij artrose. 
Het methodologisch niveau van veel gepubliceerd onderzoek, zoals weergegeven 
in hoofdstuk 2, was matig. De schade aan het subchondrale bot en de synovitis 
geven geen duidelijk antwoord op de vraag wat de bron is van de pijn bij artrose. 
In toekomstige studies zou er met verschillende factoren rekening moeten worden 
gehouden: ten eerste, pijn in artrose komt en gaat. Idealiter zou in toekomstige 
studies een case-crossover design moeten worden gebruikt. In een dergelijke studie 
wordt de beeldvorming uitgevoerd als een patiënt pijn heeft en vergeleken met de 
beeldvorming bij dezelfde patiënt wanneer deze geen pijn heeft. Ten tweede is het 
waarschijnlijk dat pijn complexer is dan simpelweg structurele of weefselschade. 
Psychosociale factoren, zoals het omgaan met pijn, zouden ook een rol kunnen 
spelen. Een mogelijke oplossing zou kunnen zijn om studies te doen in een populatie 
die bestaat uit patiënten met artrose aan de ene kant en geen artrose aan de andere 





































en een gezonde linkerknie). De pijn bij artrose kan dan worden vergeleken tussen 
gewrichten bij dezelfde patiënt. Ook het gebruik van nieuwe beeldvormende 
technieken zoals functionele MRI (fMRI) om het pijnmechanisme in de hersenen te 
onderzoeken kan worden overwogen.
 
10.2.2. Stratificatie van patiënten met artrose
Veel klinische trials kunnen de werkzaamheid van nieuwe medicijnen voor het 
remmen van progressie van artrose niet aantonen. Een van de redenen is de gemengde 
populatie in deze studies. We weten dat artrosepatiënten nadat de diagnose is 
gesteld op lange termijn een verschillende prognose hebben. Bij sommigen van 
hen zal de aandoening verergeren, bij sommigen zal die dezelfde blijven en met 
sommigen zal het beter gaan. Als de studiepopulatie bestaat uit patiënten van al deze 
subgroepen kan de heterogeniteit leiden tot een onderschatting van het effect van 
de onderzochte medicijnen. Het kunnen indelen (stratificatie) in een vroeg stadium 
om te voorspellen welke patiënten progressie zullen vertonen, is belangrijk omdat 
met name deze patiënten zullen profiteren van artrosemedicatie.
 
Verschillende klinische factoren, zoals verergering op korte termijn van 
zelfgerapporteerde pijn en functiebeperking, beperkte bewegingsmogelijkheid van 
gewrichten en hogere osteofyten- en gewrichtsversmallingsscores kunnen worden 
gebruikt om de progressie op lange termijn (zes jaar in onze studie, beschreven 
in hoofdstuk 3) te voorspellen. In de toekomst zullen klinische trials een nieuw 
geneesmiddel onderzoeken in een studiepopulatie met factoren die een slechte 
prognose voorspellen. In een dergelijke ‘zuivere’ studiepopulatie zal beter het effect 
van een nieuw geneesmiddel kunnen worden aangetoond dan in de heterogene 
groepen. Aangezien de progressie over een langere duur (b.v. 6 jaar) kan worden 
voorspeld door de progressie over een korte termijn (b.v. 1 jaar), kan een kortere 
klinische trial uitgevoerd worden. 
Klinische prognostische factoren kunnen worden gecombineerd met de biomarkers 
zoals uCTX-II in de stratificatie van patiënten. Toekomstige studies moeten een 






































klinische factoren en biomarkers. De uitkomsten van deze studies kunnen klinische 
of radiologische bevindingen zijn of een combinatie van beide.
Het gebruik van beeldvorming zoals röntgenfoto en MRI als middel om de prognose 
van artrose te meten heeft ook nadelen. Beeldvorming is een momentopname; 
ze laat alleen het eindresultaat zien van processen in een gewricht. Beeldvorming 
geeft geen informatie over de dynamiek in de structuren of weefsels die een rol 
spelen in artrose. Een meting van biomarkers op een bepaald tijdstip is ook zo’n 
momentopname, maar meerdere metingen hiervan zijn waarschijnlijk een goede 
optie om de progressie van artrose te bestuderen. Meerdere metingen van uCTX-
II zijn geassocieerd met toename van kraakbeenbeschadiging op de röntgenfoto 
(hoofdstuk 4). Dit wekt de suggestie dat uCTX-II de potentie heeft om te worden 
gebruikt als een vervanging van röntgenfoto’s in observationele en klinische studies. 
In toekomstige studies kunnen ook andere structuren dan kraakbeen die betrokken 
zijn bij artrose, zoals beenmerglesies en synovitis of effusie, worden bestudeerd. 
De afname van beenmerglesies en synovitis of effusie kan worden gebruikt als een 
uitkomst voor een studie naar de effecten van een nieuw geneesmiddel.
10.2.3 Overtollig vet heeft op verschillende manieren een invloed op artrose 
Op basis van de resultaten gepresenteerd in dit proefschrift kunnen we concluderen 
dat een overmaat aan lichaamsvet effect heeft op gewrichten. Niet alleen door de 
extra mechanische belasting, maar ook door de productie van metabole factoren 
(adipokinen). Adiponectine is een van de adipokinen die door vetweefsel gemaakt 
worden. Interessant is dat obesitas een omgekeerd verband heeft met adiponectine: 
meer vet leidt tot minder adiponectine. Het hebben van weinig adiponectine 
lijkt slecht te zijn voor het kraakbeen, zoals beschreven is in hoofdstuk 6. Terwijl 
adiponectine geassocieerd is met de progressie van artrose, is er geen verband 
gevonden tussen adiponectine en pijn en de verergering van pijn (data zijn niet 
gepubliceerd). Waarschijnlijk stimuleren de adipokinen de nociceptoren niet direct. 
Adipokinen kan eerst leiden tot kraakbeenschade en vervolgens tot pijn. Het verschil 
van het effect van de adipokinen op de progressie van de kraakbeenschade en pijn 





































De heilige graal in het onderzoek naar artrose is de verklaring te vinden voor de 
discrepantie tussen pathologische structuren en pijn.
De constatering dat het effect van obesitas ‘gemedieerd’ is door weefselschade in 
knieartrose maar niet in heupartrose (hoofdstuk 7) houdt in dat het mechanisch 
effect van overgewicht op artrose niet moet worden vergeten (ervan uitgaande 
dat het kniegewricht meer gewicht draagt, d.w.z. zwaarder belast wordt dan het 
heupgewricht). Toekomstige studies over het effect van overtollig vet moeten de 
metabole en mechanische effecten combineren.
Ook moet een opmerking gemaakt worden over de wijze waarop het overtollig vet 
gemeten wordt, met name in studies naar metabole effecten. De BMI, die vaak 
wordt gebruikt in epidemiologische studies, is eigenlijk alleen maar een benadering 
van de hoeveelheid menselijk lichaamsvet. Daarom kan men in toekomstige 
epidemiologische studies beter gebruik maken van de metabole producten van 
het vet zelf. De metingen van die producten zouden het verband tussen obesitas 
en artrose beter kunnen verklaren. Naast adipokinen, zouden de metingen van 
andere vetproducten, zoals cholesterol en triglyceride, ook in artrosestudies gebruikt 
kunnen worden.
Toekomstig basaal onderzoek zou zich kunnen richten op een verbetering van het 
inzicht in het effect van adipokinen op de ontstekingsverschijnselen in de weefsels 
die betrokken zijn bij artrose. De structurele of weefselschade die op de MRI 
verband houdt met pijn in artrose, namelijk beenmerglesies en synovitis of effusie, 
zijn namelijk geassocieerd met ontstekingsverschijnselen. Voor knieartrose zou 
het interessant zijn als er meer onderzoek wordt gedaan naar de rol van Hoffa’s 
vetlichaam. Het kniegewricht is uniek omdat het in de buurt van een grote vetmassa 







































10.3. IN ENKELE ZINNEN
Artrose is een progressieve ziekte die kan worden gedefinieerd als pathologie of 
symptoom. Bij artrose speelt overtollig vet een belangrijke rol op de incidentie en de 
progressie. Of het effect van overtollig vet voornamelijk mechanisch of metabool is, 
hangt van het betrokken gewricht af. Het meten van het vet zelf of vetproducten moet 
worden uitgevoerd in aanvulling op, of in plaats van BMI in toekomstige studies naar 
het effect van obesitas op artrose. De producten van vetweefsels en hun receptoren 















































































Data that have been used to write chapter 7 of this thesis, were obtained from the 
‘OARSI-OMERACT Task Force for total articular replacement as outcome measure 
in OA’. After the thesis was read by the “promotiecommissie” and was approved, 
mistakes have been found in the data file concerning the Western Ontario and 
MacMaster (WOMAC) Index. These mistakes could possibly influence the results in 
chapter 7. 
Gegevens die zijn gebruikt om hoofdstuk 7 van dit proefschrift te schrijven, zijn 
verkregen door de ‘OARSI-OMERACT Task Force for total articular replacement as 
outcome measure in OA’. Nadat de goedkeuring voor dit proefschrift is gegeven door 
de leescomissie, zijn fouten ontdekt in de gebruikte Western Ontario and MacMaster 
(WOMAC) Index data. Deze fout zou mogelijk de resultaten beschreven in hoofdstuk 






































1. A. WESTERN ONTARIO AND McMASTER UNIVERSITIES (WOMAC) – LK 3-0
In sections A, B and C questions will be asked in the following format and you should 
give your answers by putting an “X” in one of the boxes.
Note:
If you put your X in the left-hand box, i.e.,
0 1 2 3 4
None Mild Moderate Severe Extreme
Then you are indicating that you have no pain.
If you put your X in the right-hand box, i.e.,
0 1 2 3 4
None Mild Moderate Severe Extreme
Then you are indicating that your pain is extreme.
Please note:
a) that the further to the right you place your “X” the more pain you are 
experiencing,
b) that the further to the left you place your “X” the less pain you are 
experiencing.
c) Please do not place your “X” outside the box.
You will be asked to indicate on this type of scale the mount of pain, stiffness or 
disability you are experiencing. Please remember the further you place your “X” to 





































SECTION A (PAIN SUBSCALE)
Instructions to patients: 
The following questions concern the amount of pain you are currently experiencing 
due to arthritis in your hips and/or knees. For each situation please enter the amount 
of pain recently experienced (please mark your answers with an “X”).
Questions: How much pain do you have? 
1. Walking on a flat surface. 0 1 2 3 4
None Mild Moderate Severe Extreme
2. Going up or down stairs 0 1 2 3 4
None Mild Moderate Severe Extreme
3. At night while in bed. 0 1 2 3 4
None Mild Moderate Severe Extreme
4. Sitting or lying. 0 1 2 3 4
None Mild Moderate Severe Extreme
5. Standing upright. 0 1 2 3 4





































SECTION B (STIFFNESS SUBSCALE)
Instructions to patients: 
The following questions concern the amount of joint stiffness (not pain) you are 
currently experiencing due to arthritis in your hips and/or knees. Stiffness is a 
sensation of restriction or slowness in the ease with which you move your joints 
(please mark your answers with an “X”).
6. How severe is your 
stiffness after first 
wakening in the 
morning?
0 1 2 3 4
None Mild Moderate Severe Extreme
7. How severe is your 
stiffness after sitting, 
lying or resting later 
in the day?
0 1 2 3 4
None Mild Moderate Severe Extreme 
SECTION C (PHYSICAL FUNCTION SUBSCALE)
Instructions to patients: 
The following questions concern your physical function. By this we mean your ability 
to move around and to look after yourself. For each of the following activities, please 
indicate the degree of difficulty you are currently experiencing due to arthritis in your 
hips and/or knees (please mark your answers with an “X”).
Questions: What degree of difficulty do you have with
8. Descending stairs 0 1 2 3 4





































9. Ascending stairs 0 1 2 3 4
None Mild Moderate Severe Extreme
10. Rising from sitting 0 1 2 3 4
None Mild Moderate Severe Extreme
11. Standing 0 1 2 3 4
None Mild Moderate Severe Extreme
12. Bending to floor 0 1 2 3 4
None Mild Moderate Severe Extreme
13. Walking on flat 0 1 2 3 4
None Mild Moderate Severe Extreme
14. Getting in/out of car 0 1 2 3 4
None Mild Moderate Severe Extreme
15. Going shopping 0 1 2 3 4
None Mild Moderate Severe Extreme
16. Putting on socks/
stockings
0 1 2 3 4
None Mild Moderate Severe Extreme
17. Rising from bed 0 1 2 3 4
None Mild Moderate Severe Extreme
18. Taking off socks/
stockings
0 1 2 3 4
None Mild Moderate Severe Extreme
19. Lying in bed 0 1 2 3 4





































20. Getting in/out of bath 0 1 2 3 4
None Mild Moderate Severe Extreme
21. Sitting 0 1 2 3 4
None Mild Moderate Severe Extreme
22. Getting on/off toilet 0 1 2 3 4
None Mild Moderate Severe Extreme
23. Heavy domestic duties 0 1 2 3 4
None Mild Moderate Severe Extreme
24. Light domestic duties 0 1 2 3 4
None Mild Moderate Severe Extreme
1.B.  WESTERN ONTARIO AND McMASTER UNIVERSITIES (WOMAC) – LK 3-0, 
DUTCH VALIDATED
Instructies voor patiënten:
In deze vragenlijst worden vragen gesteld, die u kunt beantwoorden door een “x’ in 
één van de vakjes te zetten.
Voorbeelden:
1. Als u een “x” in het linker vakje zet, zoals in het voorbeeld hieronder, duidt 
u aan dat u geen pijn hebt:
geen lichte matige ernstige hevige
  □ □ □ □ □ 
2. Als u een “x” in de rechter vakje zet, zoals in het voorbeeld hieronder, duidt 
u aan dat u hevige pijn hebt:
geen lichte matige ernstige hevige







































3. Vergeet a.u.b. niet
a. dat naarmate u de “x”verder naar links zet, des te minder pijn u 
aanduidt.
b. dat naarmate u de “x”verder naar rechts zet, des te meer pijn u 
aanduidt.
c. dat u de “x”niet buiten het vakje zet.
Wij vragen u om de hevigheid van uw pijn, stijfheid of lichamelijke beperking 
In de afgelopen 48 uur op deze schaal aan te duiden. 
Deze vragenlijst a.u.b. invullen mbt uw knieën en/of heupen: aub aanduiden hoeveel 
pijn, stijfheid en lichamelijke beperking u hebt, ten gevolge van de artrose in uw 
knieën en/of heupen.
PIJN 
Het gaat om de pijn die u had in uw knieën en/of heupen, in de afgelopen 48 uur ten 
gevolge van uw artrose.
(antwoorden a.u.b. met een “x” aankruisen.)
Vraag: Hoeveel pijn hebt u…….
1. wanneer u op vlakke grond loopt?
geen lichte matige ernstige hevige
  □ □ □ □ □ 
2. wanneer u trappen op- en afloopt?
geen lichte matige ernstige hevige
□ □ □ □ □ 
3. wanneer u ’s nachts in bed ligt; bijvoorbeeld pijn die de slaap verstoort?
geen lichte matige ernstige hevige





































4. wanneer u zit of ligt?
geen lichte matige ernstige hevige
  □ □ □ □ □ 
5. wanneer u gewoon staat?
geen lichte matige ernstige hevige
  □ □ □ □ □
STIJFHEID
Het gaat om de stijfheid (niet pijn) die u had in uw knieën en/of heupen in de 
afgelopen 48 uur ten gevolge van de artrose.
Stijfheid is een gevoel van traagheid in de beweging van uw gewrichten.
(antwoorden a.u.b. met een “x” aankruisen.)
6.  Hoe erg is uw stijfheid als u ’s ochtends wakker wordt?
geen lichte matige ernstige hevige
  □ □ □ □ □ 
7.  Hoe erg is uw stijfheid na zitten, liggen of rusten later op de dag?
geen lichte matige ernstige hevige





































MOEITE MET UITVOEREN VAN DAGELIJKSE ACTIVITEITEN
Het gaat om de moeite die u had met uw dagelijks lichamelijk functioneren ten 
gevolge van de artrose in uw knieën en/of heupen in de afgelopen 48 uur.
Wij bedoelen hiermee of u zich kunt verplaatsen en voor zichzelf kunt zorgen.
(antwoorden a.u.b. met een “x “ aankruisen.)
Vraag: Hoeveel moeite heeft u……
8.    om trappen af te lopen?
geen lichte matige ernstige hevige
  □ □ □ □ □ 
9. om trappen op te lopen?
geen lichte matige ernstige hevige
  □ □ □ □ □
10. om op te staan na gezeten te hebben?
geen lichte matige ernstige hevige
  □ □ □ □ □ 
11. om te staan?
geen lichte matige ernstige hevige
  □ □ □ □ □
12. om voorover te buigen, bijvoorbeeld om iets op te rapen?
geen lichte matige ernstige hevige
  □ □ □ □ □ 
13.   om op vlak terrein te lopen?
geen lichte matige ernstige hevige





































14. om in of uit een bus of auto te stappen?
geen lichte matige ernstige hevige
  □ □ □ □ □
 
15. om boodschappen te doen?
geen lichte matige ernstige hevige
  □ □ □ □ □
16. om sokken/panty’s aan te trekken?
geen lichte matige ernstige hevige
  □ □ □ □ □ 
17. om uit bed op te staan?
geen lichte matige ernstige hevige
  □ □ □ □ □ 
 
18. om sokken/panty’s uit te trekken?
geen lichte matige ernstige hevige
  □ □ □ □ □ 
19. om in bed te liggen?
geen lichte matige ernstige hevige
  □ □ □ □ □ 
20. om in of uit het bad te stappen?
geen lichte matige ernstige hevige
  □ □ □ □ □ 
21. om te zitten?
geen lichte matige ernstige hevige





































22. om op het toilet te gaan zitten of er vanaf te komen?
geen lichte matige ernstige hevige
  □ □ □ □ □ 
23. om zware huishoudelijke taken te verrichten?
geen lichte matige ernstige hevige
  □ □ □ □ □ 
24. om lichte huishoudelijke taken te verrichten?
geen lichte matige ernstige hevige
  □ □ □ □ □
2. A MEASURE OF INTERMITTENT AND CONSTANT OSTEOARTHRITIS PAIN 
(ICOAP): HIP VERSION
People have told us that they experience different kinds of pain (including aching or 
discomfort) in their hip. To get a better sense of the different types of hip pain you 
may experience, we would like to ask you about any “constant pain” (pain you have 
all the time) separately from any pain that you may experience less often, that is, 
“pain that comes and goes”. The following questions will ask you about the pain that 
you have experienced in your hip in the PAST WEEK. Please answer ALL questions.
A. CONSTANT PAIN
For each of the following questions, please select the response that best describes, 
on average, your constant hip pain in the PAST WEEK.
1. In the past week, how intense has your constant hip pain been?
0 1 2 3 4





































2. In the past week, how much has your constant hip pain affected your sleep?
0 1 2 3 4
Not at all/No constant hip pain Mildly Moderately Severely Extremely
3. In the past week, how much has your constant hip pain affected your overall 
quality of life?
0 1 2 3 4
Not at all/No constant hip pain Mildly Moderately Severely Extremely
4. In the past week, how frustrated or annoyed have you been by your constant hip 
pain?
0 1 2 3 4
Not at all/No constant hip pain Mildly Moderately Severely Extremely
5. In the past week, how upset or worried have you been by your constant hip pain?
0 1 2 3 4
Not at all/No constant hip pain Mildly Moderately Severely Extremely
B. PAIN THAT COMES AND GOES
Now we would like to ask you about hip pain that comes and goes. For example, 
people have told us that they may get a pain in their hip that is brought on by a 
specific activity or movement or that they sometimes get pain for a period of time 
but then this pain goes away for no apparent reason. People use lots of different 
words to describe this type of pain but we are going to refer to this as hip pain that 
comes and goes. For each of the following questions, please select the response that 
best describes your hip pain that comes and goes in the PAST WEEK.
6. In the past week, how intense has your most severe hip pain that comes and goes 
been?
0 1 2 3 4





































7. In the past week, how frequently has your hip pain that comes and goes occurred?
0 1 2 3 4
Not at all/No constant hip pain Rarely Sometimes Often Very often
8. In the past week, how much has your hip pain that comes and goes affected your 
sleep?
0 1 2 3 4
Not at all/No constant hip pain Mildly Moderately Severely Extremely
9. In the past week, how much has your hip pain that comes and goes affected your 
overall quality of life?
0 1 2 3 4
Not at all/No constant hip pain Mildly Moderately Severely Extremely
10. In the past week, how frustrated or annoyed have you been by your hip pain that 
comes and goes?
0 1 2 3 4
Not at all/No constant hip pain Mildly Moderately Severely Extremely
11. In the past week, how upset or worried have you been by your hip pain that 
comes and goes? 





































3. A MEASURE OF INTERMITTENT AND CONSTANT OSTEOARTHRITIS PAIN 
(ICOAP): KNEE VERSION
People have told us that they experience different kinds of pain (including aching or 
discomfort) in their knee. To get a better sense of the different types of knee pain you 
may experience, we would like to ask you about any “constant pain” (pain you have 
all the time) separately from any pain that you may experience less often, that is, 
“pain that comes and goes”. The following questions will ask you about the pain that 
you have experienced in your knee in the PAST WEEK. Please answer ALL questions.
A. CONSTANT PAIN
For each of the following questions, please select the response that best describes, 
on average, your constant knee pain in the PAST WEEK.
1. In the past week, how intense has your constant knee pain been?
0 1 2 3 4
Not at all/No constant knee pain Mildly Moderately Severely Extremely
2. In the past week, how much has your constant knee pain affected your sleep?
0 1 2 3 4
Not at all/No constant knee pain Mildly Moderately Severely Extremely
3. In the past week, how much has your constant knee pain affected your overall 
quality of life?
0 1 2 3 4
Not at all/No constant knee pain Mildly Moderately Severely Extremely
4. In the past week, how frustrated or annoyed have you been by your constant knee 
pain?
0 1 2 3 4





































5. In the past week, how upset or worried have you been by your constant knee pain?
0 1 2 3 4
Not at all/No constant knee pain Mildly Moderately Severely Extremely
B. PAIN THAT COMES AND GOES
For each of the following questions, please select the response that best describes 
your knee pain that comes and goes, on average, in the PAST WEEK.
6. In the past week, how intense has your most severe knee pain that comes and 
goes been?
0 1 2 3 4
Not at all/No constant knee pain Mildly Moderately Severely Extremely
7. In the past week, how frequently has this knee pain that comes and goes occurred?
0 1 2 3 4
Not at all/No constant knee pain Rarely Sometimes Often Very often
8. In the past week, how much has your knee pain that comes and goes affected your 
sleep?
0 1 2 3 4
Not at all/No constant knee pain Mildly Moderately Severely Extremely
9. In the past week, how much has your knee pain that comes and goes affected your 
overall quality of life?
0 1 2 3 4





































10. In the past week, how frustrated or annoyed have you been by your knee pain 
that comes and goes?
0 1 2 3 4
Not at all/No constant knee pain Mildly Moderately Severely Extremely
11. In the past week, how upset or worried have you been by your knee pain that 
comes and goes?
0 1 2 3 4
Not at all/No constant knee pain Mildly Moderately Severely Extremely
4. SHORT FORM-36 (SF-36)
Instructies voor patiënten:
In deze vragenlijst wordt naar uw gezondheid gevraagd. Wilt u elke vraag 
beantwoorden door het juiste hokje aan te kruisen. Wanneer u twijfelt over het 
antwoord op een vraag, probeer dan het antwoord te geven dat het meest van 
toepassing is.






2. In vergelijking met een jaar geleden, hoe zou u nu uw gezondheid in het algemeen
beoordelen?
o veel beter dan een jaar geleden
o iets beter dan een jaar geleden
o ongeveer hetzelfde als een jaar geleden
o iets slechter dan een jaar geleden





































3. De volgende vragen gaan over de dagelijkse bezigheden. Wordt u door uw 
gezondheid op dit moment beperkt bij deze bezigheden? Zo ja, in welke mate?
a. Forse inspanning 
zoals hardlopen, zware voorwerpen tillen, inspanend sporten.
 □ ja, ernstig beperkt □ ja, matig beperkt □ nee, helemaal niet beperkt 
b. Matige inspanning
 zoals het verplaatsen van een tafel, stofzuigen, fietsen
 □ ja, ernstig beperkt □ ja, matig beperkt □ nee, helemaal niet beperkt 
c. Tillen of boodschappen dragen
 □ ja, ernstig beperkt □ ja, matig beperkt □ nee, helemaal niet beperkt 
d. Een paar trappen oplopen
 □ ja, ernstig beperkt □ ja, matig beperkt □ nee, helemaal niet beperkt 
e. Eén trap oplopen
 □ ja, ernstig beperkt □ ja, matig beperkt □ nee, helemaal niet beperkt 
f. Buigen, knielen of bukken
 □ ja, ernstig beperkt □ ja, matig beperkt □ nee, helemaal niet beperkt 
g. Meer dan een kilometer lopen
 □ ja, ernstig beperkt □ ja, matig beperkt □ nee, helemaal niet beperkt 
h. Een halve kilometer lopen
 □ ja, ernstig beperkt □ ja, matig beperkt □ nee, helemaal niet beperkt 
i. Honderd meter lopen
 □ ja, ernstig beperkt □ ja, matig beperkt □ nee, helemaal niet beperkt 
j. Uzelf wassen of aankleden





































4. Had u, ten gevolge van uw lichamelijke gezondheid, de afgelopen 4 weken één 
van de
volgende problemen bij uw werk of andere dagelijkse bezigheden?
a. U heeft minder tijd kunnen besteden aan werk of andere bezigheden
 □ ja □ nee
b. U heeft minder bereikt dan u zou willen
 □ ja □ nee
c. U was beperkt in het soort werk of het soort bezigheden
 □ ja □ nee
d. U had moeite met het werk of andere bezigheden
(het kostte u bijvoorbeeld extra inspanning)
 □ ja □ nee
5. Had u, ten gevolge van een emotioneel probleem (bijvoorbeeld doordat u zich 
depressief of angstig voelde), de afgelopen 4 weken één van de volgende problemen 
bij uw werk of andere dagelijkse bezigheden?
a. U heeft minder tijd kunnen besteden aan werk of andere bezigheden
 □ ja □ nee
b. U heeft minder bereikt dan u zou willen
 □ ja □ nee
c. U heeft het werk of andere bezigheden niet zo zorgvuldig gedaan als u gewend 
bent
 □ ja □ nee
6. In hoeverre heeft uw lichamelijke gezondheid of hebben uw emotionele problemen 
u de afgelopen 4 weken belemmerd in uw normale sociale bezigheden met gezin, 

















































8. In welke mate heeft pijn u de afgelopen 4 weken belemmerd bij uw normale 
werkzaamheden (zowel erk buitenshuis als huishoudelijk werk)?
o helemaal niet
o een klein beetje
o nogal
o veel
o heel erg veel
9. Deze vragen gaan over hoe u zich de afgelopen 4 weken heeft gevoeld. Wilt u 
bij elke vraag het antwoord aankruisen dat het beste aansluit bij hoe u zich heeft 
gevoeld.
Hoe vaak gedurende de afgelopen 4 weken:
a. voelde u zich levenslustig?
□ voortdurend □ meestal □ vaaks □ soms □ zelden □ nooit
b. voelde u zich zenuwachtig?
□ voortdurend □ meestal □ vaaks □ soms □ zelden □ nooit
c. zat u zo erg in de put dat niets u kon opvrolijken?
□ voortdurend □ meestal □ vaaks □ soms □ zelden □ nooit
d. voelde u zich kalm en rustig?





































e. voelde u zich erg energiek?
□ voortdurend □ meestal □ vaaks □ soms □ zelden □ nooit
f. voelde u zich neerslachtig en somber?
□ voortdurend □ meestal □ vaaks □ soms □ zelden □ nooit
g. voelde u zich uitgeblust?
□ voortdurend □ meestal □ vaaks □ soms □ zelden □ nooit
h. voelde u zich gelukkig?
□ voortdurend □ meestal □ vaaks □ soms □ zelden □ nooit
i. voelde u zich moe?
□ voortdurend □ meestal □ vaaks □ soms □ zelden □ nooit
10. Hoe vaak hebben uw lichamelijke gezondheid of emotionele problemen gedurende 







11. Wilt u het antwoord kiezen dat het beste weergeeft hoe juist of onjuist u elk van 
de volgende uitspraken voor u zelf vindt.
a. Ik lijk gemakkelijker ziek te worden dan andere mensen.
□ volkomen juist   □ grotendeels juist   □ weet ik niet   □ grotendeels onjuist 
□ volkomen onjuist
b. Ik ben net zo gezond als andere mensen die ik ken.






































c. Ik verwacht dat mijn gezondheid achteruit zal gaan.
□ volkomen juist   □ grotendeels juist   □ weet ik niet   □ grotendeels onjuist 
□ volkomen onjuist
d. Mijn gezondheid is uitstekend.






































C. RADIOGRAPHIC SCORES USED IN THIS THESIS TO ASSESS 
OSTEOARTHRITIS 
1. THE KELLGREN AND LAWRENCE (K&L) RADIOGRAPHIC SCORING SYSTEM 
(from Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis. Annals of 
Rheumatic Diseases 1957;16(4):494-502)






































K&L scores for hip joints (grade 1 to 4)





































2. OSTEAOARTHRITIS RESEACH SOCIETY INTERNATIONAL (OARSI) ATLAS
(from Altman RD, Gold GE. Atlas of individual radiographic features in osteoarthritis, 
revised. Osteoarthritis Cartilage 2007;15 Suppl A:A1-56.)
Joint space narrowing scores for hand, for example proximal interphalangeal joint 
(from 0 to 3, from left to right)
 
Joint space narrowing scores for hip (from 0 to 3, from left to right)
Joint space narrowing scores for knee, for example lateral compartment 
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